diff --git "a/PHEE_test_v1.conll" "b/PHEE_test_v1.conll"
new file mode 100644--- /dev/null
+++ "b/PHEE_test_v1.conll"
@@ -0,0 +1,20274 @@
+After	O
+therapy	O
+with	O
+parenteral	O
+amiodarone	O
+(2300	O
+mg	O
+in	O
+3	O
+days)	O
+and	O
+other	O
+measures	O
+signs	O
+of	O
+congestive	O
+heart	O
+failure	O
+disappeared	O
+subsequently	O
+the	O
+patient	O
+developed	O
+jaundice	B-Adev
+marked	I-Adev
+increase	I-Adev
+in	I-Adev
+serum	I-Adev
+transaminase	I-Adev
+levels	I-Adev
+and	I-Adev
+fall	I-Adev
+in	I-Adev
+prothrombin	I-Adev
+time	I-Adev
+and	I-Adev
+histologic	I-Adev
+changes	I-Adev
+of	I-Adev
+severe	I-Adev
+centrilobular	I-Adev
+necrosis	I-Adev
+were	I-Adev
+observed	I-Adev
+in	I-Adev
+hepatic	I-Adev
+biopsy	I-Adev
+	O
+
+We	O
+report	O
+one	O
+case	O
+of	O
+non-Hodgkin	B-Adev
+lymphoma	I-Adev
+in	O
+a	O
+patient	O
+with	O
+a	O
+30-year	O
+history	O
+of	O
+rheumatoid	O
+arthritis	O
+taking	O
+low	O
+dose	O
+methotrexate	O
+weekly	O
+over	O
+a	O
+10-month	O
+period	O
+
+We	O
+recommend	O
+the	O
+cautious	O
+use	O
+of	O
+alum	O
+irrigation	O
+in	O
+patients	O
+with	O
+renal	O
+impairment	O
+and	O
+monitoring	O
+of	O
+serum	O
+aluminum	O
+levels	O
+to	O
+prevent	O
+excessive	B-Adev
+accumulation	I-Adev
+and	I-Adev
+toxicity	I-Adev
+
+RESULTS	O
+A	O
+44-year-old	O
+man	O
+taking	O
+naproxen	O
+for	O
+chronic	O
+low	O
+back	O
+pain	O
+and	O
+a	O
+20-year-old	O
+woman	O
+on	O
+oxaprozin	O
+for	O
+rheumatoid	O
+arthritis	O
+presented	O
+with	O
+tense	B-Adev
+bullae	I-Adev
+and	I-Adev
+cutaneous	I-Adev
+fragility	I-Adev
+on	I-Adev
+the	I-Adev
+face	I-Adev
+and	I-Adev
+the	I-Adev
+back	I-Adev
+of	I-Adev
+the	I-Adev
+hands	I-Adev
+	O
+
+RESULTS	O
+A	O
+44-year-old	O
+man	O
+taking	O
+naproxen	O
+for	O
+chronic	O
+low	O
+back	O
+pain	O
+and	O
+a	O
+20-year-old	O
+woman	O
+on	O
+oxaprozin	O
+for	O
+rheumatoid	O
+arthritis	O
+presented	O
+with	O
+tense	B-Adev
+bullae	I-Adev
+and	I-Adev
+cutaneous	I-Adev
+fragility	I-Adev
+on	I-Adev
+the	I-Adev
+face	I-Adev
+and	I-Adev
+the	I-Adev
+back	I-Adev
+of	I-Adev
+the	I-Adev
+hands	I-Adev
+	O
+
+CASE	O
+REPORT	O
+We	O
+report	O
+a	O
+case	O
+of	O
+intracerebral	B-Adev
+hemorrhage	I-Adev
+occurring	O
+in	O
+a	O
+middle-aged	O
+man	O
+who	O
+suffered	O
+from	O
+chronic	O
+sinusitis	O
+and	O
+had	O
+been	O
+ingesting	O
+pseudoephedrine	O
+daily	O
+for	O
+one	O
+year	O
+
+Lymphoma	B-Adev
+developing	O
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+taking	O
+methotrexate	O
+
+The	O
+Naranjo	O
+probability	O
+scale	O
+suggests	O
+a	O
+highly	O
+probable	O
+relationship	O
+between	O
+AIN	B-Adev
+and	O
+pantoprazole	O
+therapy	O
+in	O
+this	O
+patient	O
+
+In	O
+one	O
+case	O
+disulfiram	O
+was	O
+the	O
+only	O
+potential	O
+teratogen	B-Adev
+exposed	O
+to	O
+the	O
+fetus	O
+
+Pancreatitis	B-Adev
+has	O
+been	O
+noted	O
+to	O
+be	O
+a	O
+complication	O
+in	O
+2-16%	O
+of	O
+patients	O
+undergoing	O
+treatment	O
+with	O
+L-asparaginase	O
+for	O
+a	O
+variety	O
+of	O
+pediatric	O
+neoplasms	O
+
+Myopathy	B-Adev
+including	I-Adev
+rhabdomyolysis	I-Adev
+	O
+is	O
+a	O
+well-known	O
+albeit	O
+rare	O
+complication	O
+of	O
+statin	O
+therapy	O
+
+Management	O
+and	O
+successful	O
+desensitization	O
+in	O
+methotrexate-induced	O
+anaphylaxis	B-Adev
+	O
+
+Mitomycin-C	O
+induced	O
+hemolytic	B-Adev
+uremic	I-Adev
+syndrome	I-Adev
+	O
+a	O
+case	O
+report	O
+
+Acute	B-Adev
+hepatic	I-Adev
+failure	I-Adev
+is	O
+a	O
+rare	O
+and	O
+potentially	O
+lethal	O
+complication	O
+of	O
+propylthiouracil	O
+(PTU)	O
+use	O
+for	O
+hyperthyroidism	O
+
+Monoclonal	B-Adev
+gammopathy	I-Adev
+and	I-Adev
+subsequent	I-Adev
+multiple	I-Adev
+myeloma	I-Adev
+in	O
+a	O
+patient	O
+on	O
+chronic	O
+diphenylhydantoin	O
+therapy	O
+
+Unexpected	O
+severe	O
+reversible	O
+cyclosporine	O
+A-induced	O
+nephrotoxicity	B-Adev
+in	O
+a	O
+patient	O
+with	O
+systemic	O
+lupus	O
+erythematosus	O
+and	O
+tubulointerstitial	O
+renal	O
+disease	O
+
+As	O
+far	O
+as	O
+we	O
+know	O
+this	O
+is	O
+the	O
+first	O
+case	O
+report	O
+of	O
+acute	B-Adev
+hemorrhagic	I-Adev
+gastritis	I-Adev
+associated	O
+with	O
+AZ	O
+intoxication	O
+
+Toxic	B-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+resulted	O
+after	O
+19	O
+days	O
+of	O
+treatment	O
+with	O
+5-fluorocytosine	O
+and	O
+amphotericin	O
+B	O
+
+Since	O
+1979	O
+over	O
+30	O
+published	O
+case	O
+reports	O
+have	O
+documented	O
+the	O
+relationship	O
+between	O
+phenylpropanolamine	O
+and	O
+stroke	B-Adev
+	O
+
+CASE	O
+SUMMARY	O
+A	O
+61-year-old	O
+woman	O
+with	O
+no	O
+apparent	O
+risk	O
+factors	O
+for	O
+liver	O
+injury	O
+developed	O
+acute	B-Adev
+hepatitis	I-Adev
+one	O
+week	O
+after	O
+the	O
+final	O
+dose	O
+of	O
+a	O
+long-term	O
+course	O
+of	O
+pulse	O
+itraconazole	O
+therapy	O
+(200	O
+mg	O
+orally	O
+twice	O
+daily	O
+1	O
+wk	O
+on	O
+3	O
+wk	O
+off	O
+for	O
+24	O
+wk)	O
+for	O
+onychomycosis	O
+
+We	O
+experienced	O
+a	O
+case	O
+of	O
+chronic	O
+renal	O
+failure	O
+in	O
+a	O
+patient	O
+suffering	O
+from	O
+acute	B-Adev
+hemorrhagic	I-Adev
+gastritis	I-Adev
+associated	O
+with	O
+AZ	O
+intoxication	O
+
+Rhabdomyolysis	B-Adev
+caused	O
+by	O
+tocolysis	O
+with	O
+oral	O
+ritodrine	O
+hydrochloride	O
+in	O
+a	O
+pregnant	O
+patient	O
+with	O
+myotonic	O
+dystrophy	O
+
+While	O
+sulindac	O
+failed	O
+to	O
+affect	O
+significantly	O
+warfarin-induced	O
+hypoprothrombinemia	O
+in	O
+normal	O
+male	O
+volunteers	O
+it	O
+markedly	B-Adev
+prolonged	I-Adev
+prothrombin	I-Adev
+time	I-Adev
+in	O
+a	O
+patient	O
+with	O
+a	O
+renal	O
+tubular	O
+defect	O
+who	O
+had	O
+been	O
+anticoagulated	O
+with	O
+warfarin	O
+
+While	O
+sulindac	O
+failed	O
+to	O
+affect	O
+significantly	O
+warfarin-induced	O
+hypoprothrombinemia	B-Adev
+in	O
+normal	O
+male	O
+volunteers	O
+it	O
+markedly	O
+prolonged	O
+prothrombin	O
+time	O
+in	O
+a	O
+patient	O
+with	O
+a	O
+renal	O
+tubular	O
+defect	O
+who	O
+had	O
+been	O
+anticoagulated	O
+with	O
+warfarin	O
+
+While	O
+sulindac	O
+failed	O
+to	O
+affect	B-Adev
+significantly	I-Adev
+warfarin-induced	I-Adev
+hypoprothrombinemia	I-Adev
+in	O
+normal	O
+male	O
+volunteers	O
+it	O
+markedly	O
+prolonged	O
+prothrombin	O
+time	O
+in	O
+a	O
+patient	O
+with	O
+a	O
+renal	O
+tubular	O
+defect	O
+who	O
+had	O
+been	O
+anticoagulated	O
+with	O
+warfarin	O
+
+Painful	B-Adev
+erosion	I-Adev
+of	I-Adev
+psoriatic	I-Adev
+plaques	I-Adev
+is	O
+a	O
+less	O
+common	O
+sign	O
+of	O
+methotrexate	O
+toxicity	O
+that	O
+may	O
+precede	O
+evidence	O
+of	O
+bone	O
+marrow	O
+suppression	O
+
+Drug-induced	O
+hepatitis	B-Adev
+in	O
+an	O
+acromegalic	O
+patient	O
+during	O
+combined	O
+treatment	O
+with	O
+pegvisomant	O
+and	O
+octreotide	O
+long-acting	O
+repeatable	O
+attributed	O
+to	O
+the	O
+use	O
+of	O
+pegvisomant	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+a	O
+patient	O
+in	O
+a	O
+promethazine-induced	O
+coma	O
+responding	O
+to	O
+treatment	O
+with	O
+flumazenil	O
+
+Ocular	B-Adev
+hypertension	I-Adev
+occurred	O
+1	O
+month	O
+after	O
+the	O
+second	O
+ranibizumab	O
+injection	O
+in	O
+patients	O
+1	O
+and	O
+3	O
+and	O
+1	O
+month	O
+after	O
+the	O
+first	O
+ranibizumab	O
+in	O
+patient	O
+2	O
+
+Priapism	B-Adev
+associated	O
+with	O
+zuclopenthixol	O
+
+Reversible	B-Adev
+MR	I-Adev
+imaging	I-Adev
+and	I-Adev
+MR	I-Adev
+spectroscopy	I-Adev
+abnormalities	I-Adev
+in	O
+association	O
+with	O
+metronidazole	O
+therapy	O
+
+PURPOSE	O
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+report	O
+on	O
+the	O
+possible	O
+development	O
+of	O
+corneal	B-Adev
+endothelial	I-Adev
+deposits	I-Adev
+resulting	O
+from	O
+the	O
+use	O
+of	O
+rifabutin	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+calcineurin-induced	O
+pain	B-Adev
+syndrome	I-Adev
+(CIPS)	I-Adev
+in	O
+a	O
+child	O
+undergoing	O
+his	O
+second	O
+hematopoietic	O
+stem	O
+cell	O
+transplant	O
+(HSCT)	O
+
+We	O
+experienced	O
+a	O
+male	O
+patient	O
+with	O
+psoriasis	O
+and	O
+hypertension	O
+whose	O
+conditions	O
+were	O
+treated	O
+with	O
+tacalcitol	O
+ointment	O
+and	O
+thiazide	O
+respectively	O
+resulting	O
+in	O
+hypercalciuria	B-Adev
+and	I-Adev
+hypercalcemia	I-Adev
+	O
+
+To	O
+our	O
+knowledge	O
+this	O
+is	O
+the	O
+first	O
+granulomatous	B-Adev
+reaction	I-Adev
+described	O
+after	O
+calcium	O
+hydroxylapatite	O
+injection	O
+
+Previous	O
+studies	O
+have	O
+demonstrated	O
+the	O
+interaction	O
+of	O
+MTX	O
+and	O
+a	O
+variety	O
+of	O
+non-steroidal	O
+anti-inflammatory	O
+drugs	O
+(NSAIDs)	O
+with	O
+various	O
+clinical	O
+manifestations	O
+including	O
+acute	B-Adev
+renal	I-Adev
+failure	I-Adev
+pancytopenia	I-Adev
+vomiting	I-Adev
+diarrhea	I-Adev
+elevated	I-Adev
+liver	I-Adev
+transaminases	I-Adev
+jaundice	I-Adev
+mucosal	I-Adev
+ulcerations	I-Adev
+and	I-Adev
+pyrexia	I-Adev
+	O
+
+We	O
+present	O
+a	O
+case	O
+report	O
+of	O
+a	O
+patient	O
+with	O
+alveolar	O
+hydatid	O
+disease	O
+whose	O
+treatment	O
+with	O
+mebendazole	O
+was	O
+brief	O
+due	O
+to	O
+side	O
+effects	O
+of	O
+alopecia	B-Adev
+and	I-Adev
+granulocytopenia	I-Adev
+	O
+and	O
+review	O
+the	O
+features	O
+of	O
+this	O
+disease	O
+which	O
+with	O
+increasing	O
+international	O
+migration	O
+may	O
+be	O
+encountered	O
+more	O
+frequently	O
+in	O
+Australia	O
+
+Niacin	O
+causes	O
+a	O
+reversible	B-Adev
+toxic	I-Adev
+cystoid	I-Adev
+maculopathy	I-Adev
+that	O
+occurs	O
+in	O
+approximately	O
+0.67%	O
+of	O
+patients	O
+taking	O
+high	O
+doses	O
+of	O
+the	O
+drug	O
+
+When	O
+tuberculosis	O
+patients	O
+on	O
+isoniazid	O
+eat	O
+certain	O
+varieties	O
+of	O
+fish	O
+they	O
+may	O
+develop	O
+a	O
+histamine	B-Adev
+reaction	I-Adev
+	O
+
+CONCLUSIONS	O
+Priapism	B-Adev
+is	O
+an	O
+uncommon	O
+but	O
+potentially	O
+serious	O
+adverse	O
+effect	O
+of	O
+zuclopenthixol	O
+that	O
+practitioners	O
+as	O
+with	O
+many	O
+other	O
+antipsychotics	O
+should	O
+be	O
+aware	O
+of	O
+
+To	O
+report	O
+a	O
+case	O
+of	O
+possible	B-Adev
+interaction	I-Adev
+of	I-Adev
+smokeless	I-Adev
+tobacco	I-Adev
+with	I-Adev
+warfarin	I-Adev
+in	O
+a	O
+patient	O
+treated	O
+after	O
+several	O
+thromboembolic	O
+events	O
+
+Hepatotoxicity	B-Adev
+induced	O
+by	O
+cyproterone	O
+acetate	O
+a	O
+report	O
+of	O
+three	O
+cases	O
+
+Neurotoxicity	B-Adev
+of	O
+intrathecal	O
+methotrexate	O
+MR	O
+imaging	O
+findings	O
+
+Isonicotinic	O
+acid	O
+hydrazide	O
+induced	O
+anagen	B-Adev
+effluvium	I-Adev
+and	I-Adev
+associated	I-Adev
+lichenoid	I-Adev
+eruption	I-Adev
+	O
+
+Only	O
+one	O
+case	O
+of	O
+severe	B-Adev
+symptomatic	I-Adev
+hepatitis	I-Adev
+occurring	O
+after	O
+pulse	O
+therapy	O
+with	O
+itraconazole	O
+for	O
+onychomycosis	O
+and	O
+requiring	O
+transplantation	O
+has	O
+been	O
+reported	O
+previously	O
+
+The	O
+elicitation	O
+of	O
+a	O
+movement	B-Adev
+disorder	I-Adev
+by	O
+trazodone	O
+case	O
+report	O
+
+Pulmonary	B-Adev
+fibrosis	I-Adev
+subsequent	O
+to	O
+high	O
+doses	O
+of	O
+CCNU	O
+for	O
+chronic	O
+myeloid	O
+leukemia	O
+
+PURPOSE/OBJECTIVES	O
+To	O
+describe	O
+the	O
+pharmacogenetic	O
+syndrome	O
+of	O
+dihydropyrimidine	O
+dehydrogenase	O
+(DPD)	O
+deficiency	O
+which	O
+predisposes	O
+patients	O
+with	O
+cancer	O
+to	O
+potentially	O
+lethal	B-Adev
+adverse	I-Adev
+reactions	I-Adev
+following	O
+5-fluorouracil	O
+(5-FU)-based	O
+chemotherapy	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+sustained	B-Adev
+hypotension	I-Adev
+after	O
+administration	O
+of	O
+parenteral	O
+verapamil	O
+
+Methadone	O
+has	O
+two	O
+roles	O
+in	O
+human	O
+immunodeficiency	O
+viral	O
+infection	O
+pain	O
+management	O
+and	O
+treatment	O
+of	O
+opioid	O
+abuse	O
+
+Each	O
+time	O
+he	O
+arrived	O
+at	O
+the	O
+anticoagulation	O
+clinic	O
+after	O
+his	O
+BCG	O
+therapy	O
+his	O
+INR	B-Adev
+was	I-Adev
+supratherapeutic	I-Adev
+	O
+except	O
+after	O
+his	O
+fourth	O
+treatment	O
+(INR	O
+of	O
+2.5)	O
+which	O
+can	O
+be	O
+explained	O
+by	O
+residual	O
+effects	O
+from	O
+the	O
+phytonadione	O
+he	O
+received	O
+a	O
+week	O
+earlier	O
+
+A	O
+70-year-old	O
+man	O
+had	O
+been	O
+treated	O
+with	O
+warfarin	O
+for	O
+atrial	O
+fibrillation	O
+
+This	O
+is	O
+a	O
+case	O
+report	O
+of	O
+fatal	B-Adev
+cryptococcal	I-Adev
+meningitis	I-Adev
+in	O
+a	O
+child	O
+with	O
+systemic	O
+lupus	O
+erythematosus	O
+being	O
+treated	O
+with	O
+prednisolone	O
+and	O
+azathioprine	O
+
+Acute	B-Adev
+hemorrhagic	I-Adev
+gastritis	I-Adev
+associated	O
+with	O
+acetazolamide	O
+intoxication	O
+in	O
+a	O
+patient	O
+with	O
+chronic	O
+renal	O
+failure	O
+
+Although	O
+the	O
+movement	B-Adev
+disorder	I-Adev
+could	O
+not	O
+with	O
+certainty	O
+be	O
+attributed	O
+to	O
+trazodone	O
+alone	O
+the	O
+drug	O
+at	O
+least	O
+acted	O
+as	O
+an	O
+eliciting	O
+agent	O
+
+CONCLUSIONS	O
+Prolonged	O
+exposure	O
+to	O
+itraconazole	O
+administered	O
+either	O
+continuously	O
+or	O
+intermittently	O
+may	O
+precipitate	O
+severe	B-Adev
+and	I-Adev
+irreversible	I-Adev
+hepatotoxic	I-Adev
+events	I-Adev
+	O
+
+In	O
+two	O
+patients	O
+with	O
+mycosis	O
+fungoides	O
+a	O
+squamous	B-Adev
+cell	I-Adev
+carcinoma	I-Adev
+developed	O
+during	O
+therapy	O
+with	O
+psoralens	O
+plus	O
+long-wave	O
+ultraviolet	O
+radiation	O
+(PUVA)	O
+
+Scrotal	B-Adev
+ulceration	I-Adev
+induced	O
+by	O
+all-trans	O
+retinoic	O
+acid	O
+in	O
+a	O
+patient	O
+with	O
+acute	O
+promyelocytic	O
+leukemia	O
+
+A	O
+61	O
+year-old	O
+male	O
+patient	O
+developed	O
+gynecomastia	B-Adev
+after	O
+starting	O
+theophylline	O
+
+Several	O
+possible	O
+explanations	O
+of	O
+the	O
+mechanism	O
+of	O
+renal	B-Adev
+failure	I-Adev
+associated	O
+with	O
+the	O
+use	O
+of	O
+dextran-40	O
+are	O
+discussed	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+the	O
+syndrome	B-Adev
+of	I-Adev
+inappropriate	I-Adev
+antidiuretic	I-Adev
+hormone	I-Adev
+(SIADH)	I-Adev
+secondary	O
+to	O
+cisplatin	O
+therapy	O
+in	O
+a	O
+patient	O
+with	O
+advanced-stage	O
+large	O
+cell	O
+neuroendocrine	O
+carcinoma	O
+of	O
+the	O
+cervix	O
+
+An	O
+80-year-old	O
+white	O
+female	O
+followed	O
+up	O
+at	O
+the	O
+Memory	O
+Clinic	O
+for	O
+mild	O
+cognitive	O
+impairment	O
+had	O
+been	O
+taking	O
+propafenone	O
+900	O
+mg/d	O
+for	O
+>10	O
+years	O
+for	O
+paroxysmal	O
+atrial	O
+fibrillation	O
+without	O
+adverse	O
+effects	O
+
+A	O
+total	O
+of	O
+109	O
+patients	O
+had	O
+a	O
+cardiovascular	B-Adev
+event	I-Adev
+	O
+with	O
+event	O
+rates	O
+of	O
+4.9%	O
+with	O
+omeprazole	O
+and	O
+5.7%	O
+with	O
+placebo	O
+(hazard	O
+ratio	O
+with	O
+omeprazole	O
+0.99	O
+95%	O
+CI	O
+0.68	O
+to	O
+1.44	O
+P	O
+=	O
+0.96)	O
+high-risk	O
+subgroups	O
+did	O
+not	O
+show	O
+significant	O
+heterogeneity	O
+
+The	O
+mechanism	O
+of	O
+anaphylactoid	B-Adev
+reaction	O
+to	O
+zomepirac	O
+in	O
+this	O
+case	O
+therefore	O
+remains	O
+unclear	O
+
+New	O
+onset	O
+of	O
+CD	B-Adev
+may	O
+be	O
+considered	O
+as	O
+an	O
+immune-mediated	O
+injury	O
+induced	O
+by	O
+etanercept	O
+
+This	O
+supports	O
+the	O
+well-reported	O
+potential	O
+of	O
+bleomycin	O
+to	O
+trigger	O
+acral	B-Adev
+vascular	I-Adev
+toxicity	I-Adev
+	O
+
+Results	O
+of	O
+a	O
+Phase	O
+III	O
+double-blind	O
+randomized	O
+parallel-group	O
+non-inferiority	O
+study	O
+evaluating	O
+the	O
+safety	O
+and	O
+efficacy	O
+of	O
+isotretinoin-Lidose	O
+in	O
+patients	O
+with	O
+severe	O
+recalcitrant	O
+nodular	O
+acne	O
+
+This	O
+treatment	O
+has	O
+the	O
+potential	O
+to	O
+cause	O
+severe	B-Adev
+vision	I-Adev
+loss	I-Adev
+as	O
+a	O
+result	O
+of	O
+intractable	O
+corticosteroid-induced	O
+glaucoma	O
+
+Therefore	O
+parenteral	O
+amiodarone	O
+was	O
+implicated	O
+as	O
+the	O
+cause	O
+of	O
+acute	B-Adev
+hepatitis	I-Adev
+in	O
+this	O
+patient	O
+
+Twenty-four	O
+hours	O
+after	O
+the	O
+administration	O
+of	O
+gemcitabine	O
+a	B-Adev
+symmetric	I-Adev
+bullous	I-Adev
+herpetiform	I-Adev
+eruption	I-Adev
+appeared	I-Adev
+on	I-Adev
+his	I-Adev
+trunk	I-Adev
+and	I-Adev
+upper	I-Adev
+limbs	I-Adev
+	O
+
+The	O
+rate	O
+of	O
+overt	O
+upper	O
+gastrointestinal	O
+bleeding	O
+was	O
+also	O
+reduced	O
+with	O
+omeprazole	O
+as	O
+compared	O
+with	O
+placebo	O
+(hazard	O
+ratio	O
+0.13	O
+95%	O
+CI	O
+0.03	O
+to	O
+0.56	O
+P	O
+=	O
+0.001)	O
+
+The	O
+association	O
+of	O
+phenothiazine	O
+overdose	O
+and	O
+respiratory	B-Adev
+distress	I-Adev
+syndrome	I-Adev
+merits	O
+consideration	O
+
+Patients	O
+from	O
+endemic	O
+areas	O
+referred	O
+to	O
+transplant	O
+centers	O
+may	O
+be	O
+at	O
+high	O
+risk	O
+for	O
+disseminated	B-Adev
+histoplasmosis	I-Adev
+when	O
+treated	O
+with	O
+long-term	O
+prednisone	O
+for	O
+graft-versus-host	O
+disease	O
+
+Atypical	O
+endometriosis	O
+may	O
+act	O
+as	O
+a	O
+precancerous	O
+lesion	O
+in	O
+the	O
+process	O
+of	O
+tamoxifen-induced	O
+malignant	B-Adev
+transformation	I-Adev
+of	I-Adev
+endometriosis	I-Adev
+	O
+
+A	O
+28	O
+year	O
+old	O
+white	O
+schizophrenic	O
+male	O
+has	O
+been	O
+under	O
+risperidone	O
+monotherapy	O
+for	O
+about	O
+one	O
+year	O
+when	O
+he	O
+developed	O
+dyskinetic	B-Adev
+movements	I-Adev
+	O
+
+Subjects	O
+receiving	O
+ivacaftor	O
+were	O
+55%	O
+less	O
+likely	O
+to	O
+have	O
+a	O
+pulmonary	O
+exacerbation	O
+than	O
+were	O
+patients	O
+receiving	O
+placebo	O
+through	O
+week	O
+48	O
+(P<0.001)	O
+
+Subjects	O
+receiving	O
+ivacaftor	O
+were	O
+55%	O
+less	O
+likely	O
+to	O
+have	O
+a	O
+pulmonary	O
+exacerbation	O
+than	O
+were	O
+patients	O
+receiving	O
+placebo	O
+through	O
+week	O
+48	O
+(P<0.001)	O
+
+Spinal	B-Adev
+cord	I-Adev
+infarction	I-Adev
+during	O
+use	O
+of	O
+zolmitriptan	O
+a	O
+case	O
+report	O
+
+Case	O
+2	O
+a	O
+29-year-old	O
+woman	O
+developed	O
+bilateral	B-Adev
+optic	I-Adev
+neuritis	I-Adev
+combined	I-Adev
+with	I-Adev
+numbness	I-Adev
+of	I-Adev
+the	I-Adev
+lower	I-Adev
+extremities	I-Adev
+as	I-Adev
+well	I-Adev
+as	I-Adev
+bowel	I-Adev
+and	I-Adev
+bladder	I-Adev
+dysfunction	I-Adev
+after	O
+a	O
+22-month	O
+use	O
+of	O
+recombinant	O
+interferon	O
+alpha-2b	O
+for	O
+chronic	O
+myelogenous	O
+leukemia	O
+
+These	O
+features	O
+have	O
+not	O
+previously	O
+been	O
+reported	O
+as	O
+side	O
+effects	O
+of	O
+glibenclamide	O
+therapy	O
+but	O
+intrahepatic	B-Adev
+cholestasis	I-Adev
+may	O
+occur	O
+with	O
+chlorpropamide	O
+a	O
+similar	O
+sulphonylurea	O
+agent	O
+
+Risperidone-induced	O
+tardive	B-Adev
+dyskinesia	I-Adev
+	O
+
+Caution	O
+in	O
+longterm	O
+usage	O
+and	O
+early	O
+recognition	O
+of	O
+pentazocine	O
+toxicity	B-Adev
+as	O
+a	O
+neuromuscular	O
+complication	O
+are	O
+important	O
+in	O
+order	O
+to	O
+prevent	O
+irreversible	O
+drug-induced	O
+fibrous	O
+myopathy	O
+and	O
+localized	O
+neuropathy	O
+
+Based	O
+upon	O
+the	O
+observed	O
+fall	B-Adev
+of	I-Adev
+the	I-Adev
+filtration	I-Adev
+fraction	I-Adev
+the	I-Adev
+rise	I-Adev
+in	I-Adev
+the	I-Adev
+relative	I-Adev
+clearance	I-Adev
+of	I-Adev
+99Tc-dimercaptosuccinic	I-Adev
+acid	I-Adev
+and	I-Adev
+the	I-Adev
+increase	I-Adev
+in	I-Adev
+proteinuria	I-Adev
+	O
+we	O
+suggest	O
+that	O
+in	O
+this	O
+case	O
+the	O
+tubules	O
+and/or	O
+interstitium	O
+are	O
+the	O
+main	O
+targets	O
+for	O
+cyclosporine	O
+A	O
+nephrotoxicity	O
+
+Niacin	O
+maculopathy	B-Adev
+	O
+
+We	O
+report	O
+a	O
+case	O
+in	O
+which	O
+a	O
+potential	O
+drug	O
+interaction	O
+between	O
+clobazam	O
+and	O
+etravirine	O
+may	O
+have	O
+led	O
+to	O
+increased	B-Adev
+concentrations	I-Adev
+of	I-Adev
+clobazam	I-Adev
+and	I-Adev
+its	I-Adev
+pharmacologically	I-Adev
+active	I-Adev
+metabolite	I-Adev
+N-desmethylclobazam	I-Adev
+	O
+causing	O
+neurotoxic	O
+symptoms	O
+
+A	O
+review	O
+of	O
+the	O
+literature	O
+revealed	O
+two	O
+other	O
+cases	O
+of	O
+hepatic	B-Adev
+angiosarcoma	I-Adev
+in	O
+patients	O
+after	O
+long-term	O
+cyclophosphamide	O
+treatment	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+cutaneous	B-Adev
+leucocytoclastic	I-Adev
+vasculitis	I-Adev
+in	O
+which	O
+amphotericin	O
+B	O
+might	O
+presumably	O
+be	O
+the	O
+aetiological	O
+factor	O
+
+There	O
+have	O
+been	O
+numerous	O
+case	O
+reports	O
+of	O
+hyperglycemia	B-Adev
+with	O
+olanzapine	O
+in	O
+the	O
+literature	O
+but	O
+none	O
+reported	O
+hyperglycemia	O
+within	O
+days	O
+of	O
+initiation	O
+of	O
+the	O
+medication	O
+
+This	O
+case	O
+report	O
+describes	O
+two	O
+severe	O
+antiretroviral	O
+drug	O
+adverse	B-Adev
+reactions	I-Adev
+that	O
+occurred	O
+in	O
+the	O
+same	O
+patient	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+presenting	O
+with	O
+successive	B-Adev
+anaphylactic	I-Adev
+reaction	I-Adev
+and	I-Adev
+extra-pyramidal	I-Adev
+syndrome	I-Adev
+after	O
+treatment	O
+with	O
+thiethylperazine	O
+maleate	O
+(thiethylperazine)	O
+
+Renal	B-Adev
+failure	I-Adev
+associated	O
+with	O
+the	O
+use	O
+of	O
+dextran-40	O
+
+Acute	B-Adev
+lung	I-Adev
+injury	I-Adev
+associated	O
+with	O
+5-fluorouracil	O
+and	O
+oxaliplatinum	O
+combined	O
+chemotherapy	O
+
+Type	O
+II	O
+heparin-induced	O
+thrombocytopenia	B-Adev
+(HIT)	O
+is	O
+an	O
+immunological	O
+disorder	O
+characterized	O
+by	O
+antibodies	O
+to	O
+heparin-platelet	O
+factor	O
+4	O
+complexes	O
+and	O
+a	O
+high	O
+risk	O
+of	O
+thrombotic	O
+complications	O
+
+RESULTS	O
+Similar	O
+to	O
+previous	O
+findings	O
+of	O
+drug-induced	O
+vortex	O
+keratopathy	O
+atovaquone	O
+vortex	B-Adev
+keratopathy	I-Adev
+is	O
+presumably	O
+caused	O
+by	O
+its	O
+lipophilic	O
+properties	O
+
+Gangrene	B-Adev
+of	I-Adev
+the	I-Adev
+fingertips	I-Adev
+after	O
+bleomycin	O
+and	O
+methotrexate	O
+
+These	O
+cases	O
+demonstrate	O
+that	O
+CBZ	O
+can	O
+induce	O
+simple	B-Adev
+motor	I-Adev
+tics	I-Adev
+in	O
+children	O
+
+Esophageal	B-Adev
+spasm	I-Adev
+following	O
+propranolol	O
+overdose	O
+relieved	O
+by	O
+glucagon	O
+
+She	O
+was	O
+thus	O
+diagnosed	O
+as	O
+having	O
+AZ	B-Adev
+intoxication	I-Adev
+	O
+
+Severe	O
+rhabdomyolysis	O
+following	O
+massive	O
+ingestion	O
+of	O
+oolong	O
+tea	O
+caffeine	B-Adev
+intoxication	I-Adev
+with	I-Adev
+coexisting	I-Adev
+hyponatremia	I-Adev
+	O
+
+The	O
+ulcer	O
+did	O
+not	O
+respond	O
+to	O
+antibiotic	O
+treatment	O
+and	O
+healed	O
+shortly	O
+after	O
+withholding	O
+ATRA	O
+
+The	O
+ulcer	O
+did	O
+not	O
+respond	O
+to	O
+antibiotic	O
+treatment	O
+and	O
+healed	O
+shortly	O
+after	O
+withholding	O
+ATRA	O
+
+Gemfibrozil-warfarin	O
+drug	O
+interaction	O
+resulting	O
+in	O
+profound	B-Adev
+hypoprothrombinemia	I-Adev
+	O
+
+Drug-induced	O
+eosinophilia	B-Adev
+is	O
+a	O
+non-dose-dependent	O
+side	O
+effect	O
+of	O
+clozapine	O
+
+Vortex	B-Adev
+keratopathy	I-Adev
+associated	O
+with	O
+atovaquone	O
+
+DIAGNOSIS	O
+Sustained	B-Adev
+ventricular	I-Adev
+tachycardia	I-Adev
+possibly	O
+owing	O
+to	O
+thalidomide	O
+treatment	O
+
+In	O
+one	O
+instance	O
+a	O
+systemic	B-Adev
+hypoglycemic	I-Adev
+reaction	I-Adev
+resulting	I-Adev
+in	I-Adev
+head	I-Adev
+trauma	I-Adev
+and	I-Adev
+confusion	I-Adev
+ended	O
+in	O
+an	O
+emegency	O
+hospital	O
+admission	O
+following	O
+the	O
+substitution	O
+of	O
+acetohexamide	O
+for	O
+acetazolamide	O
+
+However	O
+an	O
+association	O
+of	O
+Ritalin	O
+with	O
+glaucoma	B-Adev
+has	O
+been	O
+reported	O
+
+After	O
+a	O
+two-month	O
+interruption	O
+of	O
+interferon	O
+administration	O
+natural	O
+interferon	O
+alpha	O
+was	O
+given	O
+but	O
+followed	O
+by	O
+another	O
+episode	O
+of	O
+the	O
+same	O
+neurological	B-Adev
+manifestations	I-Adev
+	O
+
+This	O
+article	O
+discusses	O
+the	O
+clinical	O
+manifestations	O
+of	O
+the	O
+serotonin	O
+syndrome	O
+and	O
+highlights	O
+reported	O
+cases	O
+of	O
+serotonin	B-Adev
+syndrome	I-Adev
+specifically	O
+related	O
+to	O
+an	O
+interaction	O
+between	O
+SSRIs	O
+and	O
+fentanyl	O
+a	O
+commonly	O
+used	O
+opioid	O
+in	O
+anesthesia	O
+practice	O
+
+While	O
+the	O
+mechanism	O
+of	O
+dextran-associated	O
+renal	B-Adev
+failure	I-Adev
+remains	O
+unsolved	O
+plasma	O
+exchange	O
+seems	O
+to	O
+be	O
+effective	O
+therapy	O
+
+While	O
+the	O
+mechanism	O
+of	O
+dextran-associated	O
+renal	O
+failure	O
+remains	O
+unsolved	O
+plasma	O
+exchange	O
+seems	O
+to	O
+be	O
+effective	O
+therapy	O
+
+The	O
+use	O
+of	O
+pamidronate	O
+for	O
+hypercalcemia	O
+secondary	O
+to	O
+acute	O
+vitamin	O
+D	O
+intoxication	O
+
+The	O
+use	O
+of	O
+pamidronate	O
+for	O
+hypercalcemia	B-Adev
+secondary	O
+to	O
+acute	O
+vitamin	O
+D	O
+intoxication	O
+
+Early	B-Adev
+overanticoagulation	I-Adev
+with	O
+acenocoumarol	O
+due	O
+to	O
+a	O
+genetic	O
+polymorphism	O
+of	O
+cytochrome	O
+P450	O
+CYP2C9	O
+
+We	O
+report	O
+an	O
+unusual	O
+pattern	O
+of	O
+supravenous	B-Adev
+hyperpigmentation	I-Adev
+occurring	O
+after	O
+CHOP	O
+chemotherapy	O
+
+Proton	O
+MRS	O
+examination	O
+demonstrated	O
+a	O
+persistent	B-Adev
+lactate	I-Adev
+elevation	I-Adev
+during	O
+metronidazole	O
+treatment	O
+
+Encephalopathy	B-Adev
+and	I-Adev
+seizures	I-Adev
+induced	O
+by	O
+intravesical	O
+alum	O
+irrigations	O
+
+Dermal	B-Adev
+side	I-Adev
+reactions	I-Adev
+to	O
+SSRI-drugs	O
+in	O
+these	O
+patients	O
+may	O
+be	O
+due	O
+to	O
+high	O
+activity	O
+in	O
+the	O
+serotonergic	O
+system	O
+at	O
+the	O
+dermal	O
+and	O
+epidermo-dermal	O
+junctional	O
+area	O
+rather	O
+than	O
+a	O
+hypersensitivity	O
+to	O
+the	O
+drug	O
+molecule	O
+itself	O
+
+CASE	O
+SUMMARY	O
+A	O
+febrile	O
+36-year-old	O
+seaman	O
+from	O
+Mumbai	O
+(Bombay)	O
+was	O
+prescribed	O
+>5	O
+times	O
+the	O
+usual	O
+dose	O
+of	O
+chloroquine	O
+for	O
+malaria	O
+diagnosed	O
+empirically	O
+onboard	O
+ship	O
+
+MATERIALS	O
+AND	O
+METHODS	O
+We	O
+present	O
+two	O
+cases	O
+of	O
+significant	B-Adev
+morbidity	I-Adev
+related	I-Adev
+to	I-Adev
+primary	I-Adev
+and	I-Adev
+secondary	I-Adev
+perforation	I-Adev
+of	I-Adev
+the	I-Adev
+bladder	I-Adev
+following	O
+two	O
+instillations	O
+of	O
+epirubicin	O
+
+Angio-oedema	B-Adev
+as	O
+an	O
+unusual	O
+tolerable	O
+side	O
+effect	O
+of	O
+voriconazole	O
+therapy	O
+
+Oxycodone-gabapentin	O
+reduced	O
+pain	O
+score	O
+by	O
+33%	O
+from	O
+baseline	O
+to	O
+end	O
+of	O
+treatment	O
+
+OBJECTIVE	O
+We	O
+report	O
+a	O
+patient	O
+who	O
+developed	O
+neutropenia	B-Adev
+on	O
+clozapine	O
+but	O
+behind	O
+the	O
+cell	O
+count	O
+decrease	O
+showed	O
+to	O
+be	O
+a	O
+diurnal	O
+variation	O
+of	O
+the	O
+white	O
+blood	O
+cells	O
+(WBC)	O
+
+RESULTS	O
+Five	O
+of	O
+70	O
+patients	O
+who	O
+had	O
+begun	O
+leflunomide	O
+therapy	O
+had	O
+significant	B-Adev
+weight	I-Adev
+loss	I-Adev
+that	O
+could	O
+not	O
+be	O
+linked	O
+to	O
+other	O
+identifiable	O
+etiologies	O
+
+Only	O
+one	O
+report	O
+links	O
+phenylpropanolamine	O
+consumption	O
+to	O
+an	O
+intracerebral	B-Adev
+hemorrhage	I-Adev
+in	O
+a	O
+patient	O
+with	O
+an	O
+AVM	O
+
+Anaphylactic	B-Adev
+reaction	I-Adev
+and	O
+unrelated	O
+subsequent	O
+known	O
+side	O
+effects	O
+during	O
+therapy	O
+with	O
+thiethylperazine	O
+
+PURPOSE	O
+To	O
+investigate	O
+the	O
+concentration-side	O
+effect	O
+relationship	O
+in	O
+a	O
+patient	O
+with	O
+severe	O
+acyclovir-induced	O
+neurotoxicity	B-Adev
+and	O
+to	O
+summarize	O
+the	O
+information	O
+available	O
+in	O
+the	O
+literature	O
+about	O
+central	O
+nervous	O
+system	O
+side	O
+effects	O
+due	O
+to	O
+acyclovir	O
+
+Radiation	B-Adev
+recall	I-Adev
+from	O
+gemcitabine	O
+is	O
+rare	O
+but	O
+can	O
+potentially	O
+arise	O
+in	O
+any	O
+site	O
+that	O
+has	O
+been	O
+previously	O
+irradiated	O
+
+Most	O
+cases	O
+of	O
+pancreatitis	B-Adev
+associated	O
+with	O
+L-asparaginase	O
+toxicity	O
+are	O
+self-limiting	O
+and	O
+respond	O
+favorably	O
+to	O
+nasogastric	O
+decompression	O
+and	O
+intravenous	O
+hyperalimentation	O
+
+Shortly	O
+after	O
+commencing	O
+the	O
+drug	O
+the	O
+patient	O
+developed	O
+a	O
+severe	B-Adev
+adverse	I-Adev
+drug	I-Adev
+reaction	I-Adev
+manifesting	I-Adev
+as	I-Adev
+Drug	I-Adev
+Reaction	I-Adev
+(or	I-Adev
+Rash)	I-Adev
+with	I-Adev
+Eosinophilia	I-Adev
+and	I-Adev
+Systemic	I-Adev
+Symptoms	I-Adev
+(DRESS)	I-Adev
+syndrome	I-Adev
+	O
+
+This	O
+report	O
+presents	O
+a	O
+potential	O
+case	O
+of	O
+risperidone-induced	O
+tardive	B-Adev
+dyskinesia	I-Adev
+	O
+
+The	O
+patient	O
+described	O
+feeling	B-Adev
+cold	I-Adev
+with	I-Adev
+worsening	I-Adev
+headache	I-Adev
+and	I-Adev
+chills	I-Adev
+approximately	O
+one	O
+hour	O
+after	O
+infusion	O
+of	O
+the	O
+first	O
+dose	O
+of	O
+penicillin	O
+
+Early-onset	B-Adev
+pentamidine-associated	O
+second-degree	O
+heart	O
+block	O
+and	O
+sinus	O
+bradycardia	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+Fatal	O
+pulmonary	B-Adev
+fibrosis	I-Adev
+associated	O
+with	O
+BCNU	O
+the	O
+relative	O
+role	O
+of	O
+platelet-derived	O
+growth	O
+factor-B	O
+insulin-like	O
+growth	O
+factor	O
+I	O
+transforming	O
+growth	O
+factor-beta1	O
+and	O
+cyclooxygenase-2	O
+
+CONCLUSIONS	O
+This	O
+case	O
+suggests	O
+that	O
+losartan	O
+can	O
+induce	O
+late-onset	B-Adev
+angioedema	I-Adev
+in	O
+patients	O
+with	O
+normal	O
+renal	O
+function	O
+and	O
+that	O
+the	O
+reaction	O
+can	O
+recur	O
+after	O
+initial	O
+resolution	O
+of	O
+the	O
+symptoms	O
+
+Two	O
+cases	O
+of	O
+widespread	B-Adev
+cutaneous	I-Adev
+vasculitis	I-Adev
+are	O
+described	O
+in	O
+association	O
+with	O
+diltiazem	O
+a	O
+recently	O
+introduced	O
+calcium	O
+antagonist	O
+
+The	O
+incidence	O
+of	O
+angioedema	B-Adev
+secondary	O
+to	O
+losartan	O
+an	O
+angiotensin	O
+II	O
+receptor	O
+antagonist	O
+is	O
+unknown	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+young	O
+man	O
+affected	O
+by	O
+rheumatoid	O
+arthritis	O
+who	O
+developed	O
+a	B-Adev
+rapid-onset	I-Adev
+short-of-breath	I-Adev
+hemoptysis	I-Adev
+and	I-Adev
+severe	I-Adev
+weakness	I-Adev
+	O
+about	O
+2	O
+weeks	O
+after	O
+the	O
+administration	O
+of	O
+leflunomide	O
+
+Toxicity	B-Adev
+related	O
+to	O
+chloroquine	O
+treatment	O
+of	O
+resistant	O
+vivax	O
+malaria	O
+
+Patients	O
+with	O
+vitamin	O
+B12	O
+deficiency	O
+are	O
+exceedingly	O
+sensitive	O
+to	O
+neurologic	B-Adev
+deterioration	I-Adev
+following	O
+nitrous	O
+oxide	O
+anesthesia	O
+
+However	O
+here	O
+we	O
+reported	O
+two	O
+patients	O
+presenting	O
+with	O
+PD	B-Adev
+during	O
+high	O
+dose	O
+colchicine	O
+treatment	O
+for	O
+familiar	O
+mediterranean	O
+fever	O
+(FMF)	O
+
+We	O
+report	O
+two	O
+patients	O
+with	O
+infectious	B-Adev
+mononucleosis-like	I-Adev
+syndrome	I-Adev
+induced	O
+by	O
+salazosulfapyridine	O
+(SASP)	O
+
+Myocardial	B-Adev
+ischemia	I-Adev
+associated	O
+with	O
+high-dose	O
+carmustine	O
+infusion	O
+
+Hepatic	B-Adev
+drug	I-Adev
+interaction	I-Adev
+between	O
+tacrolimus	O
+and	O
+lansoprazole	O
+in	O
+a	O
+bone	O
+marrow	O
+transplant	O
+patient	O
+receiving	O
+voriconazole	O
+and	O
+harboring	O
+CYP2C19	O
+and	O
+CYP3A5	O
+heterozygous	O
+mutations	O
+
+Gabapentin	O
+withdrawal	O
+presenting	O
+as	O
+status	B-Adev
+epilepticus	I-Adev
+	O
+
+Atypical	B-Adev
+ventricular	I-Adev
+tachycardia	I-Adev
+(torsade	I-Adev
+de	I-Adev
+pointes)	I-Adev
+induced	O
+by	O
+amiodarone	O
+arrhythmia	O
+previously	O
+induced	O
+by	O
+quinidine	O
+and	O
+disopyramide	O
+
+Colchicine-induced	O
+rhabdomyolysis	B-Adev
+is	O
+a	O
+rare	O
+complication	O
+and	O
+the	O
+postulated	O
+mechanisms	O
+and	O
+risk	O
+factors	O
+for	O
+this	O
+severe	O
+complication	O
+are	O
+discussed	O
+
+Spindle	B-Adev
+coma	I-Adev
+in	O
+benzodiazepine	O
+toxicity	O
+case	O
+report	O
+
+A	O
+typical	O
+case	O
+of	O
+dextran-40	O
+associated	O
+acute	B-Adev
+renal	I-Adev
+failure	I-Adev
+is	O
+presented	O
+
+After	O
+the	O
+second	O
+infliximab	O
+infusion	O
+he	O
+was	O
+found	O
+to	O
+have	O
+a	O
+severe	B-Adev
+transient	I-Adev
+neutropenia	I-Adev
+(0.5	I-Adev
+x	I-Adev
+10(9)/L)	I-Adev
+	O
+
+Lithium	O
+for	O
+irritability	O
+in	O
+post-traumatic	O
+stress	O
+disorder	O
+
+Iatrogenic	B-Adev
+hypercalcemia	I-Adev
+due	O
+to	O
+vitamin	O
+D3	O
+ointment	O
+(1,24(OH)2D3)	O
+combined	O
+with	O
+thiazide	O
+diuretics	O
+in	O
+a	O
+case	O
+of	O
+psoriasis	O
+
+A	O
+case	O
+of	O
+mania	B-Adev
+associated	O
+with	O
+fluoxetine	O
+
+RESULTS	O
+Extensive	B-Adev
+squamous	I-Adev
+metaplasia	I-Adev
+was	I-Adev
+found	I-Adev
+in	I-Adev
+endometrial	I-Adev
+glands	I-Adev
+following	O
+progestin	O
+therapy	O
+
+Acute	B-Adev
+generalized	I-Adev
+exanthematous	I-Adev
+pustulosis	I-Adev
+caused	O
+by	O
+morphine	O
+confirmed	O
+by	O
+positive	O
+patch	O
+test	O
+and	O
+lymphocyte	O
+transformation	O
+test	O
+
+Eleven	O
+days	O
+after	O
+initiation	O
+of	O
+therapy	O
+with	O
+amiodarone	O
+the	O
+patient	O
+experienced	O
+syncope	B-Adev
+and	I-Adev
+was	I-Adev
+noted	I-Adev
+to	I-Adev
+have	I-Adev
+recurrent	I-Adev
+episodes	I-Adev
+of	I-Adev
+polymorphous	I-Adev
+ventricular	I-Adev
+tachycardia	I-Adev
+	O
+
+Prolonged	O
+used	O
+of	O
+hydroxyurea	O
+in	O
+patients	O
+with	O
+ET	O
+may	O
+lead	O
+to	O
+therapy-associated	B-Adev
+acute	I-Adev
+leukemia	I-Adev
+	O
+
+Metastatic	B-Adev
+osteomyelitis	I-Adev
+following	O
+BCG	O
+vaccination	O
+
+Carbamyl	O
+phosphate	O
+synthetase-1	O
+deficiency	O
+discovered	O
+after	O
+valproic	O
+acid-induced	O
+coma	B-Adev
+	O
+
+We	O
+describe	O
+two	O
+patients	O
+in	O
+whom	O
+painful	B-Adev
+erosions	I-Adev
+of	I-Adev
+their	I-Adev
+psoriasis	I-Adev
+developed	O
+as	O
+the	O
+presenting	O
+sign	O
+of	O
+methotrexate	O
+toxicity	O
+and	O
+review	O
+the	O
+literature	O
+emphasizing	O
+the	O
+risk	O
+factors	O
+associated	O
+with	O
+this	O
+manifestation	O
+
+Methysergide-induced	O
+retroperitoneal	B-Adev
+fibrosis	I-Adev
+	O
+successful	O
+outcome	O
+and	O
+two	O
+new	O
+laboratory	O
+features	O
+
+We	O
+describe	O
+2	O
+children	O
+with	O
+cerebral	O
+palsy	O
+who	O
+suffered	O
+significant	B-Adev
+morbidity	I-Adev
+immediately	I-Adev
+after	O
+treatment	O
+with	O
+hyperbaric	O
+oxygen	O
+
+A	O
+patient	O
+is	O
+described	O
+with	O
+polycythemia	B-Adev
+vera	I-Adev
+who	O
+was	O
+taking	O
+anticoagulants	O
+and	O
+developed	O
+a	O
+spontaneous	O
+retropharyngeal	O
+hemorrhage	O
+after	O
+a	O
+violent	O
+sneezing	O
+episode	O
+
+CD4	B-Adev
+T-lymphocyte	I-Adev
+depletion	I-Adev
+myelosuppression	I-Adev
+and	I-Adev
+subsequent	I-Adev
+severe	I-Adev
+infections	I-Adev
+are	O
+the	O
+major	O
+side	O
+effects	O
+of	O
+fludarabine	O
+phosphate	O
+therapy	O
+
+Penicillin-induced	O
+Jarisch-Herxheimer	B-Adev
+reaction	I-Adev
+	O
+
+The	O
+authors	O
+suggest	O
+that	O
+risperidone	O
+may	O
+increase	B-Adev
+affect	I-Adev
+in	O
+patients	O
+with	O
+schizophrenia	O
+and	O
+that	O
+some	O
+patients	O
+especially	O
+those	O
+with	O
+anxiety	O
+may	O
+have	O
+difficulty	O
+managing	O
+the	O
+increase	O
+
+We	O
+cared	O
+for	O
+a	O
+patient	O
+with	O
+progressive	O
+renal	O
+impairment	O
+who	O
+presented	O
+with	O
+blurred	B-Adev
+vision	I-Adev
+QRS	I-Adev
+broadening	I-Adev
+and	I-Adev
+cardiac	I-Adev
+failure	I-Adev
+due	O
+to	O
+chronic	O
+cibenzoline	O
+intoxication	O
+
+In	O
+a	O
+postoperative	O
+patient	O
+with	O
+pre-existent	O
+myasthenia	O
+gravis	O
+oral	O
+verapamil	O
+caused	O
+a	O
+marked	B-Adev
+exacerbation	I-Adev
+in	I-Adev
+myasthenic	I-Adev
+weakness	I-Adev
+	O
+
+An	O
+objective	O
+causality	O
+assessment	O
+suggests	O
+that	O
+the	O
+JHR	B-Adev
+in	O
+our	O
+patient	O
+was	O
+probably	O
+related	O
+to	O
+penicillin	O
+
+RESULTS	O
+A	O
+34-year-old	O
+man	O
+acquired	O
+visual	B-Adev
+field	I-Adev
+defects	I-Adev
+and	I-Adev
+severe	I-Adev
+vision	I-Adev
+loss	I-Adev
+in	I-Adev
+both	I-Adev
+eyes	I-Adev
+after	O
+intravitreal	O
+injection	O
+of	O
+triamcinolone	O
+for	O
+diabetic	O
+macular	O
+edema	O
+
+Simvastatin-amiodarone	O
+interaction	O
+resulting	O
+in	O
+rhabdomyolysis	B-Adev
+azotemia	I-Adev
+and	I-Adev
+possible	I-Adev
+hepatotoxicity	I-Adev
+	O
+
+A	O
+73-year-old	O
+woman	O
+receiving	O
+high-dosage	O
+olanzapine	O
+for	O
+bipolar	O
+disorder	O
+developed	O
+parkinsonism	B-Adev
+after	O
+smoking	O
+cessation	O
+
+Fatal	O
+pulmonary	B-Adev
+fibrosis	I-Adev
+induced	O
+by	O
+paclitaxel	O
+a	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+Raltegravir-induced	O
+Drug	O
+Reaction	O
+with	O
+Eosinophilia	B-Adev
+and	I-Adev
+Systemic	I-Adev
+Symptoms	I-Adev
+(DRESS)	I-Adev
+syndrome	I-Adev
+-	O
+implications	O
+for	O
+clinical	O
+practice	O
+and	O
+patient	O
+safety	O
+
+A	O
+10-year-old	O
+boy	O
+with	O
+osteosarcoma	O
+and	O
+normal	O
+renal	O
+function	O
+manifested	O
+laboratory	O
+evidence	O
+of	O
+[['impending	B-Adev
+renal	I-Adev
+toxicity	I-Adev
+and	I-Adev
+extreme	I-Adev
+elevation	I-Adev
+of	I-Adev
+aspartate	I-Adev
+aminotrasferase	I-Adev
+and	I-Adev
+alanine	I-Adev
+aminotransferase']	I-Adev
+['acute	I-Adev
+renal	I-Adev
+failure	I-Adev
+with	I-Adev
+life-threatening	I-Adev
+hyperkalemia	I-Adev
+29	I-Adev
+hours	I-Adev
+later']]	I-Adev
+pending	O
+renal	O
+toxicity	O
+and	O
+extreme	O
+elevation	O
+of	O
+aspartate	O
+aminotrasferase	O
+and	O
+alanine	O
+aminotransferase	O
+within	O
+2	O
+hours	O
+after	O
+the	O
+completion	O
+of	O
+a	O
+4-hour	O
+infusion	O
+of	O
+high-dose	O
+methotrexate	O
+(MTX)	O
+(12	O
+g/m2)	O
+and	O
+went	O
+on	O
+to	O
+develop	O
+acute	O
+renal	O
+failure	O
+with	O
+life-threatening	O
+hyperkalemia	O
+29	O
+hours	O
+later	O
+
+Transient	O
+trazodone-induced	O
+hypomanic	B-Adev
+symptoms	I-Adev
+occurred	O
+in	O
+three	O
+depressed	O
+patients	O
+
+We	O
+describe	O
+a	O
+case	O
+of	O
+disseminated	B-Adev
+muscular	I-Adev
+cysticercosis	I-Adev
+followed	I-Adev
+by	I-Adev
+myositis	I-Adev
+(fever	I-Adev
+diffuse	I-Adev
+myalgia	I-Adev
+weakness	I-Adev
+of	I-Adev
+the	I-Adev
+lower	I-Adev
+limbs	I-Adev
+and	I-Adev
+inflammatory	I-Adev
+reaction	I-Adev
+around	I-Adev
+dying	I-Adev
+cysticerci)	I-Adev
+induced	O
+by	O
+praziquantel	O
+therapy	O
+an	O
+event	O
+not	O
+described	O
+previously	O
+
+Drug-induced	O
+[['fever']	B-Adev
+['unexplained	I-Adev
+high	I-Adev
+temperatures']]	I-Adev
+ver	O
+should	O
+be	O
+considered	O
+in	O
+patients	O
+who	O
+have	O
+unexplained	O
+high	O
+temperatures	O
+during	O
+diltiazem	O
+therapy	O
+
+Hemodialysis	O
+was	O
+also	O
+shown	O
+to	O
+reverse	O
+ifosfamide-related	O
+neurotoxicity	B-Adev
+	O
+
+Hemodialysis	O
+was	O
+also	O
+shown	O
+to	O
+reverse	O
+ifosfamide-related	O
+neurotoxicity	O
+
+Palpable	B-Adev
+purpuric	I-Adev
+skin	I-Adev
+lesions	I-Adev
+on	I-Adev
+the	I-Adev
+anterior	I-Adev
+surface	I-Adev
+of	I-Adev
+both	I-Adev
+legs	I-Adev
+appeared	O
+on	O
+the	O
+55th	O
+day	O
+of	O
+amphotericin	O
+B	O
+treatment	O
+
+Transient	B-Adev
+left	I-Adev
+homonymous	I-Adev
+hemianopsia	I-Adev
+and	I-Adev
+encephalopathy	I-Adev
+following	O
+treatment	O
+of	O
+testicular	O
+carcinoma	O
+with	O
+cisplatinum	O
+vinblastine	O
+and	O
+bleomycin	O
+
+We	O
+report	O
+a	O
+46-yr-old	O
+woman	O
+with	O
+ovarian	O
+carcinoma	O
+who	O
+developed	O
+porphyria	B-Adev
+cutanea	I-Adev
+tarda	I-Adev
+while	O
+undergoing	O
+treatment	O
+with	O
+cisplatin	O
+and	O
+cyclophosphamide	O
+
+In	O
+one	O
+child	O
+a	O
+second	O
+course	O
+of	O
+carbamazepine	O
+resulted	O
+in	O
+a	B-Adev
+return	I-Adev
+of	I-Adev
+the	I-Adev
+dystonia	I-Adev
+	O
+
+Does	O
+acyclovir	O
+increase	O
+serum	B-Adev
+lithium	I-Adev
+levels	I-Adev
+?	O
+
+Sulfadiazine	O
+crystalluria	B-Adev
+revisited	O
+
+Administration	O
+of	O
+sumatriptan	O
+in	O
+subarachnoid	O
+haemorrhage	O
+(SAH)	O
+patients	O
+misdiagnosed	O
+as	O
+migraine	O
+patients	O
+may	O
+induce	O
+symptomatic	B-Adev
+cerebral	I-Adev
+vasospasm	I-Adev
+with	O
+potentially	O
+dangerous	O
+consequences	O
+
+Six	O
+of	O
+13	O
+outpatients	O
+with	O
+schizophrenia	O
+who	O
+participated	O
+in	O
+a	O
+ten-week	O
+open	O
+trial	O
+of	O
+risperidone	O
+had	O
+an	O
+initial	O
+good	O
+response	O
+to	O
+the	O
+medication	O
+followed	O
+by	O
+development	O
+of	O
+intolerable	B-Adev
+affect	I-Adev
+including	I-Adev
+feelings	I-Adev
+of	I-Adev
+agitation	I-Adev
+and	I-Adev
+depression	I-Adev
+and	I-Adev
+periods	I-Adev
+of	I-Adev
+crying	I-Adev
+and	I-Adev
+insomnia	I-Adev
+	O
+
+Pulmonary	O
+edema	O
+during	O
+acute	O
+infusion	O
+of	O
+epoprostenol	O
+in	O
+a	O
+patient	O
+with	O
+pulmonary	O
+hypertension	O
+and	O
+limited	O
+scleroderma	O
+
+Recent	O
+reports	O
+have	O
+shown	O
+that	O
+Decadron	O
+(dexamethasone	O
+Merck	O
+Sharp	O
+&	O
+Dohme	O
+West	O
+Point	O
+Pa)	O
+has	O
+a	O
+significant	O
+antiemetic	O
+effect	O
+on	O
+cisplatin-induced	O
+vomiting	O
+
+Pleuropulmonary	B-Adev
+fibrosis	I-Adev
+after	O
+long-term	O
+treatment	O
+with	O
+the	O
+dopamine	O
+agonist	O
+pergolide	O
+for	O
+Parkinson	O
+Disease	O
+
+An	O
+infertile	O
+patient	O
+with	O
+amenorrhea-galactorrhea	O
+syndrome	O
+lost	B-Adev
+vision	I-Adev
+during	O
+a	O
+pregnancy	O
+occurring	O
+after	O
+Bromocryptine	O
+treatment	O
+
+CONCLUSIONS	O
+The	O
+observation	O
+that	O
+neurotoxicity	B-Adev
+developed	O
+with	O
+a	O
+delay	O
+of	O
+24	O
+to	O
+48	O
+hours	O
+after	O
+acyclovir	O
+peak	O
+serum	O
+concentrations	O
+could	O
+explain	O
+the	O
+wide	O
+range	O
+of	O
+acyclovir	O
+levels	O
+reported	O
+in	O
+similar	O
+cases	O
+
+Two	O
+cases	O
+of	O
+mequitazine-induced	O
+photosensitivity	B-Adev
+reactions	I-Adev
+	O
+
+Rhabdomyolysis	B-Adev
+associated	O
+with	O
+clozapine	O
+treatment	O
+in	O
+a	O
+patient	O
+with	O
+decreased	O
+calcium-dependent	O
+potassium	O
+permeability	O
+of	O
+cell	O
+membranes	O
+
+A	O
+47	O
+year-old	O
+woman	O
+who	O
+had	O
+a	O
+4-year	O
+history	O
+of	O
+intramuscular	O
+pentazocine	O
+injections	O
+in	O
+the	O
+lower	O
+extremities	O
+developed	O
+gradual	B-Adev
+stiffness	I-Adev
+and	I-Adev
+weakness	I-Adev
+of	I-Adev
+the	I-Adev
+lower	I-Adev
+extremities	I-Adev
+	O
+
+The	O
+possibility	O
+of	O
+severe	B-Adev
+rhabdomyolysis	I-Adev
+should	O
+be	O
+considered	O
+in	O
+a	O
+patient	O
+with	O
+water	O
+intoxication	O
+due	O
+to	O
+massive	O
+ingestion	O
+of	O
+caffeine-containing	O
+beverages	O
+
+CASE	O
+SUMMARY	O
+A	O
+25-year-old	O
+postpartum	O
+white	O
+woman	O
+developed	O
+multiple	B-Adev
+watery	I-Adev
+stools	I-Adev
+and	I-Adev
+abdominal	I-Adev
+cramping	I-Adev
+on	O
+day	O
+6	O
+of	O
+therapy	O
+with	O
+clindamycin	O
+vaginal	O
+cream	O
+for	O
+bacterial	O
+vaginosis	O
+
+Dose-dependent	O
+olanzapine-associated	O
+leukopenia	B-Adev
+	O
+three	O
+case	O
+reports	O
+
+He	O
+became	O
+completely	O
+premorbid	B-Adev
+2	O
+weeks	O
+after	O
+administration	O
+of	O
+levodopa	O
+
+The	O
+authors	O
+describe	O
+a	O
+case	O
+of	O
+interstitial	B-Adev
+granulomatous	I-Adev
+dermatitis	I-Adev
+associated	O
+with	O
+darifenacin	O
+
+Amiodarone	O
+was	O
+the	O
+third	O
+drug	O
+to	O
+induce	O
+AVT	B-Adev
+in	O
+this	O
+patient	O
+she	O
+received	O
+200	O
+mg/day	O
+six	O
+days	O
+per	O
+week	O
+for	O
+six	O
+months	O
+
+A	O
+young	O
+diamond	O
+dealer	O
+developed	O
+visual	B-Adev
+impairment	I-Adev
+attributed	I-Adev
+to	I-Adev
+bilateral	I-Adev
+posterior	I-Adev
+subcapsular	I-Adev
+cataracts	I-Adev
+following	O
+only	O
+four	O
+courses	O
+of	O
+intermittent	O
+Decadron	O
+used	O
+as	O
+part	O
+of	O
+a	O
+five-drug	O
+antiemetic	O
+regimen	O
+for	O
+cisplatin-associated	O
+nausea	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+angioedema	B-Adev
+associated	O
+with	O
+losartan	O
+administration	O
+
+The	O
+authors	O
+present	O
+a	O
+case	O
+report	O
+of	O
+a	O
+[['granulomatous	B-Adev
+reaction']	I-Adev
+['urethral	I-Adev
+prolapse']]	I-Adev
+anulomatous	O
+reaction	O
+leading	O
+to	O
+urethral	O
+prolapse	O
+3	O
+months	O
+after	O
+the	O
+transurethral	O
+injection	O
+of	O
+calcium	O
+hydroxylapatite	O
+
+Epstein-Barr	B-Adev
+virus-associated	I-Adev
+lymphoproliferative	I-Adev
+disorder	I-Adev
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+on	O
+methotrexate	O
+and	O
+rofecoxib	O
+idiosyncratic	O
+reaction	O
+or	O
+pharmacogenetics?	O
+
+On	O
+the	O
+other	O
+hand	O
+aspirin	O
+may	O
+have	O
+promoted	O
+the	O
+enlargement	B-Adev
+of	I-Adev
+spontaneous	I-Adev
+hemorrhage	I-Adev
+from	I-Adev
+meningioma	I-Adev
+	O
+
+The	O
+two	O
+groups	O
+did	O
+not	O
+differ	O
+significantly	O
+in	O
+the	O
+rate	O
+of	O
+serious	O
+adverse	O
+events	O
+though	O
+the	O
+risk	B-Adev
+of	I-Adev
+diarrhea	I-Adev
+was	I-Adev
+increased	I-Adev
+with	O
+omeprazole	O
+
+Treatment	O
+of	O
+a	O
+patient	O
+with	O
+severe	O
+digitoxin	O
+intoxication	O
+by	O
+Fab	O
+fragments	O
+of	O
+anti-digitalis	O
+antibodies	O
+
+Development	O
+of	O
+porphyria	B-Adev
+cutanea	I-Adev
+tarda	I-Adev
+after	O
+treatment	O
+with	O
+cyclophosphamide	O
+
+We	O
+report	O
+a	O
+premature	O
+infant	O
+who	O
+developed	O
+seizures	B-Adev
+associated	O
+with	O
+intraventricular	O
+administration	O
+of	O
+nafcillin	O
+and	O
+discuss	O
+the	O
+need	O
+for	O
+electroencephalographic	O
+monitoring	O
+of	O
+patients	O
+receiving	O
+intraventricular	O
+antibiotics	O
+
+OBJECTIVE	O
+To	O
+present	O
+a	O
+single	O
+case	O
+of	O
+zuclopenthixol-induced	O
+priapism	B-Adev
+and	O
+a	O
+literature	O
+review	O
+
+CASE	O
+REPORT	O
+We	O
+hereby	O
+report	O
+a	O
+case	O
+of	O
+radiation	B-Adev
+recall	I-Adev
+dermatitis	I-Adev
+and	I-Adev
+myositis	I-Adev
+occurring	O
+on	O
+gemcitabine	O
+monotherapy	O
+five	O
+months	O
+after	O
+completing	O
+chemoradiation	O
+for	O
+locally	O
+advanced	O
+pancreatic	O
+cancer	O
+
+Stroke-like	O
+syndrome	O
+after	O
+gold	O
+sodium	O
+thiomalate	O
+induced	O
+vasomotor	B-Adev
+reaction	I-Adev
+	O
+
+MTX-induced	O
+hepatic	B-Adev
+injury	I-Adev
+and	I-Adev
+liver	I-Adev
+enzyme	I-Adev
+elevations	I-Adev
+have	O
+been	O
+demonstrated	O
+after	O
+treatment	O
+of	O
+leukemia	O
+gestational	O
+disease	O
+and	O
+during	O
+treatment	O
+of	O
+psoriasis	O
+and	O
+rheumatoid	O
+arthritis	O
+
+MTX-induced	O
+hepatic	O
+injury	O
+and	O
+liver	O
+enzyme	O
+elevations	O
+have	O
+been	O
+demonstrated	O
+after	O
+treatment	O
+of	O
+leukemia	O
+gestational	O
+disease	O
+and	O
+during	O
+treatment	O
+of	O
+psoriasis	O
+and	O
+rheumatoid	O
+arthritis	O
+
+An	B-Adev
+adverse	I-Adev
+drug	I-Adev
+reaction	I-Adev
+(ADR)	I-Adev
+induced	O
+by	O
+fluoxetine	O
+was	O
+suspected	O
+and	O
+fluoxetine	O
+treatment	O
+was	O
+discontinued	O
+
+New	B-Adev
+onset	I-Adev
+of	I-Adev
+Crohn's	I-Adev
+disease	I-Adev
+during	O
+treatment	O
+of	O
+active	O
+ankylosing	O
+spondylitis	O
+with	O
+etanercept	O
+
+Fatal	B-Adev
+hepatitis	I-Adev
+after	O
+long-term	O
+pulse	O
+itraconazole	O
+treatment	O
+for	O
+onychomycosis	O
+
+Fatal	O
+outcome	O
+of	O
+intravesical	O
+formalin	O
+instillation	O
+with	B-Adev
+changes	I-Adev
+mimicking	I-Adev
+renal	I-Adev
+tuberculosis	I-Adev
+	O
+
+Both	O
+reactions	O
+were	O
+caused	O
+due	O
+to	O
+this	O
+anti-emetic	O
+drug	O
+but	O
+an	O
+additive	B-Adev
+effect	I-Adev
+of	O
+clemastine	O
+fumarate	O
+prescribed	O
+to	O
+treat	O
+the	O
+anaphylactic	O
+reaction	O
+is	O
+suggested	O
+by	O
+the	O
+sequence	O
+of	O
+events	O
+
+Reversible	O
+posterior	O
+leukoencephalopathy	O
+syndrome	O
+in	O
+systemic	O
+lupus	O
+erythematosus	O
+with	O
+thrombocytopenia	O
+treated	O
+with	O
+cyclosporine	O
+
+Among	O
+patients	O
+receiving	O
+aspirin	O
+and	O
+clopidogrel	O
+prophylactic	O
+use	O
+of	O
+a	O
+PPI	O
+reduced	O
+the	O
+rate	O
+of	O
+upper	O
+gastrointestinal	O
+bleeding	O
+
+Clofazimine	O
+enteropathy	B-Adev
+in	O
+a	O
+pediatric	O
+bone	O
+marrow	O
+transplant	O
+recipient	O
+
+Anisocoria	B-Adev
+from	O
+transdermal	O
+scopolamine	O
+
+His	O
+fever	O
+resolved	O
+but	O
+he	O
+developed	O
+symptoms	B-Adev
+consistent	I-Adev
+with	I-Adev
+those	I-Adev
+of	I-Adev
+chloroquine	I-Adev
+toxicity	I-Adev
+	O
+
+A	O
+36-year-old	O
+man	O
+being	O
+treated	O
+with	O
+cisplatinum	O
+vinblastine	O
+and	O
+bleomycin	O
+for	O
+testicular	O
+carcinoma	O
+developed	O
+a	O
+dense	B-Adev
+left	I-Adev
+homonymous	I-Adev
+hemianopsia	I-Adev
+encephalopathy	I-Adev
+and	I-Adev
+a	I-Adev
+partial	I-Adev
+nondominant	I-Adev
+parietal	I-Adev
+lobe	I-Adev
+syndrome	I-Adev
+	O
+
+We	O
+report	O
+the	O
+first	O
+death	B-Adev
+associated	I-Adev
+with	I-Adev
+rhabdomyolysis	I-Adev
+in	O
+a	O
+patient	O
+treated	O
+with	O
+a	O
+statin	O
+and	O
+a	O
+protease	O
+inhibitor	O
+which	O
+produced	O
+a	O
+significant	O
+drug-drug	O
+interaction	O
+
+Methotrexate	O
+(MTX)	O
+is	O
+a	O
+commonly	O
+used	O
+second	O
+line	O
+agent	O
+for	O
+RA	O
+and	O
+there	O
+have	O
+been	O
+several	O
+recent	O
+reports	O
+of	O
+Epstein-Barr	B-Adev
+virus	I-Adev
+(EBV)-associated	I-Adev
+polyclonal	I-Adev
+B	I-Adev
+cell	I-Adev
+lymphoproliferative	I-Adev
+disorder	I-Adev
+in	O
+MTX-treated	O
+RA	O
+patients	O
+
+To	O
+describe	O
+a	O
+case	O
+of	O
+azathioprine-induced	O
+warfarin	B-Adev
+resistance	I-Adev
+	O
+present	O
+a	O
+literature	O
+review	O
+on	O
+warfarin-azathioprine	O
+interactions	O
+and	O
+provide	O
+recommendations	O
+on	O
+appropriate	O
+management	O
+of	O
+this	O
+clinically	O
+significant	O
+interaction	O
+
+Pulmonary	B-Adev
+fibrosis	I-Adev
+is	O
+a	O
+complication	O
+of	O
+paclitaxel	O
+therapy	O
+that	O
+may	O
+occur	O
+despite	O
+treatments	O
+with	O
+corticosteroids	O
+
+Two	O
+patients	O
+with	O
+adrenal	O
+carcinoma	O
+treated	O
+with	O
+2,2-bis	O
+(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane	O
+(o,p'-DDD)	O
+as	O
+adjuvant	O
+therapy	O
+were	O
+studied	O
+
+METHODS	O
+Repeated	O
+blood	O
+samples	O
+were	O
+drawn	O
+in	O
+a	O
+patient	O
+with	O
+severe	O
+acyclovir	O
+overdose	O
+who	O
+developed	O
+coma	B-Adev
+and	I-Adev
+nonoliguric	I-Adev
+renal	I-Adev
+failure	I-Adev
+	O
+
+An	O
+8-year-old	O
+girl	O
+who	O
+had	O
+been	O
+vaccinated	O
+with	O
+BCG	O
+without	O
+subsequent	O
+regional	O
+reactions	O
+developed	O
+osteomyelitis	B-Adev
+in	O
+the	O
+left	O
+calcaneus	O
+7	O
+months	O
+later	O
+
+Since	O
+this	O
+amount	O
+of	O
+FAB	O
+was	O
+insufficient	O
+to	O
+bind	O
+all	O
+DGTX	O
+present	O
+in	O
+the	O
+serum	O
+cardiac	B-Adev
+DGTX	I-Adev
+toxicity	I-Adev
+(total	I-Adev
+AV-block)	I-Adev
+persisted	O
+
+Abnormalities	O
+of	O
+the	O
+pupil	O
+and	O
+visual-evoked	O
+potential	O
+in	O
+quinine	O
+amblyopia	B-Adev
+	O
+
+A	O
+case	O
+is	O
+reported	O
+in	O
+which	O
+severe	B-Adev
+hypocalcemia	I-Adev
+with	I-Adev
+a	I-Adev
+low	I-Adev
+plasma	I-Adev
+parathyroid	I-Adev
+hormone	I-Adev
+(PTH)	I-Adev
+concentration	I-Adev
+	O
+resulted	O
+from	O
+the	O
+therapeutic	O
+use	O
+of	O
+magnesium	O
+sulfate	O
+for	O
+toxemia	O
+of	O
+pregnancy	O
+
+Concurrent	B-Adev
+acute	I-Adev
+megaloblastic	I-Adev
+anaemia	I-Adev
+and	I-Adev
+pneumonitis	I-Adev
+	O
+a	O
+severe	O
+side-effect	O
+of	O
+low-dose	O
+methotrexate	O
+therapy	O
+during	O
+rheumatoid	O
+arthritis	O
+
+Patients	O
+should	O
+be	O
+informed	O
+about	O
+the	O
+risk	O
+of	O
+osteonecrosis	B-Adev
+when	O
+taking	O
+dexamethasone	O
+as	O
+an	O
+antiemetic	O
+drug	O
+
+We	O
+report	O
+a	O
+patient	O
+with	O
+inoperable	O
+pancreatic	O
+cancer	O
+who	O
+developed	O
+gastrointestinal	B-Adev
+bleeding	I-Adev
+secondary	O
+to	O
+radiation-recall	O
+related	O
+to	O
+gemcitabine	O
+and	O
+review	O
+literature	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+SJS	B-Adev
+in	O
+a	O
+14-year-old	O
+male	O
+with	O
+nephrotic	O
+syndrome	O
+who	O
+was	O
+treated	O
+with	O
+oral	O
+prednisolone	O
+for	O
+6	O
+weeks	O
+
+A	O
+45-year-old	O
+woman	O
+with	O
+thyrotoxicosis	O
+developed	O
+agranulocytosis	B-Adev
+after	O
+treatment	O
+with	O
+propylthiouracil	O
+
+We	O
+wish	O
+to	O
+call	O
+for	O
+cautious	O
+approach	O
+at	O
+time	O
+of	O
+cessation	O
+of	O
+prolonged	O
+ACTH	O
+therapy	O
+because	O
+of	O
+possible	O
+unexpected	O
+and	O
+only	O
+partially	O
+understood	O
+hazardous	O
+side	O
+effects	O
+such	O
+as	O
+hyperkalemia	B-Adev
+	O
+
+Haemolytic-uraemic	B-Adev
+syndrome	I-Adev
+complicating	O
+long-term	O
+mitomycin	O
+C	O
+and	O
+5-fluorouracil	O
+therapy	O
+for	O
+gastric	O
+carcinoma	O
+
+Although	O
+this	O
+article	O
+focuses	O
+on	O
+serotonin	B-Adev
+syndrome	I-Adev
+as	O
+a	O
+result	O
+of	O
+an	O
+adverse	O
+interaction	O
+of	O
+selective	O
+serotonin	O
+reuptake	O
+inhibitors	O
+(SSRI)	O
+and	O
+fentanyl	O
+it	O
+is	O
+important	O
+for	O
+not	O
+only	O
+anesthesia	O
+professionals	O
+but	O
+all	O
+clinicians--such	O
+as	O
+those	O
+in	O
+emergency	O
+medicine	O
+and	O
+critical	O
+care--to	O
+be	O
+aware	O
+of	O
+this	O
+syndrome	O
+and	O
+its	O
+management	O
+
+Intrahepatic	B-Adev
+cholestasis	I-Adev
+and	I-Adev
+cutaneous	I-Adev
+bullae	I-Adev
+associated	O
+with	O
+glibenclamide	O
+therapy	O
+are	O
+described	O
+in	O
+a	O
+61-year-old	O
+diabetic	O
+patient	O
+who	O
+presented	O
+wit	O
+hypoglycaemic	O
+coma	O
+
+In	O
+the	O
+presented	O
+case	O
+the	O
+temporal	O
+relationship	O
+between	O
+the	O
+administration	O
+of	O
+cloxacillin	O
+and	O
+increased	O
+INR	O
+suggests	O
+that	O
+the	O
+cloxacillin	O
+was	O
+responsible	O
+for	O
+the	O
+[['enhanced	B-Adev
+warfarin	I-Adev
+activity.']	I-Adev
+['increased	I-Adev
+INR']]	I-Adev
+hanced	O
+warfarin	O
+activity	O
+
+Cardiac	B-Adev
+arrest	I-Adev
+following	O
+use	O
+of	O
+sumatriptan	O
+
+We	O
+report	O
+four	O
+cases	O
+of	O
+encephalopathy	O
+coincident	O
+with	O
+elevated	O
+aluminum	O
+levels	O
+as	O
+well	O
+as	O
+one	O
+patient	O
+who	O
+developed	O
+seizures	B-Adev
+while	O
+receiving	O
+continuous	O
+bladder	O
+irrigations	O
+with	O
+alum	O
+
+Nine	O
+azotemic	O
+patients	O
+who	O
+developed	O
+a	O
+coagulopathy	B-Adev
+associated	O
+with	O
+the	O
+use	O
+of	O
+either	O
+cephalosporin	O
+or	O
+moxalactam	O
+antibiotics	O
+are	O
+reported	O
+
+This	O
+report	O
+suggests	O
+that	O
+the	O
+poor	B-Adev
+prognosis	I-Adev
+previously	O
+given	O
+to	O
+fetuses	O
+exposed	O
+to	O
+disulfiram	O
+in	O
+the	O
+first	O
+trimester	O
+may	O
+not	O
+be	O
+warranted	O
+
+We	O
+hypothesize	O
+that	O
+caffeine	O
+toxicity	O
+injured	O
+the	O
+muscle	B-Adev
+cells	I-Adev
+which	I-Adev
+were	I-Adev
+fragile	I-Adev
+due	I-Adev
+to	I-Adev
+the	I-Adev
+potassium	I-Adev
+depletion	I-Adev
+induced	I-Adev
+by	I-Adev
+the	I-Adev
+coexisting	I-Adev
+hyponatremia	I-Adev
+to	I-Adev
+result	I-Adev
+in	I-Adev
+unusually	I-Adev
+severe	I-Adev
+rhabdomyolysis	I-Adev
+	O
+
+The	O
+aim	O
+of	O
+this	O
+paper	O
+is	O
+to	O
+report	O
+the	O
+case	O
+of	O
+rosaceiform	B-Adev
+eruption	I-Adev
+induced	O
+by	O
+erlotinib	O
+in	O
+an	O
+81-year-old-man	O
+and	O
+to	O
+discuss	O
+the	O
+pathogenetic	O
+role	O
+of	O
+Demodex	O
+folliculorum	O
+mites	O
+found	O
+in	O
+the	O
+present	O
+patient	O
+using	O
+skin	O
+scraping	O
+
+An	O
+11-year-old	O
+boy	O
+developed	O
+a	O
+severe	B-Adev
+enteropathy	I-Adev
+2	O
+years	O
+after	O
+initiation	O
+of	O
+clofazimine	O
+treatment	O
+for	O
+graft-versus-host	O
+disease	O
+
+The	O
+authors	O
+conclude	O
+that	O
+among	O
+patients	O
+taking	O
+high	O
+doses	O
+of	O
+oral	O
+niacin	O
+only	O
+those	O
+who	O
+experience	O
+visual	B-Adev
+symptoms	I-Adev
+need	O
+to	O
+be	O
+ophthalmologically	O
+evaluated	O
+
+Reflex	B-Adev
+sympathetic	I-Adev
+dystrophy	I-Adev
+syndrome	I-Adev
+in	O
+renal	O
+transplanted	O
+patients	O
+under	O
+immunosuppression	O
+with	O
+tacrolimus	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+an	O
+11-year-old	O
+female	O
+treated	O
+for	O
+mediastinal	O
+T-cell	O
+lymphoma	O
+who	O
+presented	O
+renal	B-Adev
+failure	I-Adev
+following	O
+the	O
+second	O
+cycle	O
+of	O
+high-dose	O
+methotrexate	O
+(HDMTX)	O
+
+We	O
+report	O
+three	O
+cases	O
+of	O
+patients	O
+who	O
+developed	O
+leukopenia	B-Adev
+during	O
+olanzapine	O
+treatment	O
+
+Rapid	B-Adev
+onset	I-Adev
+of	I-Adev
+muscle	I-Adev
+weakness	I-Adev
+(rhabdomyolysis)	I-Adev
+associated	O
+with	O
+the	O
+combined	O
+use	O
+of	O
+simvastatin	O
+and	O
+colchicine	O
+
+A	O
+35-year-old	O
+man	O
+with	O
+seropositive	O
+rheumatoid	O
+arthritis	O
+developed	O
+selective	B-Adev
+IgA	I-Adev
+deficiency	I-Adev
+during	O
+treatment	O
+with	O
+fenclofenac	O
+
+In	O
+this	O
+report	O
+two	O
+newborns	O
+with	O
+congenital	O
+heart	O
+anomalies	O
+demonstrated	O
+the	O
+harlequin	B-Adev
+color	I-Adev
+change	I-Adev
+	O
+one	O
+whose	O
+skin	O
+findings	O
+showed	O
+a	O
+course	O
+related	O
+to	O
+the	O
+dose	O
+of	O
+systemic	O
+prostaglandin	O
+E1	O
+suggesting	O
+a	O
+possible	O
+association	O
+
+Nonspecific	O
+but	O
+significant	O
+abnormalities	B-Adev
+have	O
+been	O
+described	O
+in	O
+the	O
+infants	O
+of	O
+women	O
+treated	O
+with	O
+disulfiram	O
+in	O
+the	O
+first	O
+trimester	O
+of	O
+their	O
+pregnancies	O
+
+These	O
+data	O
+indicated	O
+that	O
+infliximab	O
+possibly	O
+triggered	O
+production	B-Adev
+of	I-Adev
+granulocyte	I-Adev
+and	I-Adev
+neutrophil	I-Adev
+autoantibodies	I-Adev
+with	I-Adev
+resultant	I-Adev
+autoimmune	I-Adev
+agranulocytosis	I-Adev
+	O
+
+Ovarian	B-Adev
+endometrioid	I-Adev
+adenocarcinoma	I-Adev
+arising	O
+from	O
+an	O
+endometriotic	O
+cyst	O
+in	O
+a	O
+postmenopausal	O
+woman	O
+under	O
+tamoxifen	O
+therapy	O
+for	O
+breast	O
+cancer	O
+a	O
+case	O
+report	O
+
+Tacrolimus-induced	O
+HUS	B-Adev
+	O
+an	O
+unusual	O
+cause	O
+of	O
+acute	O
+renal	O
+failure	O
+in	O
+nephrotic	O
+syndrome	O
+
+OBJECTIVE	O
+To	O
+report	O
+the	O
+clinical	O
+course	O
+of	O
+a	O
+woman	O
+with	O
+cryptococcal	O
+meningitis	O
+and	O
+no	O
+previous	O
+cardiac	O
+disease	O
+who	O
+developed	O
+a	B-Adev
+fatal	I-Adev
+cardiac	I-Adev
+arrhythmia	I-Adev
+after	O
+an	O
+acute	O
+overdose	O
+of	O
+amphotericin	O
+B	O
+and	O
+to	O
+review	O
+its	O
+toxicity	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+bullous	B-Adev
+lichenoid	I-Adev
+eruption	I-Adev
+due	O
+to	O
+the	O
+intake	O
+of	O
+captopril	O
+
+The	O
+hypoadrenalism	O
+was	O
+overcome	O
+by	O
+increasing	O
+steroid	O
+replacement	O
+therapy	O
+
+DIAGNOSIS	O
+Interferon	O
+alpha-2b-induced	O
+cardiomyopathy	B-Adev
+	O
+
+Choroidal	B-Adev
+hemorrhage	I-Adev
+associated	O
+with	O
+systemic	O
+tissue	O
+plasminogen	O
+activator	O
+
+Clozapine-induced	O
+eosinophilia	B-Adev
+and	O
+switch	O
+to	O
+quetiapine	O
+in	O
+a	O
+patient	O
+with	O
+chronic	O
+schizophrenia	O
+with	O
+suicidal	O
+tendencies	O
+
+Clozapine-induced	O
+eosinophilia	O
+and	O
+switch	O
+to	O
+quetiapine	O
+in	O
+a	O
+patient	O
+with	O
+chronic	O
+schizophrenia	O
+with	O
+suicidal	O
+tendencies	O
+
+Adverse	B-Adev
+effects	I-Adev
+of	O
+propafenone	O
+after	O
+long-term	O
+therapy	O
+with	O
+the	O
+addition	O
+of	O
+citalopram	O
+
+The	O
+case	O
+of	O
+an	O
+adult	O
+who	O
+developed	O
+both	O
+hepatic	B-Adev
+dysfunction	I-Adev
+and	I-Adev
+an	I-Adev
+impaired	I-Adev
+macrophage	I-Adev
+migration	I-Adev
+after	O
+exposure	O
+to	O
+cimetidine	O
+is	O
+discussed	O
+
+We	O
+report	O
+4	O
+patients	O
+who	O
+developed	O
+symptoms	B-Adev
+of	I-Adev
+myasthenia	I-Adev
+gravis	I-Adev
+within	O
+2	O
+weeks	O
+of	O
+starting	O
+treatment	O
+with	O
+a	O
+statin	O
+drug	O
+
+After	O
+only	O
+the	O
+third	O
+dose	O
+of	O
+pentamidine	O
+it	O
+was	O
+noted	O
+that	O
+the	O
+patient's	O
+heart	B-Adev
+rate	I-Adev
+had	I-Adev
+decreased	I-Adev
+to	I-Adev
+48	I-Adev
+beats/minute	I-Adev
+	O
+
+A	O
+44-year-old	O
+woman	O
+is	O
+described	O
+in	O
+whom	O
+amiodarone	O
+disopyramide	O
+and	O
+quinidine	O
+administered	O
+alone	O
+separately	O
+induced	O
+atypical	B-Adev
+ventricular	I-Adev
+tachycardia	I-Adev
+(AVT	I-Adev
+torsade	I-Adev
+de	I-Adev
+pointes)	I-Adev
+	O
+
+Azathioprine	O
+was	O
+the	O
+probable	O
+causative	O
+agent	O
+of	O
+warfarin	B-Adev
+resistance	I-Adev
+according	O
+to	O
+the	O
+Naranjo	O
+probability	O
+scale	O
+and	O
+a	O
+possible	O
+causative	O
+agent	O
+according	O
+to	O
+the	O
+Drug	O
+Interaction	O
+Probability	O
+Scale	O
+
+Disulfiram	O
+has	O
+been	O
+used	O
+effectively	O
+to	O
+deter	O
+alcohol	O
+consumption	O
+in	O
+patients	O
+with	O
+a	O
+history	O
+of	O
+alcohol	O
+abuse	O
+
+Nevirapine	O
+is	O
+a	O
+non-nucleoside	O
+reverse	O
+transcriptase	O
+inhibitor	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+human	O
+immunodeficiency	O
+virus	O
+(HIV)-infected	O
+patients	O
+and	O
+in	O
+post-exposure	O
+prophylaxis	O
+
+Vasospasm	B-Adev
+associated	O
+with	O
+ergotamine	O
+is	O
+a	O
+well-known	O
+phenomenon	O
+
+After	O
+a	O
+six-week	O
+course	O
+of	O
+low-dose	O
+cyclosporine	O
+A	O
+she	O
+developed	O
+a	O
+severe	O
+but	O
+reversible	O
+loss	B-Adev
+of	I-Adev
+glomerular	I-Adev
+filtration	I-Adev
+rate	I-Adev
+and	I-Adev
+effective	I-Adev
+renal	I-Adev
+plasma	I-Adev
+flow	I-Adev
+despite	O
+of	O
+low	O
+cyclosporine	O
+A	O
+plasma	O
+levels	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+severe	O
+simvastatin-induced	O
+rhabdomyolysis	B-Adev
+triggered	O
+by	O
+the	O
+addition	O
+of	O
+amiodarone	O
+to	O
+previously	O
+well-tolerated	O
+chronic	O
+statin	O
+therapy	O
+
+In	O
+January	O
+2010	O
+a	O
+50-year-old	O
+transgender	O
+female	O
+with	O
+HIV	O
+infection	O
+and	O
+recurrent	O
+deep	O
+vein	O
+thrombosis	O
+began	O
+treatment	O
+with	O
+the	O
+TRIO	O
+study	O
+regimen	O
+
+In	O
+vitro	O
+inhibition	O
+of	O
+CYP2C9	O
+by	O
+zafirlukast	O
+is	O
+consistent	O
+with	O
+clinical	O
+studies	O
+showing	O
+impaired	O
+clearance	O
+of	O
+S-warfarin	O
+and	O
+enhanced	O
+anti-thrombotic	O
+effects	O
+although	O
+the	O
+in	O
+vitro	O
+IC(50)	O
+value	O
+is	O
+higher	O
+than	O
+the	O
+usual	O
+range	O
+of	O
+clinically	O
+relevant	O
+plasma	O
+concentrations	O
+
+Although	O
+it	O
+is	O
+difficult	O
+to	O
+solely	O
+attribute	O
+intratumoral	B-Adev
+hemorrhage	I-Adev
+to	O
+aspirin	O
+we	O
+have	O
+to	O
+be	O
+careful	O
+when	O
+prescribing	O
+aspirin	O
+for	O
+patients	O
+who	O
+have	O
+asymptomatic	O
+meningioma	O
+
+CONCLUSIONS	O
+The	O
+fundus	O
+picture	O
+shown	O
+in	O
+these	O
+cases	O
+may	O
+be	O
+typical	O
+of	O
+ASPPC	B-Adev
+after	O
+IVTA	O
+injection	O
+
+The	O
+probable	O
+proarrhythmic	B-Adev
+action	O
+of	O
+amiodarone	O
+although	O
+rare	O
+is	O
+reviewed	O
+along	O
+with	O
+a	O
+discussion	O
+of	O
+the	O
+novel	O
+use	O
+of	O
+intravenous	O
+magnesium	O
+sulfate	O
+therapy	O
+
+We	O
+present	O
+two	O
+cases	O
+of	O
+severe	O
+atypical	B-Adev
+ASRs	I-Adev
+which	O
+occurred	O
+during	O
+NMSC	O
+treatment	O
+with	O
+imiquimod	O
+in	O
+the	O
+context	O
+of	O
+infliximab	O
+administration	O
+for	O
+psoriasis	O
+and	O
+consider	O
+the	O
+grounds	O
+supporting	O
+a	O
+non-fortuitous	O
+association	O
+
+A	O
+case	O
+of	O
+propranolol	O
+overdose	O
+complicated	O
+by	O
+esophageal	B-Adev
+spasm	I-Adev
+preventing	I-Adev
+extrication	I-Adev
+of	I-Adev
+an	I-Adev
+orogastric	I-Adev
+lavage	I-Adev
+tube	I-Adev
+and	O
+relieved	O
+by	O
+intravenous	O
+glucagon	O
+is	O
+presented	O
+
+A	O
+case	O
+of	O
+propranolol	O
+overdose	O
+complicated	O
+by	O
+esophageal	O
+spasm	O
+preventing	O
+extrication	O
+of	O
+an	O
+orogastric	O
+lavage	O
+tube	O
+and	O
+relieved	O
+by	O
+intravenous	O
+glucagon	O
+is	O
+presented	O
+
+Fenclofenac-induced	O
+selective	B-Adev
+IgA	I-Adev
+deficiency	I-Adev
+in	I-Adev
+rheumatoid	I-Adev
+arthritis	I-Adev
+	O
+
+Naproxen	O
+the	O
+most	O
+common	O
+offender	O
+has	O
+been	O
+associated	O
+with	O
+a	O
+dimorphic	O
+clinical	O
+pattern	O
+a	O
+PCT-like	O
+presentation	O
+and	O
+one	O
+simulating	O
+erythropoietic	B-Adev
+protoporphyria	I-Adev
+in	O
+the	O
+pediatric	O
+population	O
+
+Zafirlukast	O
+is	O
+a	O
+cysteinyl	O
+leukotriene	O
+antagonist	O
+used	O
+to	O
+treat	O
+allergic	O
+and	O
+exercise-induced	O
+asthma	O
+
+Rapidly	B-Adev
+developing	I-Adev
+hyperglycemia	I-Adev
+during	O
+treatment	O
+with	O
+olanzapine	O
+
+The	O
+first	O
+patient	O
+was	O
+a	O
+61-year-old	O
+man	O
+with	O
+a	O
+30-year	O
+history	O
+of	O
+fistulizing	O
+CD	O
+in	O
+whom	O
+B-cell	B-Adev
+non-Hodgkin's	I-Adev
+lymphoma	I-Adev
+was	O
+diagnosed	O
+9	O
+months	O
+after	O
+treatment	O
+with	O
+infliximab	O
+
+Recognition	O
+of	O
+a	O
+potential	O
+drug-induced	B-Adev
+Fanconi	I-Adev
+syndrome	I-Adev
+is	O
+important	O
+when	O
+managing	O
+pediatric	O
+oncology	O
+patients	O
+previously	O
+treated	O
+with	O
+ifosfamide	O
+
+We	O
+report	O
+a	O
+patient	O
+with	O
+chronic	O
+renal	O
+failure	O
+and	O
+ischemic	O
+heart	O
+disease	O
+who	O
+developed	O
+clinically	B-Adev
+significant	I-Adev
+methemoglobinemia	I-Adev
+after	O
+an	O
+axillary	O
+block	O
+with	O
+bupivacaine	O
+and	O
+additional	O
+injection	O
+of	O
+lidocaine	O
+in	O
+the	O
+operative	O
+field	O
+
+Amikacin-induced	O
+type	B-Adev
+5	I-Adev
+Bartter-like	I-Adev
+syndrome	I-Adev
+with	I-Adev
+severe	I-Adev
+hypocalcemia	I-Adev
+	O
+
+L-asparaginase-induced	O
+severe	O
+necrotizing	O
+pancreatitis	O
+successfully	O
+treated	O
+with	O
+percutaneous	O
+drainage	O
+
+L-asparaginase-induced	O
+severe	B-Adev
+necrotizing	I-Adev
+pancreatitis	I-Adev
+successfully	O
+treated	O
+with	O
+percutaneous	O
+drainage	O
+
+This	O
+report	O
+describes	O
+the	O
+first	O
+case	O
+of	O
+insulin-induced	O
+cardiac	B-Adev
+failure	I-Adev
+in	O
+a	O
+patient	O
+without	O
+underlying	O
+heart	O
+disease	O
+
+OBJECTIVE	O
+To	O
+determine	O
+the	O
+frequency	O
+of	O
+weight	B-Adev
+loss	I-Adev
+in	O
+patients	O
+treated	O
+with	O
+leflunomide	O
+for	O
+rheumatoid	O
+arthritis	O
+at	O
+an	O
+arthritis	O
+referral	O
+center	O
+
+INH	O
+which	O
+is	O
+a	O
+leading	O
+cause	O
+of	O
+drug	B-Adev
+eruptions	I-Adev
+in	O
+the	O
+above	O
+group	O
+of	O
+drugs	O
+was	O
+withdrawn	O
+
+Complications	B-Adev
+associated	I-Adev
+with	I-Adev
+primary	I-Adev
+and	I-Adev
+secondary	I-Adev
+perforation	I-Adev
+of	I-Adev
+the	I-Adev
+bladder	I-Adev
+following	O
+immediate	O
+instillations	O
+of	O
+epirubicin	O
+after	O
+transurethral	O
+resection	O
+of	O
+superficial	O
+urothelial	O
+tumours	O
+
+Ofloxacin	O
+a	O
+probable	O
+cause	O
+of	O
+toxic	B-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+	O
+
+Fatal	B-Adev
+lung	I-Adev
+fibrosis	I-Adev
+caused	O
+by	O
+paclitaxel	O
+toxicity	O
+has	O
+not	O
+been	O
+reported	O
+In	O
+this	O
+report	O
+we	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+62-year-old	O
+woman	O
+who	O
+received	O
+six	O
+cycles	O
+of	O
+paclitaxel	O
+and	O
+carboplatin	O
+as	O
+combination	O
+chemotherapy	O
+for	O
+advanced	O
+ovarian	O
+cancer	O
+
+A	O
+21-year-old	O
+patient	O
+developed	O
+rhabdomyolysis	B-Adev
+during	O
+his	O
+nineteenth	O
+week	O
+of	O
+treatment	O
+with	O
+clozapine	O
+for	O
+drug-resistant	O
+schizophrenia	O
+
+Cisplatin-induced	O
+syndrome	B-Adev
+of	I-Adev
+inappropriate	I-Adev
+antidiuretic	I-Adev
+hormone	I-Adev
+(SIADH)	I-Adev
+in	O
+a	O
+patient	O
+with	O
+neuroendocrine	O
+tumor	O
+of	O
+the	O
+cervix	O
+a	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+Myoglobinuria	B-Adev
+and	I-Adev
+acute	I-Adev
+renal	I-Adev
+failure	I-Adev
+associated	O
+with	O
+intravenous	O
+vasopressin	O
+infusion	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+fulminant	O
+adult	B-Adev
+respiratory	I-Adev
+distress	I-Adev
+syndrome	I-Adev
+(ARDS)	I-Adev
+associated	O
+with	O
+pegylated	O
+interferon	O
+alpha-2a	O
+(pegIFNalpha-2a)	O
+and	O
+ribavirin	O
+use	O
+for	O
+hepatitis	O
+C	O
+complicated	O
+by	O
+subsequent	O
+and	O
+ultimately	O
+fatal	O
+sepsis	O
+and	O
+multiorgan	O
+failure	O
+
+Catatonia	B-Adev
+associated	O
+with	O
+disulfiram	O
+therapy	O
+
+To	O
+date	O
+no	O
+relation	O
+has	O
+ever	O
+been	O
+suggested	O
+between	O
+TNF-alpha	O
+inhibitors	O
+and	O
+increased	O
+susceptibility	O
+to	O
+developing	O
+exaggerated	B-Adev
+ASRs	I-Adev
+with	O
+imiquimod	O
+
+Losartan-induced	O
+angioedema	B-Adev
+	O
+
+However	O
+dermatologists	O
+should	O
+be	O
+cautious	O
+about	O
+a	O
+photosensitivity	B-Adev
+reaction	O
+induced	O
+by	O
+mequitazine	O
+or	O
+other	O
+phenothiazine-derivative	O
+drugs	O
+
+Oxycodone-gabapentin	O
+also	O
+significantly	O
+improved	O
+pain	O
+relief	O
+vs	O
+gabapentin	O
+alone	O
+(P	O
+=	O
+0.003)	O
+
+In	O
+2	O
+of	O
+the	O
+3	O
+cases	O
+the	O
+patients	O
+were	O
+also	O
+taking	O
+lithium	O
+carbonate	O
+and	O
+beta-blockers	O
+both	O
+of	O
+which	O
+could	O
+have	O
+contributed	O
+to	O
+the	O
+incontinence	B-Adev
+	O
+
+Pulmonary	B-Adev
+fibrosis	I-Adev
+is	I-Adev
+a	I-Adev
+severe	I-Adev
+complication	I-Adev
+associated	O
+with	O
+bis-chloronitrosourea	O
+(BCNU)	O
+therapy	O
+
+We	O
+report	O
+here	O
+a	O
+26-year-old	O
+female	O
+with	O
+diffuse	O
+large	O
+B-cell	O
+lymphoma	O
+who	O
+died	B-Adev
+of	I-Adev
+severe	I-Adev
+pulmonary	I-Adev
+fibrosis	I-Adev
+81	O
+days	O
+after	O
+the	O
+administration	O
+of	O
+high-dose	O
+BCNU	O
+(600	O
+mg/m2)	O
+
+The	O
+patient	O
+was	O
+given	O
+methimazole	O
+instead	O
+of	O
+propylthiouracil	O
+but	O
+10	O
+weeks	O
+later	O
+agranulocytosis	B-Adev
+again	O
+occurred	O
+
+Three	O
+months	O
+after	O
+starting	O
+citalopram	O
+she	O
+experienced	O
+episodes	O
+of	O
+chest	B-Adev
+tightness	I-Adev
+and	I-Adev
+dizziness	I-Adev
+	O
+
+Although	O
+differential	O
+diagnostic	O
+alternatives	O
+can	O
+be	O
+considered	O
+in	O
+all	O
+described	O
+cases	O
+it	O
+is	O
+very	O
+likely	O
+that	O
+vincristine	O
+does	O
+cause	O
+severe	B-Adev
+visual	I-Adev
+loss	I-Adev
+in	O
+a	O
+small	O
+number	O
+of	O
+patients	O
+
+This	O
+case	O
+is	O
+remarkable	O
+since	O
+1)	O
+ECM	O
+developed	O
+after	O
+subcutaneous	O
+and	O
+not	O
+after	O
+intramuscular	O
+injection	O
+2)	O
+the	O
+injection	O
+was	O
+given	O
+by	O
+the	O
+patient	O
+himself	O
+and	O
+3)	O
+glatiramer	O
+acetate	O
+can	O
+induce	O
+skin	B-Adev
+necrosis	I-Adev
+as	O
+a	O
+side	O
+effect	O
+
+SSRI-drugs	O
+increase	B-Adev
+serotonin	I-Adev
+concentrations	I-Adev
+and	O
+are	O
+known	O
+to	O
+have	O
+pruritus	O
+and	O
+other	O
+dermal	O
+side	O
+effects	O
+
+Dabigatran	O
+etexilate	O
+and	O
+concomitant	O
+use	O
+of	O
+non-steroidal	O
+anti-inflammatory	O
+drugs	O
+or	O
+acetylsalicylic	O
+acid	O
+in	O
+patients	O
+undergoing	O
+total	O
+hip	O
+and	O
+total	O
+knee	O
+arthroplasty	O
+no	B-Adev
+increased	I-Adev
+risk	I-Adev
+of	I-Adev
+bleeding	I-Adev
+	O
+
+Our	O
+literature	O
+review	O
+revealed	O
+an	O
+additional	O
+six	O
+cases	O
+of	O
+onset	O
+of	O
+inflammatory	B-Adev
+arthritis	I-Adev
+in	O
+MS	O
+patients	O
+receiving	O
+IFN-beta	O
+
+Two	O
+years	O
+later	O
+24	O
+hours	O
+following	O
+an	O
+increase	O
+in	O
+the	O
+dose	O
+of	O
+disopyramide	O
+from	O
+300	O
+to	O
+600	O
+mg/day	O
+AVT	B-Adev
+with	I-Adev
+syncope	I-Adev
+occurred	O
+isoproterenol	O
+abolished	O
+the	O
+arrhythmia	O
+instantly	O
+
+Two	O
+years	O
+later	O
+24	O
+hours	O
+following	O
+an	O
+increase	O
+in	O
+the	O
+dose	O
+of	O
+disopyramide	O
+from	O
+300	O
+to	O
+600	O
+mg/day	O
+AVT	O
+with	O
+syncope	O
+occurred	O
+isoproterenol	O
+abolished	O
+the	O
+arrhythmia	O
+instantly	O
+
+The	O
+patient	O
+was	O
+initially	O
+treated	O
+with	O
+hydration	O
+and	O
+furosemide	O
+but	O
+developed	O
+congestive	B-Adev
+heart	I-Adev
+failure	I-Adev
+	O
+
+We	O
+present	O
+an	O
+interesting	O
+case	O
+of	O
+an	O
+HIV-positive	O
+woman	O
+on	O
+antiretroviral	O
+therapy	O
+having	O
+tubal	B-Adev
+pregnancies	I-Adev
+on	O
+two	O
+separate	O
+occasions	O
+with	O
+Implanon	O
+in	O
+place	O
+
+We	O
+hypothesize	O
+that	O
+decreased	O
+renal	O
+elimination	O
+of	O
+MTX	O
+induced	O
+by	O
+the	O
+COX-2	O
+inhibitor	O
+resulted	O
+in	O
+enhanced	B-Adev
+hematopoietic	I-Adev
+toxicity	I-Adev
+and	I-Adev
+immunosuppression	I-Adev
+causing	O
+the	O
+EBV-associated	O
+lymphoproliferative	O
+disease	O
+
+Temsirolimus-induced	O
+glomerulopathy	B-Adev
+	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+linear	B-Adev
+immunoglobulin	I-Adev
+(Ig)	I-Adev
+A	I-Adev
+bullous	I-Adev
+dermatosis	I-Adev
+(LABD)	I-Adev
+induced	O
+by	O
+gemcitabine	O
+
+This	O
+patient	O
+developed	O
+sequential	B-Adev
+symptoms	I-Adev
+including	I-Adev
+alternative	I-Adev
+hemiparesis	I-Adev
+dysarthria	I-Adev
+and	I-Adev
+altered	I-Adev
+consciousness	I-Adev
+5	O
+days	O
+after	O
+the	O
+second	O
+course	O
+of	O
+HD-MTX	O
+(8	O
+gm/m2	O
+by	O
+6	O
+h	O
+continuous	O
+infusion)	O
+with	O
+leucovorin	O
+rescue	O
+
+Adult	O
+and	O
+adolescent	O
+patients	O
+(>	O
+or	O
+=	O
+12	O
+years	O
+old	O
+n	O
+=	O
+141)	O
+with	O
+severe	O
+persistent	O
+oral	O
+steroid	O
+(prednisone)-dependent	O
+asthma	B-Adev
+	O
+
+DISCUSSION	O
+Amphotericin	O
+B	O
+deoxycholate	O
+has	O
+been	O
+reported	O
+to	O
+produce	O
+significant	O
+cardiac	B-Adev
+toxicity	I-Adev
+with	I-Adev
+ventricular	I-Adev
+arrhythmias	I-Adev
+and	I-Adev
+bradycardia	I-Adev
+reported	O
+in	O
+overdoses	O
+in	O
+children	O
+and	O
+in	O
+adults	O
+with	O
+preexisting	O
+cardiac	O
+disease	O
+even	O
+when	O
+administered	O
+in	O
+conventional	O
+dosages	O
+and	O
+infusion	O
+rates	O
+
+Diarrhoea	B-Adev
+T-CD4+	I-Adev
+lymphopenia	I-Adev
+and	I-Adev
+bilateral	I-Adev
+patchy	I-Adev
+pulmonary	I-Adev
+infiltrates	I-Adev
+developed	O
+in	O
+a	O
+male	O
+60	O
+yrs	O
+of	O
+age	O
+who	O
+was	O
+treated	O
+with	O
+oxaliplatinum	O
+and	O
+5-fluorouracil	O
+for	O
+unresectable	O
+rectum	O
+carcinoma	O
+
+Thus	O
+tardive	B-Adev
+seizures	I-Adev
+in	O
+our	O
+cases	O
+are	O
+thought	O
+to	O
+be	O
+related	O
+to	O
+piperacillin	O
+and	O
+cefotiam	O
+
+A	O
+55-yr-old	O
+man	O
+developed	O
+prolonged	B-Adev
+jaundice	I-Adev
+and	I-Adev
+sicca	I-Adev
+complex	I-Adev
+after	O
+a	O
+course	O
+of	O
+thiabendazole	O
+therapy	O
+
+Methylphenidate	O
+(Ritalin)-associated	O
+cataract	B-Adev
+and	I-Adev
+glaucoma	I-Adev
+	O
+
+Simvastatin-nelfinavir	O
+interaction	O
+implicated	O
+in	O
+rhabdomyolysis	B-Adev
+and	I-Adev
+death	I-Adev
+	O
+
+Uncontrolled	B-Adev
+headache	I-Adev
+induced	O
+by	O
+oxcarbazepine	O
+
+We	O
+now	O
+present	O
+four	O
+cases	O
+of	O
+RSDS	B-Adev
+in	O
+kidney	O
+transplant	O
+recipients	O
+treated	O
+with	O
+tacrolimus	O
+
+Transient	B-Adev
+neurological	I-Adev
+disturbances	I-Adev
+induced	O
+by	O
+the	O
+chemotherapy	O
+of	O
+high-dose	O
+methotrexate	O
+for	O
+osteogenic	O
+sarcoma	O
+
+Long-term	O
+safety	O
+and	O
+efficacy	O
+in	O
+patients	O
+with	O
+uncontrolled	O
+partial-onset	O
+seizures	O
+treated	O
+with	O
+adjunctive	O
+lacosamide	O
+results	O
+from	O
+a	O
+Phase	O
+III	O
+open-label	O
+extension	O
+trial	O
+
+A	O
+variety	O
+of	O
+movement	B-Adev
+disorders	I-Adev
+are	O
+known	O
+to	O
+occur	O
+in	O
+association	O
+with	O
+carbamazepine	O
+(CBZ)	O
+therapy	O
+in	O
+adults	O
+and	O
+children	O
+but	O
+development	O
+of	O
+tics	O
+has	O
+been	O
+described	O
+infrequently	O
+and	O
+only	O
+in	O
+patients	O
+with	O
+underlying	O
+Tourette's	O
+syndrome	O
+or	O
+other	O
+movement	O
+disorders	O
+
+On	O
+the	O
+day	O
+before	O
+this	O
+visit	O
+he	O
+had	O
+received	O
+the	O
+third	O
+of	O
+six	O
+serial	O
+weekly	O
+BCG	O
+bladder	O
+instillations	O
+for	O
+the	O
+treatment	O
+of	O
+bladder	O
+cancer	O
+
+Following	O
+a	O
+closed	O
+mitral	O
+valvotomy	O
+she	O
+received	O
+quinidine	O
+1.2	O
+g/day	O
+without	O
+interruption	O
+for	O
+17	O
+years	O
+
+We	O
+describe	O
+a	O
+patient	O
+in	O
+whom	O
+noncardiogenic	B-Adev
+pulmonary	I-Adev
+edema	I-Adev
+developed	O
+during	O
+intrabiliary	O
+infusion	O
+of	O
+monooctanoin	O
+
+Mitomycin-C	O
+is	O
+used	O
+widely	O
+in	O
+the	O
+treatment	O
+of	O
+malignancies	O
+and	O
+is	O
+associated	O
+with	O
+serious	O
+dose	O
+related	O
+adverse	O
+effects	O
+including	O
+the	O
+occurrence	O
+of	O
+hemolytic	B-Adev
+uremic	I-Adev
+syndrome	I-Adev
+	O
+
+Valproic	O
+acid	O
+induced	O
+coma	B-Adev
+is	O
+presented	O
+in	O
+an	O
+adult	O
+patient	O
+without	O
+a	O
+history	O
+of	O
+metabolic	O
+disease	O
+
+Three	O
+patients	O
+with	O
+no	O
+history	O
+of	O
+asthma	O
+or	O
+allergy	O
+developed	O
+bronchospasm	B-Adev
+while	O
+taking	O
+propranolol	O
+for	O
+hypertension	O
+
+To	O
+report	O
+two	O
+cases	O
+of	O
+warfarin	O
+therapy	O
+in	O
+which	O
+the	O
+addition	O
+of	O
+tolterodine	O
+resulted	O
+in	O
+prolonged	B-Adev
+international	I-Adev
+normalized	I-Adev
+ratios	I-Adev
+(INRs)	I-Adev
+	O
+
+In	O
+addition	O
+an	B-Adev
+immediate	I-Adev
+erythematous	I-Adev
+macule	I-Adev
+was	O
+observed	O
+on	O
+the	O
+photopatch	O
+test	O
+site	O
+of	O
+mequitazine	O
+directly	O
+after	O
+UV	O
+exposure	O
+which	O
+was	O
+similar	O
+to	O
+the	O
+immediate	O
+erythema	O
+noted	O
+in	O
+chlorpromazine	O
+photoallergy	O
+
+Acetazolamide-accelerated	O
+anticonvulsant	B-Adev
+osteomalacia	I-Adev
+	O
+
+Both	O
+patients	O
+suddenly	O
+became	O
+hypotensive	B-Adev
+after	O
+injection	O
+of	O
+chymopapain	O
+into	O
+a	O
+disk	O
+
+Large	O
+dose	O
+of	O
+methylphenidate	O
+may	O
+cause	O
+cataract	B-Adev
+and	I-Adev
+glaucoma	I-Adev
+	O
+
+Total	B-Adev
+blindness	I-Adev
+with	I-Adev
+a	I-Adev
+transient	I-Adev
+tonic	I-Adev
+pupillary	I-Adev
+response	I-Adev
+denervation	I-Adev
+supersensitivity	I-Adev
+and	I-Adev
+abnormal	I-Adev
+visual-evoked	I-Adev
+potentials	O
+developed	O
+in	O
+a	O
+54-year-old	O
+man	O
+after	O
+the	O
+use	O
+of	O
+quinine	O
+sulfate	O
+for	O
+leg	O
+cramps	O
+
+Carbamazepine-induced	O
+tics	B-Adev
+	O
+
+Three	O
+patients	O
+are	O
+reported	O
+without	O
+a	O
+history	O
+of	O
+angina	O
+pectoris	O
+who	O
+had	O
+clinical	O
+and	O
+electrocardiographic	O
+evidence	O
+of	O
+myocardial	B-Adev
+ischemia	I-Adev
+during	O
+and	O
+immediately	O
+after	O
+BCNU	O
+infusion	O
+
+A	O
+rare	O
+debilitating	B-Adev
+neurological	I-Adev
+adverse	O
+effect	O
+of	O
+ranolazine	O
+due	O
+to	O
+drug	O
+interaction	O
+with	O
+clarithromycin	O
+
+Septic	B-Adev
+knee	I-Adev
+arthritis	I-Adev
+after	O
+intra-articular	O
+hyaluronate	O
+injection	O
+
+The	O
+concomitant	O
+use	O
+however	O
+of	O
+colchicine	O
+and	O
+statin	O
+has	O
+been	O
+associated	O
+with	O
+the	B-Adev
+rapid	I-Adev
+onset	I-Adev
+of	I-Adev
+muscle	I-Adev
+weakness	I-Adev
+	O
+
+Successful	O
+treatment	O
+of	O
+hyperthyroidism	O
+with	O
+amiodarone	O
+in	O
+a	O
+patient	O
+with	O
+propylthiouracil-induced	O
+acute	O
+hepatic	O
+failure	O
+
+Successful	O
+treatment	O
+of	O
+hyperthyroidism	O
+with	O
+amiodarone	O
+in	O
+a	O
+patient	O
+with	O
+propylthiouracil-induced	O
+acute	B-Adev
+hepatic	I-Adev
+failure	I-Adev
+	O
+
+Olanzapine-induced	O
+parkinsonism	B-Adev
+associated	O
+with	O
+smoking	O
+cessation	O
+
+CASE	O
+We	O
+present	O
+an	O
+11-year	O
+old	O
+male	O
+with	O
+Budd-Chiari	O
+syndrome	O
+who	O
+experienced	O
+profound	B-Adev
+worsening	I-Adev
+of	I-Adev
+chronic	I-Adev
+aphthous	I-Adev
+ulcers	I-Adev
+after	O
+immunosuppressive	O
+therapy	O
+was	O
+changed	O
+from	O
+tacrolimus	O
+to	O
+sirolimus	O
+
+We	O
+report	O
+the	O
+cases	O
+of	O
+two	O
+patients	O
+who	O
+developed	O
+acute	B-Adev
+hepatitis	I-Adev
+after	O
+taking	O
+riluzole	O
+at	O
+the	O
+recommended	O
+dose	O
+(100	O
+mg	O
+daily)	O
+for	O
+7	O
+and	O
+4	O
+weeks	O
+respectively	O
+
+An	O
+interaction	O
+between	O
+levodopa	O
+and	O
+enteral	O
+nutrition	O
+resulting	O
+in	O
+neuroleptic	B-Adev
+malignant-like	I-Adev
+syndrome	I-Adev
+and	I-Adev
+prolonged	I-Adev
+ICU	I-Adev
+stay	I-Adev
+	O
+
+Until	O
+further	O
+data	O
+are	O
+available	O
+clinicians	O
+should	O
+be	O
+vigilant	O
+for	O
+a	O
+possible	B-Adev
+drug	I-Adev
+interaction	I-Adev
+when	O
+tolterodine	O
+therapy	O
+is	O
+initiated	O
+in	O
+a	O
+patient	O
+maintained	O
+on	O
+warfarin	O
+therapy	O
+
+The	O
+itch	O
+spread	O
+to	O
+the	O
+arms	O
+abdomen	O
+and	O
+legs	O
+and	O
+the	O
+patient	O
+treated	O
+himself	O
+with	O
+clemastine	O
+and	O
+the	O
+itch	O
+disappeared	O
+
+In	O
+this	O
+case	O
+report	O
+we	O
+present	O
+a	O
+rare	O
+drug	O
+interaction	O
+between	O
+erythromycin	O
+and	O
+ergotamine	O
+at	O
+normal	O
+doses	O
+causing	O
+lower	B-Adev
+extremity	I-Adev
+ischemia	I-Adev
+in	O
+a	O
+36-year-old	O
+woman	O
+
+Neutropenia	B-Adev
+and	I-Adev
+agranulocytosis	I-Adev
+are	O
+risks	O
+known	O
+to	O
+occur	O
+with	O
+phenothiazines	O
+and	O
+clozapine	O
+
+She	O
+had	O
+been	O
+taking	O
+rifampin	O
+prior	O
+to	O
+admission	O
+for	O
+acid-fast	O
+bacilli	O
+
+The	O
+responsibility	O
+of	O
+CCNU	O
+in	O
+the	O
+pathogenesis	B-Adev
+of	I-Adev
+pulmonary	I-Adev
+fibrosis	I-Adev
+seems	O
+very	O
+likely	O
+
+Malignant	B-Adev
+mixed	I-Adev
+mullerian	I-Adev
+tumor	I-Adev
+of	I-Adev
+the	I-Adev
+uterus	I-Adev
+in	O
+a	O
+patient	O
+taking	O
+raloxifene	O
+
+Fatal	B-Adev
+overdoses	I-Adev
+associated	O
+with	O
+quetiapine	O
+
+Gemcitabine-induced	O
+rectus	B-Adev
+abdominus	I-Adev
+radiation	I-Adev
+recall	I-Adev
+	O
+
+We	O
+report	O
+on	O
+a	O
+serious	O
+side	O
+effect	O
+in	O
+a	O
+severely	O
+depressed	O
+55-year-old	O
+woman	O
+who	O
+presented	O
+an	O
+erythematous	B-Adev
+pigmented	I-Adev
+skin	I-Adev
+rash	I-Adev
+on	I-Adev
+the	I-Adev
+whole	I-Adev
+body	I-Adev
+under	O
+combination	O
+treatment	O
+with	O
+antidepressants	O
+atypical	O
+antipsychotic	O
+drugs	O
+the	O
+mood	O
+stabilizer	O
+lithium	O
+and	O
+the	O
+lipid-lowering	O
+drug	O
+pravastatin	O
+
+We	O
+present	O
+a	O
+20-year-old	O
+woman	O
+with	O
+Basedow-Graves'	O
+disease	O
+who	O
+developed	O
+PTU-induced	O
+fulminant	B-Adev
+hepatitis	I-Adev
+which	I-Adev
+progressed	I-Adev
+to	I-Adev
+acute	I-Adev
+hepatic	I-Adev
+failure	I-Adev
+with	I-Adev
+grade	I-Adev
+III	I-Adev
+hepatic	I-Adev
+encephalopathy	I-Adev
+	O
+
+The	O
+European	O
+Organization	O
+for	O
+Research	O
+and	O
+Treatment	O
+of	O
+Cancer	O
+58881	O
+study	O
+was	O
+designed	O
+to	O
+test	O
+in	O
+a	O
+prospective	O
+multicentric	O
+randomized	O
+trial	O
+the	O
+value	O
+of	O
+high-dose	O
+(HD)	O
+intravenous	O
+(IV)	O
+cytarabine	O
+(Ara-C)	O
+added	O
+to	O
+HD	O
+IV	O
+methotrexate	O
+(MTX)	O
+to	O
+reduce	O
+the	O
+incidence	O
+of	O
+CNS	O
+and	O
+systemic	O
+relapses	O
+in	O
+children	O
+with	O
+increased-risk	O
+acute	O
+lymphoblastic	O
+leukemia	O
+(ALL)	O
+or	O
+stage	O
+III	O
+and	O
+IV	O
+lymphoblastic	O
+lymphoma	O
+treated	O
+with	O
+a	O
+Berlin-Frankfurt-Munster	O
+(BFM)-based	O
+regimen	O
+
+The	O
+authors	O
+postulate	O
+that	O
+two	O
+types	O
+of	O
+combined	O
+lithium-	O
+neuroleptic	B-Adev
+toxicity	I-Adev
+occur	O
+a	O
+neuroleptic	O
+malignant	O
+extrapyramidal	O
+syndrome	O
+and	O
+a	O
+lithium	O
+toxicity	O
+that	O
+occurs	O
+in	O
+combination	O
+with	O
+phenothiazines	O
+primarily	O
+thioridazine	O
+
+The	O
+authors	O
+postulate	O
+that	O
+two	O
+types	O
+of	O
+combined	O
+lithium-neuroleptic	O
+toxicity	O
+occur	O
+a	B-Adev
+neuroleptic	I-Adev
+malignant	I-Adev
+extrapyramidal	I-Adev
+syndrome	I-Adev
+and	I-Adev
+a	I-Adev
+lithium	I-Adev
+toxicity	I-Adev
+that	O
+occurs	O
+in	O
+combination	O
+with	O
+phenothiazines	O
+primarily	O
+thioridazine	O
+
+Trans-catheter	O
+hepatic	O
+arterial	O
+injection	O
+of	O
+lipiodol	O
+soluble	O
+anti-cancer	O
+agent	O
+SMANCS	O
+and	O
+ADR	O
+suspension	O
+in	O
+lipiodol	O
+combined	O
+with	O
+arterial	O
+embolization	O
+and	O
+local	O
+hyperthermia	O
+for	O
+treatment	O
+of	O
+hepatocellular	O
+carcinoma	O
+
+Gynecomastia	B-Adev
+associated	O
+with	O
+theophylline	O
+
+Arthritis	O
+and	O
+bursitis	O
+in	O
+multiple	O
+sclerosis	O
+patients	O
+treated	O
+with	O
+interferon-beta	O
+
+To	O
+our	O
+knowledge	O
+drug-induced	O
+fever	B-Adev
+has	O
+not	O
+been	O
+reported	O
+with	O
+the	O
+use	O
+of	O
+diltiazem	O
+hydrochloride	O
+a	O
+commonly	O
+prescribed	O
+calcium	O
+channel	O
+blocker	O
+
+Case	O
+studies	O
+in	O
+heparin-induced	O
+thrombocytopenia	B-Adev
+	O
+
+We	O
+describe	O
+a	O
+41	O
+yr	O
+old	O
+leprosy	O
+patient	O
+treated	O
+for	O
+10	O
+yrs	O
+with	O
+clofazimine	O
+who	O
+underwent	O
+laparotomy	O
+for	O
+severe	B-Adev
+abdominal	I-Adev
+pain	I-Adev
+	O
+
+Osteonecrosis	B-Adev
+is	O
+a	O
+serious	O
+side	O
+effect	O
+of	O
+antiemetic	O
+treatment	O
+with	O
+dexamethasone	O
+and	O
+this	O
+serious	O
+complication	O
+should	O
+be	O
+incorporated	O
+in	O
+the	O
+current	O
+guidelines	O
+
+We	O
+report	O
+the	O
+development	O
+of	O
+scrotal	B-Adev
+ulcer	I-Adev
+in	O
+a	O
+patient	O
+with	O
+acute	O
+promyleocytic	O
+leukemia	O
+(APL)	O
+within	O
+10	O
+days	O
+of	O
+treatment	O
+with	O
+ATRA	O
+at	O
+a	O
+dose	O
+of	O
+40	O
+mg	O
+orally	O
+twice	O
+daily	O
+
+After	O
+initiation	O
+of	O
+topical	O
+vitamin	O
+D3	O
+ointment	O
+(20	O
+micro	O
+g/g	O
+of	O
+tacalcitol)	O
+10	O
+g/day	O
+for	O
+the	O
+skin	O
+lesions	O
+both	O
+the	O
+serum	B-Adev
+level	I-Adev
+of	I-Adev
+calcium	I-Adev
+and	I-Adev
+urinary	I-Adev
+excretion	I-Adev
+of	I-Adev
+calcium	I-Adev
+increased	I-Adev
+gradually	O
+
+Vancomycin	O
+is	O
+the	O
+most	O
+frequently	O
+implicated	O
+drug	O
+but	O
+other	O
+agents	O
+have	O
+been	O
+reported	O
+to	O
+cause	O
+LABD	B-Adev
+	O
+
+Vision	B-Adev
+declined	I-Adev
+after	O
+treatment	O
+with	O
+methylprednisolone	O
+after	O
+which	O
+fundus	O
+examination	O
+became	O
+consistent	O
+with	O
+progressive	O
+outer	O
+retinal	O
+necrosis	O
+
+Eight	O
+days	O
+after	O
+the	O
+end	O
+of	O
+interferon	O
+treatment	O
+he	O
+showed	O
+signs	B-Adev
+of	I-Adev
+inability	I-Adev
+to	I-Adev
+sit	I-Adev
+still	I-Adev
+for	I-Adev
+ten	I-Adev
+seconds	I-Adev
+and	I-Adev
+walked	I-Adev
+around	I-Adev
+constantly	I-Adev
+	O
+
+Drug-induced	B-Adev
+agranulocytosis	I-Adev
+during	O
+treatment	O
+with	O
+infliximab	O
+in	O
+enteropathic	O
+spondyloarthropathy	O
+
+Aripiprazole-induced	O
+hiccups	B-Adev
+	O
+a	O
+case	O
+report	O
+
+The	B-Adev
+hepatic	I-Adev
+enzyme	I-Adev
+disturbances	I-Adev
+normalized	O
+after	O
+discontinuation	O
+of	O
+pegvisomant	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+a	O
+58-year-old	O
+female	O
+patient	O
+with	O
+Graves'	O
+disease	O
+who	O
+developed	O
+AA	B-Adev
+in	O
+the	O
+third	O
+exposure	O
+to	O
+methimazole	O
+(MMI)	O
+
+CONCLUSIONS	O
+This	O
+is	O
+the	O
+second	O
+case	O
+report	O
+that	O
+describes	O
+gemcitabine-induced	O
+radiation	B-Adev
+recall	I-Adev
+in	I-Adev
+rectus	I-Adev
+abdominus	I-Adev
+muscles	I-Adev
+after	O
+gemcitabine-based	O
+radiation	O
+therapy	O
+
+One	O
+patient	O
+was	O
+an	O
+80-year-old	O
+woman	O
+who	O
+was	O
+admitted	O
+for	O
+Staphylococcus	B-Adev
+aureus	I-Adev
+knee	I-Adev
+arthritis	I-Adev
+after	O
+several	O
+intraarticular	O
+injections	O
+of	O
+sodium	O
+hyaluronate	O
+and	O
+corticosteroids	O
+
+Association	O
+of	O
+zomepirac	O
+administration	O
+with	O
+renal	B-Adev
+cortical	I-Adev
+necrosis	I-Adev
+is	O
+not	O
+known	O
+to	O
+have	O
+been	O
+previously	O
+demonstrated	O
+
+Vasomotor	B-Adev
+reactions	I-Adev
+after	O
+gold	O
+sodium	O
+thiomalate	O
+are	O
+well	O
+recognized	O
+
+Moxifloxacin-acetaminophen-warfarin	O
+interaction	O
+during	O
+bacille	O
+Calmette-Guerin	O
+treatment	O
+for	O
+bladder	O
+cancer	O
+
+In	O
+four	O
+patients	O
+thrombosis	B-Adev
+occurred	I-Adev
+2-45	O
+days	O
+after	O
+severe	O
+hepatic	O
+veno-occlusive	O
+disease	O
+(HVOD)	O
+secondary	O
+to	O
+intensive	O
+chemotherapy	O
+containing	O
+busulfan	O
+
+An	O
+adolescent	O
+male	O
+developed	O
+acute	B-Adev
+pancreatitis	I-Adev
+and	I-Adev
+pseudocyst	I-Adev
+of	I-Adev
+the	I-Adev
+pancreas	I-Adev
+16	O
+weeks	O
+after	O
+cessation	O
+of	O
+intramuscular	O
+L-asparaginase	O
+
+A	O
+CFTR	O
+potentiator	O
+in	O
+patients	O
+with	O
+cystic	O
+fibrosis	O
+and	O
+the	O
+G551D	O
+mutation	O
+
+Quinapril	O
+is	O
+an	O
+angiotensin-converting	O
+enzyme	O
+inhibitor	O
+(ACE-inhibitor)	O
+and	O
+overdose	O
+can	O
+lead	O
+to	O
+prolonged	B-Adev
+hypotension	I-Adev
+and	I-Adev
+less	I-Adev
+frequently	I-Adev
+transient	I-Adev
+renal	I-Adev
+impairment	I-Adev
+	O
+
+We	O
+describe	O
+a	O
+renal	O
+transplant	O
+recipient	O
+maintained	O
+on	O
+cyclosporine	O
+and	O
+prednisone	O
+developing	O
+Nocardia	B-Adev
+Asteroides	I-Adev
+brain	I-Adev
+abscess	I-Adev
+	O
+
+After	O
+an	O
+extensive	O
+review	O
+of	O
+the	O
+literature	O
+we	O
+believe	O
+that	O
+this	O
+is	O
+the	O
+first	O
+communication	O
+of	O
+the	O
+successful	O
+use	O
+of	O
+amiodarone	O
+to	O
+control	O
+hyperthyroidism	O
+in	O
+a	O
+patient	O
+with	O
+PTU-induced	O
+fulminant	O
+hepatitis	O
+
+After	O
+an	O
+extensive	O
+review	O
+of	O
+the	O
+literature	O
+we	O
+believe	O
+that	O
+this	O
+is	O
+the	O
+first	O
+communication	O
+of	O
+the	O
+successful	O
+use	O
+of	O
+amiodarone	O
+to	O
+control	O
+hyperthyroidism	O
+in	O
+a	O
+patient	O
+with	O
+PTU-induced	O
+fulminant	B-Adev
+hepatitis	I-Adev
+	O
+
+After	O
+identification	O
+of	O
+the	O
+index	O
+patient	O
+additional	O
+inquiry	O
+revealed	O
+that	O
+the	O
+patient's	O
+mother	O
+was	O
+hospitalized	O
+previously	O
+for	O
+overwhelming	B-Adev
+sepsis	I-Adev
+associated	O
+with	O
+metamizole	O
+use	O
+
+We	O
+report	O
+here	O
+on	O
+a	O
+heretofore	O
+undescribed	O
+respiratory	B-Adev
+syncytial	I-Adev
+virus	I-Adev
+(RSV)	I-Adev
+infection	I-Adev
+in	O
+a	O
+patient	O
+with	O
+a	O
+long-standing	O
+history	O
+of	O
+refractory	O
+CLL	O
+that	O
+was	O
+treated	O
+with	O
+fludarabine	O
+phosphate	O
+
+A	O
+77-year-old	O
+woman	O
+with	O
+no	O
+history	O
+of	O
+epilepsy	O
+presented	O
+a	B-Adev
+probable	I-Adev
+nonconvulsive	I-Adev
+status	I-Adev
+epilepticus	I-Adev
+while	O
+receiving	O
+continuous	O
+intravenous	O
+morphine	O
+for	O
+back	O
+pain	O
+relating	O
+to	O
+vertebral	O
+metastasis	O
+of	O
+a	O
+malignant	O
+lymphoma	O
+
+Oral	O
+corticosteroids	O
+(OCS)	O
+may	O
+be	O
+associated	O
+with	O
+systemic	B-Adev
+adverse	I-Adev
+events	I-Adev
+(AEs)	I-Adev
+	O
+which	O
+can	O
+be	O
+reduced	O
+by	O
+replacing	O
+OCS	O
+with	O
+inhaled	O
+corticosteroids	O
+(ICS)	O
+
+Development	O
+of	O
+Peyronie's	B-Adev
+disease	I-Adev
+during	O
+long-term	O
+colchicine	O
+treatment	O
+
+The	O
+principle	O
+treatment	O
+for	O
+DPD-deficient	O
+patients	O
+with	O
+severe	O
+acute	O
+5-FU	O
+reactions	O
+is	O
+supportive	O
+care	O
+however	O
+the	O
+administration	O
+of	O
+thymidine	O
+potentially	O
+may	O
+reverse	O
+severe	O
+5-FU-induced	O
+neurologic	O
+symptoms	O
+such	O
+as	O
+encephalopathy	O
+and	O
+coma	O
+
+The	O
+principle	O
+treatment	O
+for	O
+DPD-deficient	O
+patients	O
+with	O
+severe	O
+acute	O
+5-FU	O
+reactions	O
+is	O
+supportive	O
+care	O
+however	O
+the	O
+administration	O
+of	O
+thymidine	O
+potentially	O
+may	O
+reverse	O
+severe	O
+5-FU-induced	O
+neurologic	B-Adev
+symptoms	I-Adev
+such	I-Adev
+as	I-Adev
+encephalopathy	I-Adev
+and	I-Adev
+coma	I-Adev
+	O
+
+Adverse	O
+reaction	O
+in	O
+a	O
+patient	O
+with	O
+aspirin-induced	O
+asthma	B-Adev
+treated	O
+with	O
+zafirlukast	O
+
+The	O
+nephrotic	B-Adev
+syndrome	I-Adev
+developed	O
+in	O
+a	O
+patient	O
+receiving	O
+therapy	O
+with	O
+gold	O
+for	O
+rheumatoid	O
+arthritis	O
+
+This	O
+observation	O
+adds	O
+another	O
+dimension	O
+to	O
+the	O
+previously	O
+reported	O
+renal	B-Adev
+complications	I-Adev
+of	O
+nonsteroidal	O
+anti-inflammatory	O
+agents	O
+especially	O
+zomepirac	O
+
+Clinical	O
+spectroscopic	O
+and	O
+imaging	O
+abnormalities	O
+resolved	O
+with	O
+discontinuation	O
+of	O
+metronidazole	O
+
+In	O
+two	O
+other	O
+patients	O
+(one	O
+after	O
+OLTX	O
+and	O
+one	O
+with	O
+Crohn's	O
+disease)	O
+a	O
+raltegravir-based	O
+HIV	O
+therapy	O
+was	O
+started	O
+while	O
+patients	O
+received	O
+1	O
+or	O
+2	O
+mg	O
+of	O
+tacrolimus	O
+twice	O
+daily	O
+
+Reversible	B-Adev
+cardiomyopathy	I-Adev
+caused	O
+by	O
+administration	O
+of	O
+interferon	O
+alpha	O
+
+Metipranolol	O
+associated	O
+granulomatous	B-Adev
+anterior	I-Adev
+uveitis	I-Adev
+	O
+not	O
+so	O
+uncommon	O
+as	O
+thought	O
+
+There	O
+was	O
+an	O
+increase	O
+in	O
+serious	O
+adverse	O
+events	O
+with	O
+bleeding	B-Adev
+in	O
+the	O
+tifacogin	O
+group	O
+in	O
+both	O
+cohorts	O
+(6.5%	O
+tifacogin	O
+and	O
+4.8%	O
+placebo	O
+for	O
+high	O
+INR	O
+6.0%	O
+tifacogin	O
+and	O
+3.3%	O
+placebo	O
+for	O
+low	O
+INR)	O
+
+We	O
+also	O
+describe	O
+a	O
+case	O
+of	O
+timolol-induced	O
+ocular	B-Adev
+pemphigoid	I-Adev
+	O
+
+A	O
+70-year-old	O
+man	O
+was	O
+admitted	O
+to	O
+our	O
+hospital	O
+because	O
+of	O
+dyspnea	B-Adev
+after	O
+taking	O
+an	O
+antihistaminic	O
+agent	O
+(homochlorcyclizine	O
+hydrochloride)	O
+for	O
+itching	O
+
+Methadone	B-Adev
+withdrawal	I-Adev
+when	O
+starting	O
+an	O
+antiretroviral	O
+regimen	O
+including	O
+nevirapine	O
+
+The	O
+oligohidrosis	O
+caused	O
+by	O
+zonisamide	O
+was	O
+reversible	O
+in	O
+that	O
+the	O
+patient	O
+regained	O
+the	O
+ability	O
+to	O
+sweat	O
+within	O
+2	O
+weeks	O
+of	O
+the	O
+cessation	O
+of	O
+drug	O
+administration	O
+
+Radiation	B-Adev
+recall	I-Adev
+related	O
+to	O
+gemcitabine	O
+has	O
+been	O
+reported	O
+in	O
+lung	O
+and	O
+breast	O
+cancer	O
+
+It	O
+carries	O
+a	O
+well-known	O
+risk	O
+of	O
+neutropenia	B-Adev
+and	I-Adev
+agranulocytosis	I-Adev
+	O
+which	O
+necessitates	O
+the	O
+immediate	O
+discontinuation	O
+of	O
+clozapine	O
+
+Vicriviroc	O
+(SCH	O
+417690)	O
+a	O
+CCR5	O
+receptor	O
+antagonist	O
+is	O
+currently	O
+under	O
+investigation	O
+for	O
+the	O
+treatment	O
+of	O
+human	O
+immunodeficiency	O
+virus	O
+infection	O
+
+Children	O
+receiving	O
+zonisamide	O
+should	O
+be	O
+monitored	O
+for	O
+[['oligohidrosis']	B-Adev
+['development	I-Adev
+of	I-Adev
+neurological	I-Adev
+symptoms	I-Adev
+associated']]	I-Adev
+igohidrosis	O
+and	O
+the	O
+development	O
+of	O
+neurological	O
+symptoms	O
+associated	O
+with	O
+an	O
+elevation	O
+of	O
+body	O
+temperature	O
+
+This	O
+concerns	O
+2	O
+male	O
+patients	O
+who	O
+experienced	O
+incontinence	B-Adev
+while	O
+taking	O
+venlafaxine	O
+
+Polyarthritis	B-Adev
+hepatitis	I-Adev
+and	I-Adev
+anti-native	I-Adev
+DNA	I-Adev
+antibodies	I-Adev
+after	O
+treatment	O
+with	O
+ethambutol	O
+and	O
+rifampicin	O
+
+We	O
+report	O
+an	O
+HIV-infected	O
+woman	O
+who	O
+developed	O
+mild	B-Adev
+leukopenia	I-Adev
+as	O
+the	O
+first	O
+sign	O
+of	O
+a	O
+nevirapine-related	O
+adverse	O
+event	O
+which	O
+was	O
+followed	O
+by	O
+skin	O
+and	O
+hepatic	O
+toxicity	O
+associated	O
+with	O
+a	O
+more	O
+severe	O
+leukopenia	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+rapidly	O
+occurring	O
+hyperglycemia	B-Adev
+that	O
+occurred	O
+in	O
+a	O
+geriatric	O
+patient	O
+3	O
+days	O
+after	O
+treatment	O
+with	O
+olanzapine	O
+
+Tifacogin	O
+administration	O
+was	O
+associated	O
+with	O
+an	B-Adev
+increase	I-Adev
+in	I-Adev
+risk	I-Adev
+of	I-Adev
+bleeding	I-Adev
+	O
+irrespective	O
+of	O
+baseline	O
+INR	O
+
+Gynecomastia	B-Adev
+developed	O
+in	O
+two	O
+epileptic	O
+patients	O
+some	O
+months	O
+after	O
+the	O
+addition	O
+of	O
+oral	O
+fluoresone	O
+750	O
+mg	O
+daily	O
+to	O
+the	O
+phenobarbital	O
+and	O
+phenytoin	O
+already	O
+being	O
+administered	O
+
+The	O
+authors	O
+describe	O
+a	O
+case	O
+of	O
+combined	O
+lithium	O
+and	O
+haloperidol	O
+toxicity	O
+characterized	O
+by	O
+hyperpyrexia	B-Adev
+severe	I-Adev
+rigidity	I-Adev
+mutism	I-Adev
+and	I-Adev
+development	I-Adev
+of	I-Adev
+irreversible	I-Adev
+tardive	I-Adev
+dyskinesia	I-Adev
+	O
+
+Occasionally	O
+despite	O
+good	O
+therapeutic	O
+response	O
+clozapine	O
+must	O
+be	O
+stopped	O
+due	O
+to	O
+dangerous	B-Adev
+side	I-Adev
+effects	I-Adev
+such	I-Adev
+as	I-Adev
+agranulocytosis	I-Adev
+	O
+
+Three	O
+cases	O
+of	O
+pseudocyst	B-Adev
+of	I-Adev
+the	I-Adev
+pancreas	I-Adev
+in	O
+two	O
+women	O
+and	O
+one	O
+man	O
+have	O
+previously	O
+been	O
+reported	O
+with	O
+the	O
+use	O
+of	O
+intravenous	O
+L-asparaginase	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+Ritalin-associated	O
+cataract	B-Adev
+and	I-Adev
+glaucoma	I-Adev
+	O
+
+We	O
+discuss	O
+a	O
+patient	O
+who	O
+developed	O
+severe	B-Adev
+renal	I-Adev
+tubular	I-Adev
+dysfunction	I-Adev
+secondary	O
+to	O
+short-term	O
+therapy	O
+with	O
+Amikacin	O
+resulting	O
+in	O
+refractory	O
+hypokalemia	O
+hypocalcemia	O
+hypomagnesemia	O
+metabolic	O
+alkalosis	O
+and	O
+polyuria	O
+
+Cardiac	B-Adev
+toxicity	I-Adev
+related	O
+to	O
+BCNU	O
+has	O
+not	O
+been	O
+described	O
+well	O
+
+Aprepitant	O
+is	O
+a	O
+neurokinin(1)	O
+receptor	O
+antagonist	O
+that	O
+enhances	O
+prevention	O
+of	O
+chemotherapy-induced	O
+nausea	O
+and	O
+vomiting	O
+when	O
+added	O
+to	O
+conventional	O
+therapy	O
+with	O
+a	O
+corticosteroid	O
+and	O
+a	O
+5-hydroxytryptamine(3)	O
+(5-HT(3))	O
+antagonist	O
+
+Thus	O
+tacrolimus-induced	O
+HUS	B-Adev
+is	O
+a	O
+rare	O
+cause	O
+of	O
+ARF	O
+in	O
+nephrotic	O
+syndrome	O
+
+Clinicians	O
+should	O
+be	O
+vigilant	O
+when	O
+monitoring	O
+for	O
+cardiotoxicity	B-Adev
+in	O
+patients	O
+receiving	O
+pentamidine	O
+throughout	O
+the	O
+duration	O
+of	O
+therapy	O
+
+The	O
+present	O
+case	O
+is	O
+the	O
+first	O
+report	O
+of	O
+hypercalcemia	B-Adev
+induced	O
+by	O
+vitamin	O
+D3	O
+ointment	O
+and	O
+thiazide	O
+simultaneously	O
+
+CONCLUSION	O
+Significant	B-Adev
+weight	I-Adev
+loss	I-Adev
+is	O
+a	O
+potential	O
+adverse	O
+event	O
+in	O
+patients	O
+with	O
+rheumatoid	O
+arthritis	O
+treated	O
+with	O
+leflunomide	O
+
+We	O
+have	O
+described	O
+a	O
+man	O
+with	O
+classic	O
+rheumatoid	O
+arthritis	O
+who	O
+had	O
+membranous	B-Adev
+nephropathy	I-Adev
+associated	I-Adev
+with	I-Adev
+nephrotic	I-Adev
+syndrome	I-Adev
+not	O
+related	O
+to	O
+gold	O
+or	O
+penicillamine	O
+therapy	O
+
+Pharmacokinetics	O
+of	O
+etravirine	O
+in	O
+HIV-infected	O
+patients	O
+concomitantly	O
+treated	O
+with	O
+rifampin	O
+for	O
+tuberculosis	O
+
+We	O
+thus	O
+concluded	O
+that	O
+an	O
+excessive	O
+dose	O
+of	O
+AZ	O
+had	O
+probably	O
+destroyed	B-Adev
+the	I-Adev
+gastric	I-Adev
+mucosal	I-Adev
+barrier	I-Adev
+or	I-Adev
+thrombocytopenia	I-Adev
+due	O
+to	O
+bone	O
+marrow	O
+disorder	O
+and	O
+thus	O
+eventually	O
+led	O
+to	O
+the	O
+development	O
+of	O
+hemorrhagic	O
+gastritis	O
+
+Acyclovir-induced	O
+neurotoxicity	B-Adev
+	O
+concentration-side	O
+effect	O
+relationship	O
+in	O
+acyclovir	O
+overdose	O
+
+Psoriasis-like	B-Adev
+skin	I-Adev
+reaction	I-Adev
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+after	O
+sulphasalazine	O
+therapy	O
+
+We	O
+describe	O
+the	O
+clinical	O
+course	O
+of	O
+2	O
+patients	O
+with	O
+Crohn's	O
+disease	O
+(CD)	O
+in	O
+whom	O
+lymphoma	B-Adev
+was	O
+diagnosed	O
+after	O
+treatment	O
+with	O
+infliximab	O
+
+Valproic	O
+acid	O
+is	O
+commonly	O
+and	O
+effectively	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+idiopathic	O
+generalized	O
+epilepsies	O
+including	O
+juvenile	O
+absence	O
+epilepsy	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+intrathecal	O
+methotrexate	O
+neurotoxicity	O
+manifesting	O
+as	O
+left	B-Adev
+arm	I-Adev
+weakness	I-Adev
+and	I-Adev
+aphasia	I-Adev
+	O
+
+According	O
+to	O
+the	O
+Drug	O
+Interaction	O
+Probability	O
+Scale	O
+a	O
+causal	O
+relationship	O
+between	O
+the	O
+warfarin-cloxacillin	O
+interaction	O
+and	O
+increased	B-Adev
+INR	I-Adev
+value	I-Adev
+was	O
+rated	O
+"probable"	O
+
+We	O
+present	O
+the	O
+cases	O
+of	O
+two	O
+female	O
+patients	O
+diagnosed	O
+with	O
+relapsing-remitting	O
+multiple	O
+sclerosis	O
+(RRMS)	O
+who	O
+developed	O
+inflammatory	B-Adev
+musculoskeletal	I-Adev
+manifestations	I-Adev
+	O
+following	O
+IFN-beta	O
+therapy	O
+
+Dystonia	B-Adev
+associated	O
+with	O
+carbamazepine	O
+administration	O
+experience	O
+in	O
+brain-damaged	O
+children	O
+
+In	O
+all	O
+51	O
+patients	O
+had	O
+a	O
+gastrointestinal	B-Adev
+event	I-Adev
+	O
+the	O
+event	O
+rate	O
+was	O
+1.1%	O
+with	O
+omeprazole	O
+and	O
+2.9%	O
+with	O
+placebo	O
+at	O
+180	O
+days	O
+(hazard	O
+ratio	O
+with	O
+omeprazole	O
+0.34	O
+95%	O
+confidence	O
+interval	O
+[CI]	O
+0.18	O
+to	O
+0.63	O
+P<0.001)	O
+
+CONCLUSION	O
+We	O
+report	O
+a	O
+case	O
+of	O
+the	O
+use	O
+of	O
+pamidronate	O
+for	O
+significant	O
+hypercalcemia	O
+secondary	O
+to	O
+acute	O
+vitamin	O
+D	O
+poisoning	O
+
+Clopidogrel	O
+with	O
+or	O
+without	O
+omeprazole	O
+in	O
+coronary	O
+artery	O
+disease	O
+
+The	O
+cases	O
+are	O
+important	O
+in	O
+documenting	O
+that	O
+drug-induced	O
+dystonias	O
+do	O
+occur	O
+in	O
+patients	O
+with	O
+dementia	O
+that	O
+risperidone	O
+appears	O
+to	O
+have	O
+contributed	O
+to	O
+dystonia	B-Adev
+among	O
+elderly	O
+patients	O
+and	O
+that	O
+the	O
+categorization	O
+of	O
+dystonic	O
+reactions	O
+needs	O
+further	O
+clarification	O
+
+In	O
+addition	O
+there	O
+is	O
+a	O
+report	O
+on	O
+prolonged	B-Adev
+ECT	I-Adev
+seizure	I-Adev
+related	O
+to	O
+ciprofloxacin	O
+which	O
+has	O
+an	O
+epileptogenic	O
+property	O
+with	O
+a	O
+similar	O
+action	O
+to	O
+beta-lactam	O
+antibiotics	O
+
+After	O
+abstinence	O
+from	O
+oolong	O
+tea	O
+his	O
+delirium	O
+resolved	O
+
+Anaphylaxis	B-Adev
+to	O
+intrathecal	O
+diamorphine	O
+
+This	O
+case	O
+suggests	O
+that	O
+acyclovir	O
+when	O
+given	O
+intravenously	O
+in	O
+doses	O
+of	O
+10	O
+mg/kg	O
+may	O
+result	O
+in	O
+increased	B-Adev
+serum	I-Adev
+lithium	I-Adev
+concentrations	I-Adev
+	O
+
+After	O
+approximately	O
+two	O
+weeks	O
+of	O
+sertraline	O
+treatment	O
+he	O
+noted	O
+an	O
+i	O
+ntense	B-Adev
+itching	I-Adev
+sensation	I-Adev
+in	I-Adev
+his	I-Adev
+scalp	I-Adev
+after	O
+eating	O
+a	O
+piece	O
+of	O
+chocolate	O
+cake	O
+
+Pigmentary	B-Adev
+aberrations	I-Adev
+are	O
+well	O
+known	O
+side	O
+effects	O
+of	O
+cytostatic	O
+chemotherapeutic	O
+agents	O
+
+CONCLUSION	O
+Atovaquone	O
+should	O
+be	O
+added	O
+to	O
+the	O
+list	O
+of	O
+agents	O
+causing	O
+vortex	B-Adev
+keratopathy	I-Adev
+involving	I-Adev
+the	I-Adev
+corneal	I-Adev
+epithelium	I-Adev
+	O
+
+A	O
+generalized	B-Adev
+tonic-clonic	I-Adev
+seizure	I-Adev
+occurred	O
+a	O
+few	O
+minutes	O
+after	O
+injection	O
+of	O
+the	O
+morphine	O
+antagonist	O
+naloxone	O
+
+CONCLUSION	O
+Squamous	B-Adev
+metaplasia	I-Adev
+in	O
+these	O
+cases	O
+appears	O
+to	O
+be	O
+a	O
+consequence	O
+of	O
+progestin	O
+therapy	O
+
+This	O
+association	O
+should	O
+be	O
+considered	O
+in	O
+the	O
+period	O
+after	O
+vasopressin-treated	O
+gastrointestinal	B-Adev
+hemorrhage	I-Adev
+	O
+
+The	O
+gynecomastia	B-Adev
+regressed	O
+when	O
+the	O
+theophylline	O
+was	O
+discontinued	O
+
+Renal	B-Adev
+hypophosphatemia	I-Adev
+in	O
+this	O
+patient	O
+was	O
+caused	O
+by	O
+the	O
+erroneous	O
+intake	O
+of	O
+1	O
+g	O
+doxycycline	O
+
+Despite	O
+a	O
+response	O
+of	O
+the	O
+meningeal	O
+tumor	O
+the	O
+patient	O
+developed	O
+in	O
+the	O
+third	O
+week	O
+of	O
+MTX	O
+treatment	O
+a	B-Adev
+progressive	I-Adev
+visual	I-Adev
+loss	I-Adev
+and	I-Adev
+loss	I-Adev
+of	I-Adev
+consciousness	I-Adev
+which	O
+worsened	O
+during	O
+subsequent	O
+Ara-C	O
+treatment	O
+and	O
+led	O
+to	O
+death	O
+within	O
+3	O
+weeks	O
+
+After	O
+seven	O
+months'	O
+continuous	O
+treatment	O
+for	O
+suspected	O
+tuberculosis	O
+with	O
+rifampicin	O
+and	O
+ethambutol	O
+a	O
+nine-year-old	O
+boy	O
+developed	O
+polyarthritis	B-Adev
+rash	I-Adev
+and	I-Adev
+hepatitis	I-Adev
+in	I-Adev
+association	I-Adev
+with	I-Adev
+anti-native	I-Adev
+DNA	I-Adev
+antibodies	I-Adev
+and	I-Adev
+positive	I-Adev
+antinuclear	I-Adev
+factor	I-Adev
+	O
+
+A	O
+few	O
+recent	O
+individual	O
+case	O
+reports	O
+have	O
+suggested	O
+that	O
+a	O
+myasthenic	B-Adev
+syndrome	I-Adev
+may	O
+be	O
+associated	O
+with	O
+statin	O
+treatment	O
+but	O
+this	O
+association	O
+is	O
+not	O
+well	O
+described	O
+
+Topical	O
+imiquimod	O
+and	O
+tumor	O
+necrosis	O
+factor	O
+(TNF)-alpha	O
+inhibitors	O
+have	O
+gained	O
+wide	O
+acceptance	O
+as	O
+safe	O
+and	O
+effective	O
+treatments	O
+for	O
+non-melanoma	O
+skin	O
+cancer	O
+(NMSC)	O
+and	O
+moderate	O
+to	O
+severe	O
+psoriasis	O
+respectively	O
+
+Topical	O
+imiquimod	O
+and	O
+tumor	O
+necrosis	O
+factor	O
+(TNF)-alpha	O
+inhibitors	O
+have	O
+gained	O
+wide	O
+acceptance	O
+as	O
+safe	O
+and	O
+effective	O
+treatments	O
+for	O
+non-melanoma	O
+skin	O
+cancer	O
+(NMSC)	O
+and	O
+moderate	O
+to	O
+severe	O
+psoriasis	O
+respectively	O
+
+Focal	B-Adev
+renal	I-Adev
+cortical	I-Adev
+necrosis	I-Adev
+associated	O
+with	O
+zomepirac	O
+
+We	O
+experienced	O
+2	O
+cases	O
+of	O
+mequitazine-induced	O
+photosensitivity	B-Adev
+reaction	I-Adev
+in	O
+patients	O
+who	O
+took	O
+mequitazine	O
+for	O
+their	O
+dermatologic	O
+problems	O
+
+Carboplatin	O
+was	O
+substituted	O
+for	O
+cisplatin	O
+and	O
+there	O
+were	O
+no	O
+further	O
+episodes	O
+of	O
+SIADH	O
+
+Severe	O
+steroid-induced	O
+glaucoma	B-Adev
+following	O
+intravitreal	O
+injection	O
+of	O
+triamcinolone	O
+acetonide	O
+
+CD20-negative	B-Adev
+T-cell-rich	I-Adev
+B-cell	I-Adev
+lymphoma	I-Adev
+as	O
+a	O
+progression	O
+of	O
+a	O
+nodular	O
+lymphocyte-predominant	O
+Hodgkin's	O
+lymphoma	O
+treated	O
+with	O
+rituximab	O
+a	O
+molecular	O
+analysis	O
+using	O
+laser	O
+capture	O
+microdissection	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+an	O
+adult	O
+patient	O
+with	O
+acute	O
+lymphoblastic	O
+leukemia	O
+who	O
+presented	O
+with	O
+repeated	B-Adev
+transient	I-Adev
+ischemic	I-Adev
+attacks	I-Adev
+followed	I-Adev
+by	I-Adev
+a	I-Adev
+seizure	I-Adev
+during	O
+consolidation	O
+treatment	O
+with	O
+L-asparaginase	O
+
+Gemcitabine-related	O
+radiation	B-Adev
+recall	I-Adev
+in	O
+a	O
+patient	O
+with	O
+pancreatic	O
+cancer	O
+
+After	O
+development	O
+of	O
+the	O
+tics	B-Adev
+in	O
+2	O
+CBZ	O
+was	O
+continued	O
+at	O
+the	O
+same	O
+or	O
+higher	O
+dose	O
+and	O
+the	O
+tics	O
+abated	O
+and	O
+then	O
+ceased	O
+spontaneously	O
+<	O
+or	O
+=	O
+6	O
+months	O
+
+Thus	O
+any	O
+case	O
+of	O
+severe	B-Adev
+neutropenia	I-Adev
+occurring	O
+in	O
+a	O
+patient	O
+receiving	O
+olanzapine	O
+is	O
+alarming	O
+to	O
+clinicians	O
+
+We	O
+describe	O
+3	O
+AS	O
+patients	O
+treated	O
+with	O
+etanercept	O
+for	O
+active	O
+AS	O
+who	O
+developed	O
+new	O
+onset	O
+of	O
+CD	B-Adev
+while	O
+AS	O
+related	O
+symptoms	O
+responded	O
+well	O
+to	O
+etanercept	O
+
+It	O
+is	O
+concluded	O
+that	O
+the	O
+aforementioned	O
+pathological	O
+manifestations	O
+were	O
+due	O
+to	O
+chemotherapy	O
+and	O
+included	O
+a	B-Adev
+pulmonary	I-Adev
+adverse	I-Adev
+reaction	I-Adev
+	O
+a	O
+feature	O
+never	O
+previously	O
+associated	O
+with	O
+oxaliplatinum	O
+and	O
+5-fluorouracil	O
+regimens	O
+
+A	O
+case	O
+of	O
+colchicine-induced	O
+rhabdomyolysis	B-Adev
+is	O
+reported	O
+
+Because	O
+of	O
+a	O
+recurrence	O
+of	O
+paroxysmal	O
+atrial	O
+fibrillation	O
+the	O
+dose	O
+of	O
+the	O
+drug	O
+was	O
+increased	O
+to	O
+1.4	O
+g/day	O
+24	O
+hours	O
+later	O
+AVT	B-Adev
+with	I-Adev
+syncope	I-Adev
+developed	O
+but	O
+responded	O
+promptly	O
+to	O
+atropine	O
+
+Because	O
+of	O
+a	O
+recurrence	O
+of	O
+paroxysmal	O
+atrial	O
+fibrillation	O
+the	O
+dose	O
+of	O
+the	O
+drug	O
+was	O
+increased	O
+to	O
+1.4	O
+g/day	O
+24	O
+hours	O
+later	O
+AVT	O
+with	O
+syncope	O
+developed	O
+but	O
+responded	O
+promptly	O
+to	O
+atropine	O
+
+Three	O
+male	O
+patients	O
+aged	O
+78-83	O
+years	O
+are	O
+presented	O
+in	O
+whom	O
+severe	B-Adev
+hepatotoxic	I-Adev
+reactions	I-Adev
+emerged	O
+after	O
+CPA	O
+administration	O
+
+Exacerbations	B-Adev
+of	I-Adev
+the	I-Adev
+heart	I-Adev
+failure	I-Adev
+were	O
+temporally	O
+related	O
+to	O
+the	O
+administration	O
+of	O
+the	O
+antitumor	O
+antibiotics	O
+actinomycin-D	O
+(NSC-3053)	O
+and	O
+mithramycin	O
+(NSC-24559)	O
+
+Diffuse	B-Adev
+alveolar	I-Adev
+hemorrhage	I-Adev
+after	O
+leflunomide	O
+therapy	O
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+64-year-old	O
+man	O
+with	O
+secondary	B-Adev
+adrenocortical	I-Adev
+insufficiency	I-Adev
+who	O
+has	O
+been	O
+on	O
+a	O
+chronic	O
+transdermal	O
+fentanyl	O
+treatment	O
+because	O
+of	O
+sciatic	O
+pain	O
+syndrome	O
+
+A	O
+52-year-old	O
+white	O
+female	O
+developed	O
+low-grade	B-Adev
+fever	I-Adev
+cough	I-Adev
+and	I-Adev
+dyspnea	I-Adev
+after	O
+8	O
+weeks	O
+treatment	O
+with	O
+sodium	O
+aurothiomalate	O
+for	O
+rheumatoid	O
+arthritis	O
+
+In	O
+both	O
+cases	O
+high	B-Adev
+fever	I-Adev
+skin	I-Adev
+rash	I-Adev
+liver	I-Adev
+dysfunction	I-Adev
+and	I-Adev
+atypical	I-Adev
+lymphocytosis	I-Adev
+developed	O
+3	O
+weeks	O
+after	O
+initiating	O
+treatment	O
+with	O
+SASP	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+severe	B-Adev
+chloroquine	I-Adev
+toxicity	I-Adev
+in	O
+the	O
+presence	O
+of	O
+high-grade	O
+chloroquine-resistant	O
+Plasmodium	O
+vivax	O
+
+RESULTS	O
+All	O
+cases	O
+developed	O
+corneal	B-Adev
+endothelial	I-Adev
+deposits	I-Adev
+after	O
+previous	O
+use	O
+of	O
+rifabutin	O
+
+Two	O
+infants	O
+developed	O
+hyperkalemia	B-Adev
+shortly	O
+after	O
+cessation	O
+of	O
+prolonged	O
+ACTH	O
+therapy	O
+for	O
+infantile	O
+spasms	O
+
+In	O
+this	O
+case	O
+CIPS	B-Adev
+was	O
+considered	O
+to	O
+be	O
+probably	O
+associated	O
+with	O
+cyclosporine	O
+according	O
+to	O
+the	O
+Naranjo	O
+probability	O
+scale	O
+
+Acute	B-Adev
+syphilitic	I-Adev
+posterior	I-Adev
+placoid	I-Adev
+chorioretinitis	I-Adev
+following	O
+intravitreal	O
+triamcinolone	O
+acetonide	O
+injection	O
+
+Delayed	B-Adev
+pseudocyst	I-Adev
+of	I-Adev
+the	I-Adev
+pancreas	I-Adev
+can	O
+be	O
+a	O
+complication	O
+of	O
+intramuscular	O
+L-asparaginase	O
+
+I	O
+report	O
+a	O
+35-year-old	O
+woman	O
+with	O
+occult	O
+coronary	O
+artery	O
+disease	O
+who	O
+experienced	O
+cardiac	B-Adev
+arrest	I-Adev
+within	O
+minutes	O
+after	O
+receiving	O
+a	O
+first-time	O
+dose	O
+of	O
+subcutaneous	O
+sumatriptan	O
+for	O
+migraine	O
+
+Epoprostenol	O
+(prostacyclin)	O
+is	O
+currently	O
+approved	O
+for	O
+treatment	O
+of	O
+primary	O
+pulmonary	O
+hypertension	O
+however	O
+it	O
+is	O
+being	O
+evaluated	O
+in	O
+other	O
+forms	O
+of	O
+pulmonary	O
+hypertension	O
+particularly	O
+scleroderma	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+fatal	B-Adev
+case	I-Adev
+of	I-Adev
+toxic	I-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+in	O
+a	O
+man	O
+who	O
+was	O
+treated	O
+with	O
+oral	O
+ofloxacin	O
+for	O
+epididymitis	O
+
+Massive	B-Adev
+pulmonary	I-Adev
+embolism	I-Adev
+due	O
+to	O
+late-onset	O
+heparin-induced	O
+thrombocytopenia	O
+following	O
+coronary	O
+artery	O
+bypass	O
+graft	O
+surgery	O
+successful	O
+treatment	O
+with	O
+lepirudin	O
+
+Value	O
+of	O
+high-dose	O
+cytarabine	O
+during	O
+interval	O
+therapy	O
+of	O
+a	O
+Berlin-Frankfurt-Munster-based	O
+protocol	O
+in	O
+increased-risk	O
+children	O
+with	O
+acute	O
+lymphoblastic	O
+leukemia	O
+and	O
+lymphoblastic	O
+lymphoma	O
+results	O
+of	O
+the	O
+European	O
+Organization	O
+for	O
+Research	O
+and	O
+Treatment	O
+of	O
+Cancer	O
+58881	O
+randomized	O
+phase	O
+III	O
+trial	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+fulminant	B-Adev
+hepatic	I-Adev
+failure	I-Adev
+associated	O
+with	O
+didanosine	O
+and	O
+masquerading	O
+as	O
+a	O
+surgical	O
+abdomen	O
+and	O
+compare	O
+the	O
+clinical	O
+biologic	O
+histologic	O
+and	O
+ultrastructural	O
+findings	O
+with	O
+reports	O
+described	O
+previously	O
+
+An	O
+objective	O
+causal	O
+assessment	O
+suggests	O
+that	O
+rhabdomyolysis	B-Adev
+renal	I-Adev
+failure	I-Adev
+and	I-Adev
+possibly	I-Adev
+hepatotoxicity	I-Adev
+were	O
+probably	O
+related	O
+to	O
+an	O
+amiodarone-simvastatin	O
+interaction	O
+
+Nail	B-Adev
+staining	I-Adev
+from	O
+hydroquinone	O
+cream	O
+
+The	O
+development	O
+of	O
+an	B-Adev
+IgG	I-Adev
+lambda-type	I-Adev
+monoclonal	I-Adev
+gammopathy	I-Adev
+and	I-Adev
+subsequent	I-Adev
+multiple	I-Adev
+myeloma	I-Adev
+in	O
+an	O
+epilepsy	O
+patient	O
+on	O
+diphenylhydantoin	O
+(DILANTIN)	O
+therapy	O
+for	O
+20	O
+years	O
+is	O
+reported	O
+
+Ibuprofen	O
+overdose	O
+is	O
+usually	O
+characterized	O
+by	O
+GI	B-Adev
+upset	I-Adev
+dizziness	I-Adev
+and	I-Adev
+mild	I-Adev
+sedation	I-Adev
+	O
+
+His	O
+PD	O
+medications	O
+(pramipexole	O
+entacapone	O
+and	O
+immediate-release	O
+levodopa/carbidopa	O
+100	O
+mg/25	O
+mg	O
+1.5	O
+tablets	O
+4	O
+times	O
+daily)	O
+were	O
+administered	O
+via	O
+nasogastric	O
+tube	O
+
+CONCLUSIONS	O
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+a	O
+possible	O
+interaction	O
+between	O
+propafenone	O
+and	O
+citalopram	O
+which	O
+caused	O
+propafenone	O
+adverse	B-Adev
+effects	I-Adev
+(eg	I-Adev
+dizziness	I-Adev
+falls)	I-Adev
+and	I-Adev
+mimicked	I-Adev
+coronary	I-Adev
+artery	I-Adev
+disease	I-Adev
+	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+young	O
+healthy	O
+woman	O
+who	O
+presented	O
+an	O
+early	B-Adev
+overanticoagulation	I-Adev
+when	O
+receiving	O
+acenocoumarol	O
+for	O
+a	O
+first	O
+thromboembolic	O
+episode	O
+
+A	O
+patient	O
+with	O
+acute	B-Adev
+changes	I-Adev
+suggesting	I-Adev
+acute	I-Adev
+hepatitis	I-Adev
+after	O
+parenteral	O
+amiodarone	O
+administration	O
+is	O
+described	O
+
+Subsequently	O
+he	O
+developed	O
+hyperglycemia	O
+(fasting	O
+blood	O
+glucose	O
+138	O
+mg/dL)	O
+that	O
+resolved	O
+when	O
+olanzapine	O
+was	O
+stopped	O
+and	O
+recurred	O
+(fasting	O
+blood	O
+glucose	O
+150	O
+mg/dL)	O
+after	O
+2	O
+days	O
+of	O
+rechallenge	O
+with	O
+olanzapine	O
+2.5	O
+mg	O
+twice	O
+daily	O
+
+Subsequently	O
+he	O
+developed	O
+hyperglycemia	B-Adev
+(fasting	O
+blood	O
+glucose	O
+138	O
+mg/dL)	O
+that	O
+resolved	O
+when	O
+olanzapine	O
+was	O
+stopped	O
+and	O
+recurred	O
+(fasting	O
+blood	O
+glucose	O
+150	O
+mg/dL)	O
+after	O
+2	O
+days	O
+of	O
+rechallenge	O
+with	O
+olanzapine	O
+2.5	O
+mg	O
+twice	O
+daily	O
+
+Fulminant	B-Adev
+hepatitis	I-Adev
+with	I-Adev
+severe	I-Adev
+lactate	I-Adev
+acidosis	I-Adev
+in	O
+HIV-infected	O
+patients	O
+on	O
+didanosine	O
+therapy	O
+
+Persisent	B-Adev
+ocular	I-Adev
+hypertension	I-Adev
+following	O
+intravitreal	O
+ranibizumab	O
+
+STUDY	O
+DESIGN	O
+Case	O
+report	O
+of	O
+a	O
+31-year-old	O
+woman	O
+who	O
+presented	O
+with	O
+toxic	B-Adev
+myelopathy	I-Adev
+due	O
+to	O
+intrathecal	O
+administration	O
+of	O
+doxorubicin	O
+
+The	O
+patient	O
+had	O
+a	O
+background	O
+of	O
+obsessive	O
+compulsive	O
+disorder	O
+treated	O
+with	O
+paroxetine	O
+
+Clozapine	O
+is	O
+speculated	O
+to	O
+cause	O
+rhabdomyolysis	B-Adev
+in	O
+patients	O
+with	O
+defective	O
+calcium-activated	O
+K+	O
+channels	O
+
+CONCLUSIONS	O
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+gemcitabine-induced	O
+LABD	B-Adev
+	O
+
+Nitrofurantoin-induced	O
+lung	B-Adev
+disease	I-Adev
+	O
+two	O
+cases	O
+demonstrating	O
+resolution	O
+of	O
+apparently	O
+irreversible	O
+CT	O
+abnormalities	O
+
+Trazodone-induced	O
+transient	B-Adev
+hypomanic	I-Adev
+symptoms	I-Adev
+and	O
+their	O
+management	O
+
+Acute	B-Adev
+aluminum	I-Adev
+toxicity	I-Adev
+after	O
+continuous	O
+intravesical	O
+alum	O
+irrigation	O
+for	O
+hemorrhagic	O
+cystitis	O
+
+Amphotericin	O
+B-induced	O
+cutaneous	B-Adev
+leucocytoclastic	I-Adev
+vasculitis	I-Adev
+	O
+case	O
+report	O
+
+When	O
+measured	O
+the	O
+serum	B-Adev
+lithium	I-Adev
+level	I-Adev
+had	I-Adev
+increased	I-Adev
+4-fold	I-Adev
+during	O
+acyclovir	O
+therapy	O
+
+In	O
+this	O
+paper	O
+it	O
+is	O
+reported	O
+an	O
+evidence	O
+of	O
+pharmacokinetic	B-Adev
+interaction	I-Adev
+between	O
+clarithromycin	O
+and	O
+sirolimus	O
+in	O
+a	O
+kidney	O
+transplanted	O
+woman	O
+suffering	O
+from	O
+pulmonary	O
+infection	O
+sustained	O
+by	O
+a	O
+bacterial	O
+pathogen	O
+in	O
+particular	O
+Hemophilus	O
+Influenzae	O
+
+A	O
+25-year-old	O
+man	O
+with	O
+a	O
+history	O
+of	O
+mid-borderline	O
+(BB)	O
+Hansen's	O
+disease	O
+developing	O
+a	B-Adev
+reversal	I-Adev
+reaction	I-Adev
+after	O
+starting	O
+dapsone	O
+and	O
+rifampin	O
+therapy	O
+is	O
+presented	O
+
+In	O
+all	O
+cases	O
+drugs	O
+in	O
+addition	O
+to	O
+quetiapine	O
+were	O
+detected	O
+but	O
+in	O
+cases	O
+#1	O
+and	O
+#2	O
+the	O
+cause	O
+of	O
+death	B-Adev
+was	O
+considered	O
+to	O
+be	O
+a	O
+quetiapine	O
+overdose	O
+and	O
+the	O
+other	O
+drugs	O
+were	O
+not	O
+considered	O
+to	O
+be	O
+contributory	O
+
+Similar	O
+to	O
+antiarrhythmic	O
+drugs	O
+aggravating	O
+particular	O
+arrhythmias	O
+antiepileptic	O
+drugs	O
+can	O
+paradoxically	O
+induce	O
+new	B-Adev
+seizure	I-Adev
+types	I-Adev
+or	I-Adev
+exacerbate	I-Adev
+existing	I-Adev
+ones	I-Adev
+	O
+
+We	O
+report	O
+here	O
+a	O
+rare	O
+case	O
+of	O
+ritodrine-hydrochloride-induced	O
+rhabdomyolysis	B-Adev
+in	O
+a	O
+pregnant	O
+patient	O
+with	O
+myotonic	O
+dystrophy	O
+
+OBJECTIVE	O
+To	O
+report	O
+the	O
+finding	O
+of	O
+squamous	B-Adev
+metaplasia	I-Adev
+within	I-Adev
+endometrial	I-Adev
+glands	I-Adev
+occurring	O
+as	O
+a	O
+result	O
+of	O
+progestin	O
+therapy	O
+of	O
+hyperplasia	O
+
+IMPLICATIONS	O
+FOR	O
+NURSING	O
+PRACTICE	O
+Nurses	O
+must	O
+understand	O
+the	O
+pharmacology	O
+mechanism	O
+of	O
+action	O
+clinical	O
+presentation	O
+potentially	O
+lethal	O
+risks	O
+and	O
+traumatic	O
+psychosocial	O
+stresses	O
+experienced	O
+by	O
+DPD-deficient	O
+patients	O
+with	O
+cancer	O
+receiving	O
+5-FU	O
+therapy	O
+in	O
+order	O
+to	O
+develop	O
+timely	O
+interventions	O
+and	O
+alternative	O
+plans	O
+of	O
+care	O
+
+Methotrexate	O
+is	O
+an	O
+effective	O
+but	O
+potentially	O
+toxic	O
+treatment	O
+for	O
+psoriasis	O
+
+Typical	B-Adev
+symptoms	I-Adev
+of	I-Adev
+active	I-Adev
+CD	I-Adev
+occurred	O
+11	O
+12	O
+and	O
+26	O
+months	O
+after	O
+start	O
+of	O
+etanercept	O
+therapy	O
+respectively	O
+
+This	O
+progressed	O
+to	O
+tracheal	B-Adev
+compression	I-Adev
+with	I-Adev
+stridor	I-Adev
+after	O
+he	O
+had	O
+taken	O
+some	O
+aspirin	O
+for	O
+relief	O
+of	O
+the	O
+neck	O
+pain	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+toxin-positive	B-Adev
+Clostridium	I-Adev
+difficile-induced	I-Adev
+colitis	I-Adev
+(CDIC)	O
+after	O
+use	O
+of	O
+clindamycin	O
+phosphate	O
+vaginal	O
+cream	O
+
+Severe	O
+vancomycin-induced	O
+anaphylactic	B-Adev
+reaction	I-Adev
+	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+74-year-old	O
+female	O
+patient	O
+who	O
+received	O
+the	O
+antide-pressant	O
+amitriptyline	O
+because	O
+of	O
+a	O
+major	O
+depression	O
+
+Rhabdomyolysis	B-Adev
+has	O
+been	O
+recognized	O
+as	O
+a	O
+complication	O
+of	O
+tocolytic	O
+therapy	O
+with	O
+ritodrine	O
+hydrochloride	O
+
+Voriconazole	O
+(VRC)	O
+has	O
+not	O
+previously	O
+been	O
+reported	O
+to	O
+cause	O
+angio-oedema	B-Adev
+	O
+
+CONCLUSION	O
+Tamoxifen	O
+may	O
+cause	O
+malignant	B-Adev
+transformation	I-Adev
+of	I-Adev
+endometriosis	I-Adev
+through	I-Adev
+atypical	I-Adev
+endometriosis	I-Adev
+even	O
+in	O
+the	O
+postmenopausal	O
+state	O
+
+One	O
+patient	O
+had	O
+an	O
+episode	O
+of	O
+prostatitis	O
+which	O
+was	O
+treated	O
+with	O
+levofloxacin	O
+immediately	O
+prior	O
+to	O
+tolterodine	O
+initiation	O
+
+The	O
+first	O
+patient	O
+developed	O
+a	O
+monoarthritis	B-Adev
+2	O
+weeks	O
+after	O
+initiation	O
+of	O
+IFN-beta	O
+which	O
+persisted	O
+during	O
+the	O
+14	O
+months	O
+of	O
+therapy	O
+and	O
+resolved	O
+with	O
+discontinuation	O
+of	O
+the	O
+medication	O
+
+The	O
+present	O
+report	O
+illustrates	O
+a	O
+rare	O
+case	O
+of	O
+refractory	B-Adev
+akathisia	I-Adev
+after	O
+interferon-alpha	O
+treatment	O
+and	O
+also	O
+that	O
+levodopa	O
+treatment	O
+would	O
+be	O
+theoretically	O
+and	O
+practically	O
+useful	O
+in	O
+reducing	O
+the	O
+neurotoxicity	O
+associated	O
+with	O
+interferon-alpha	O
+
+The	O
+present	O
+report	O
+illustrates	O
+a	O
+rare	O
+case	O
+of	O
+refractory	O
+akathisia	O
+after	O
+interferon-alpha	O
+treatment	O
+and	O
+also	O
+that	O
+levodopa	O
+treatment	O
+would	O
+be	O
+theoretically	O
+and	O
+practically	O
+useful	O
+in	O
+reducing	O
+the	O
+neurotoxicity	O
+associated	O
+with	O
+interferon-alpha	O
+
+The	O
+present	O
+report	O
+illustrates	O
+a	O
+rare	O
+case	O
+of	O
+refractory	O
+akathisia	O
+after	O
+interferon-alpha	O
+treatment	O
+and	O
+also	O
+that	O
+levodopa	O
+treatment	O
+would	O
+be	O
+theoretically	O
+and	O
+practically	O
+useful	O
+in	O
+reducing	O
+the	O
+neurotoxicity	B-Adev
+associated	O
+with	O
+interferon-alpha	O
+
+Rosaceiform	B-Adev
+eruption	I-Adev
+induced	O
+by	O
+erlotinib	O
+
+The	O
+incidence	O
+of	O
+oral-verapamil-induced	O
+hypotension	B-Adev
+in	O
+the	O
+presence	O
+of	O
+concomitant	O
+beta-adrenergic	O
+blockade	O
+by	O
+the	O
+oral	O
+route	O
+is	O
+quite	O
+rare	O
+
+Until	O
+additional	O
+data	O
+are	O
+available	O
+if	O
+intravenous	O
+acyclovir	O
+is	O
+administered	O
+concurrently	O
+with	O
+lithium	O
+we	O
+recommend	O
+closely	O
+monitoring	O
+patients	O
+for	O
+signs	O
+of	O
+lithium	B-Adev
+toxicity	I-Adev
+and	O
+measuring	O
+serum	O
+lithium	O
+levels	O
+every	O
+second	O
+or	O
+third	O
+day	O
+
+Disappointingly	O
+with	O
+the	O
+dose	O
+schedule	O
+used	O
+in	O
+this	O
+protocol	O
+HD	O
+Ara-C	O
+added	O
+to	O
+HD	O
+MTX	O
+although	O
+well	O
+tolerated	O
+failed	O
+to	O
+further	B-Adev
+decrease	I-Adev
+the	I-Adev
+incidence	I-Adev
+of	I-Adev
+CNS	I-Adev
+relapse	I-Adev
+or	I-Adev
+to	I-Adev
+improve	I-Adev
+the	I-Adev
+overall	I-Adev
+DFS	I-Adev
+	O
+
+Theophylline	B-Adev
+intoxication	I-Adev
+following	O
+viloxazine	O
+induced	O
+decrease	O
+in	O
+clearance	O
+
+Cercarial	O
+encystment	O
+at	O
+concentrations	O
+of	O
+25000	O
+microg/l	O
+or	O
+higher	O
+was	O
+significantly	O
+impaired	O
+by	O
+all	O
+test	O
+metals	O
+however	O
+at	O
+lower	O
+concentrations	O
+only	O
+zinc	O
+demonstrated	O
+toxicity	B-Adev
+	O
+
+PURPOSE	O
+We	O
+report	O
+an	O
+unusual	B-Adev
+paradoxical	I-Adev
+effect	I-Adev
+of	O
+brimonidine	O
+
+Renal	B-Adev
+failure	I-Adev
+after	O
+high-dose	O
+methotrexate	O
+in	O
+a	O
+child	O
+homozygous	O
+for	O
+MTHFR	O
+C677T	O
+polymorphism	O
+
+Although	O
+his	O
+renal	O
+function	O
+recovered	O
+completely	O
+with	O
+high-dose	O
+leucovorin	O
+hemodialysis	O
+charcoal	O
+hemoperfusion	O
+and	O
+carboxypeptidase	O
+G2	O
+we	O
+present	O
+this	O
+case	O
+to	O
+emphasize	O
+that	O
+signs	O
+of	O
+renal	B-Adev
+toxicity	I-Adev
+may	O
+be	O
+present	O
+as	O
+early	O
+as	O
+2	O
+hours	O
+after	O
+the	O
+completion	O
+of	O
+a	O
+4-hour	O
+MTX	O
+infusion	O
+and	O
+to	O
+suggest	O
+that	O
+monitoring	O
+for	O
+MTX	O
+toxicity	O
+should	O
+perhaps	O
+begin	O
+within	O
+a	O
+few	O
+hours	O
+after	O
+the	O
+completion	O
+of	O
+4-hour	O
+MTX	O
+infusion	O
+
+Although	O
+his	O
+renal	O
+function	O
+recovered	O
+completely	O
+with	O
+high-dose	O
+leucovorin	O
+hemodialysis	O
+charcoal	O
+hemoperfusion	O
+and	O
+carboxypeptidase	O
+G2	O
+we	O
+present	O
+this	O
+case	O
+to	O
+emphasize	O
+that	O
+signs	O
+of	O
+renal	O
+toxicity	O
+may	O
+be	O
+present	O
+as	O
+early	O
+as	O
+2	O
+hours	O
+after	O
+the	O
+completion	O
+of	O
+a	O
+4-hour	O
+MTX	O
+infusion	O
+and	O
+to	O
+suggest	O
+that	O
+monitoring	O
+for	O
+MTX	O
+toxicity	O
+should	O
+perhaps	O
+begin	O
+within	O
+a	O
+few	O
+hours	O
+after	O
+the	O
+completion	O
+of	O
+4-hour	O
+MTX	O
+infusion	O
+
+Ten	O
+to	O
+15%	O
+of	O
+patients	O
+treated	O
+with	O
+ifosfamide	O
+develop	O
+an	O
+encephalopathy	B-Adev
+
+METHODS	O
+We	O
+queried	O
+35	O
+rheumatologists	O
+at	O
+the	O
+Robert	O
+Breck	O
+Brigham	O
+Arthritis	O
+Center	O
+to	O
+determine	O
+if	O
+weight	B-Adev
+loss	I-Adev
+had	O
+occurred	O
+as	O
+an	O
+adverse	O
+event	O
+in	O
+patients	O
+treated	O
+with	O
+leflunomide	O
+between	O
+November	O
+1998	O
+and	O
+January	O
+2000	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+a	O
+catatonic	B-Adev
+syndrome	I-Adev
+occurring	O
+in	O
+a	O
+patient	O
+receiving	O
+disulfiram	O
+treatment	O
+
+Management	O
+of	O
+hypophosphatemia	O
+induced	O
+by	O
+high-flux	O
+hemodiafiltration	O
+for	O
+the	O
+treatment	O
+of	O
+vancomycin	O
+toxicity	O
+intravenous	O
+phosphorus	O
+therapy	O
+versus	O
+use	O
+of	O
+a	O
+phosphorus-enriched	O
+dialysate	O
+
+Two	O
+weeks	O
+following	O
+rechallenge	O
+with	O
+alendronate	O
+sodium	O
+resulted	O
+in	O
+recurrence	O
+of	O
+his	O
+scleritis	B-Adev
+	O
+
+We	O
+believe	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+intrathecal	O
+diamorphine	O
+causing	O
+anaphylaxis	B-Adev
+	O
+
+Clearance	O
+rates	O
+of	O
+cerivastatin	O
+metabolites	O
+in	O
+a	O
+patient	O
+with	O
+cerivastatin-induced	O
+rhabdomyolysis	B-Adev
+	O
+
+This	O
+case	O
+report	O
+and	O
+several	O
+others	O
+point	O
+toward	O
+azathioprine	O
+as	O
+a	O
+clinically	O
+significant	O
+inducer	O
+of	O
+warfarin	B-Adev
+resistance	I-Adev
+	O
+
+PURPOSE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+nodular	B-Adev
+scleritis	I-Adev
+following	O
+alendronate	O
+sodium	O
+
+Most	O
+cardiac	O
+surgical	O
+patients	O
+have	O
+had	O
+previous	O
+exposure	O
+to	O
+heparin	O
+for	O
+diagnostic	O
+or	O
+therapeutic	O
+interventions	O
+and	O
+hence	O
+have	O
+an	O
+increased	O
+susceptibility	O
+to	O
+developing	O
+heparin-induced	B-Adev
+thrombocytopenia	I-Adev
+(HIT)	I-Adev
+postoperatively	O
+
+PURPOSE	O
+We	O
+studied	O
+a	O
+case	O
+of	O
+vortex	B-Adev
+keratopathy	I-Adev
+that	O
+was	O
+associated	O
+with	O
+the	O
+use	O
+of	O
+atovaquone	O
+
+While	O
+on	O
+a	O
+maximal	O
+dose	O
+of	O
+phenylephrine	O
+she	O
+developed	O
+prominent	O
+positive	B-Adev
+U	I-Adev
+waves	I-Adev
+	O
+which	O
+disappeared	O
+with	O
+the	O
+cessation	O
+of	O
+the	O
+drug	O
+
+RESULTS	O
+Two	O
+patients	O
+with	O
+ocular	O
+inflammation	O
+of	O
+unknown	O
+origin	O
+developed	O
+severe	B-Adev
+chorioretinitis	I-Adev
+after	O
+IVTA	O
+injection	O
+
+Disopyramide	O
+was	O
+started	O
+on	O
+admission	O
+for	O
+supraventricular	O
+tachycardia	O
+
+A	O
+50-year-old	O
+woman	O
+with	O
+a	O
+history	O
+of	O
+migraine	O
+without	O
+aura	O
+predominantly	O
+occurring	O
+around	O
+her	O
+menstrual	O
+periods	O
+developed	O
+a	B-Adev
+spinal	I-Adev
+cord	I-Adev
+lesion	I-Adev
+following	O
+the	O
+use	O
+of	O
+zolmitriptan	O
+
+The	O
+[['skin	B-Adev
+rash	I-Adev
+effect']	I-Adev
+['cutaneous	I-Adev
+skin	I-Adev
+condition']]	I-Adev
+in	O
+rash	O
+effect	O
+was	O
+most	O
+probably	O
+due	O
+in	O
+first	O
+line	O
+to	O
+olanzapine	O
+but	O
+the	O
+cutaneous	O
+skin	O
+condition	O
+was	O
+triggered	O
+and	O
+aggravated	O
+by	O
+pravastatin	O
+a	O
+3-hydoxy-3-methylglutaryl-coenzyme	O
+A-(HMG-CoA)-reductase	O
+inhibitor	O
+and	O
+lithium	O
+medication	O
+
+CONCLUSION	O
+Anterior	B-Adev
+ischemic	I-Adev
+optic	I-Adev
+neuropathy	I-Adev
+may	O
+complicate	O
+treatment	O
+with	O
+interferon	O
+alfa	O
+
+After	O
+5	O
+weeks	O
+of	O
+therapy	O
+she	O
+stopped	O
+taking	O
+pantoprazole	O
+due	O
+to	O
+general	B-Adev
+malaise	I-Adev
+	O
+
+We	O
+report	O
+the	O
+use	O
+of	O
+pamidronate	O
+for	O
+acute	O
+severe	O
+hypercalcemia	O
+secondary	O
+to	O
+iatrogenic	O
+vitamin	O
+D	O
+poisoning	O
+
+We	O
+report	O
+the	O
+use	O
+of	O
+pamidronate	O
+for	O
+acute	O
+severe	O
+hypercalcemia	B-Adev
+secondary	O
+to	O
+iatrogenic	O
+vitamin	O
+D	O
+poisoning	O
+
+According	O
+to	O
+the	O
+Naranjo	O
+probability	O
+scale	O
+the	O
+relationship	O
+of	O
+gemcitabine	O
+treatment	O
+with	O
+cutaneous	B-Adev
+eruption	I-Adev
+in	O
+our	O
+patient	O
+is	O
+possible	O
+
+Methylene	O
+blue	O
+was	O
+administered	O
+to	O
+a	O
+58-yr-old	O
+woman	O
+undergoing	O
+a	O
+parathyroidectomy	O
+under	O
+general	O
+anesthesia	O
+
+We	O
+describe	O
+two	O
+cases	O
+that	O
+illustrate	O
+the	O
+use	O
+of	O
+lithium	O
+in	O
+the	O
+treatment	O
+of	O
+veterans	O
+with	O
+PTSD	O
+who	O
+complained	O
+of	O
+serious	B-Adev
+problems	I-Adev
+with	I-Adev
+irritability	I-Adev
+or	I-Adev
+angry	I-Adev
+outbursts	I-Adev
+	O
+
+It	O
+is	O
+well-recognized	O
+that	O
+flucloxacillin	O
+may	O
+occasionally	O
+result	O
+in	O
+fatal	O
+hepatic	B-Adev
+injury	I-Adev
+	O
+
+Neurologic	B-Adev
+toxicity	I-Adev
+associated	O
+with	O
+hepatic	O
+artery	O
+infusion	O
+HAI	O
+of	O
+FUdR	O
+
+Hyperkalemia	B-Adev
+as	O
+a	O
+late	O
+side	O
+effect	O
+of	O
+prolonged	O
+adrenocorticotropic	O
+hormone	O
+therapy	O
+for	O
+infantile	O
+spasms	O
+
+METHODS	O
+We	O
+report	O
+two	O
+cases	O
+of	O
+pseudoporphyria	B-Adev
+caused	O
+by	O
+naproxen	O
+and	O
+oxaprozin	O
+
+She	O
+was	O
+treated	O
+with	O
+an	O
+average	O
+weekly	O
+warfarin	O
+dose	O
+of	O
+39	O
+mg	O
+(5.5	O
+mg	O
+daily)	O
+prior	O
+to	O
+beginning	O
+azathioprine	O
+therapy	O
+
+When	O
+the	O
+disease	O
+recurred	O
+conventional	O
+amphotericin	O
+B	O
+was	O
+used	O
+again	O
+but	O
+had	O
+to	O
+be	O
+stopped	O
+because	O
+of	O
+severe	O
+side	B-Adev
+effects	I-Adev
+	O
+
+Widespread	O
+cutaneous	B-Adev
+vasculitis	I-Adev
+associated	O
+with	O
+diltiazem	O
+
+The	O
+following	O
+describes	O
+a	O
+patient	O
+on	O
+a	O
+stable	O
+regimen	O
+of	O
+warfarin	O
+who	O
+developed	O
+severe	O
+hypoprothrombinemia	B-Adev
+and	I-Adev
+bleeding	I-Adev
+4	O
+weeks	O
+after	O
+starting	O
+gemfibrozil	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+40-year-old	O
+woman	O
+who	O
+developed	O
+fulminant	B-Adev
+hepatic	I-Adev
+failure	I-Adev
+and	I-Adev
+aplastic	I-Adev
+anaemia	I-Adev
+following	O
+a	O
+course	O
+of	O
+oral	O
+flucloxacillin	O
+
+This	O
+case	O
+highlights	O
+the	O
+possible	O
+development	O
+of	O
+acute	B-Adev
+coronary	I-Adev
+syndrome	I-Adev
+as	O
+a	O
+side	O
+effect	O
+of	O
+Capecitabine	O
+therapy	O
+
+These	O
+results	O
+indicate	O
+that	O
+lithium	O
+may	O
+cause	O
+biochemical	B-Adev
+hyperparathyroidism	I-Adev
+	O
+
+The	O
+relationship	O
+between	O
+infliximab	O
+treatment	O
+and	O
+lymphoma	B-Adev
+in	O
+Crohn's	O
+disease	O
+
+CONCLUSION	O
+There	O
+may	O
+be	O
+an	O
+association	O
+between	O
+raloxifene	O
+and	O
+the	O
+development	O
+of	O
+malignant	B-Adev
+mixed	I-Adev
+mesodermal	I-Adev
+tumor	I-Adev
+	O
+
+Early	O
+recognition	O
+of	O
+renal	B-Adev
+toxicity	I-Adev
+of	O
+high-dose	O
+methotrexate	O
+therapy	O
+a	O
+case	O
+report	O
+
+The	O
+mild	B-Adev
+immunosuppression	I-Adev
+that	O
+occurs	O
+with	O
+methotrexate	O
+therapy	O
+probably	O
+places	O
+patients	O
+with	O
+rheumatoid	O
+arthritis	O
+at	O
+added	O
+risk	O
+of	O
+developing	O
+lymphoproliferative	O
+diseases	O
+but	O
+coincidence	O
+cannot	O
+be	O
+excluded	O
+
+We	O
+attribute	O
+the	O
+clinical	O
+and	O
+radiographic	O
+findings	O
+to	O
+cytotoxic	B-Adev
+edema	I-Adev
+secondary	O
+to	O
+intrathecal	O
+methotrexate	O
+
+Morphine	O
+an	O
+opium	O
+alkaloid	O
+frequently	O
+causes	O
+side	O
+effects	O
+such	O
+as	O
+hyperhidrosis	B-Adev
+and	O
+facial	O
+flushing	O
+but	O
+serious	O
+cutaneous	O
+adverse	O
+drug	O
+reactions	O
+are	O
+seldom	O
+observed	O
+
+Severe	B-Adev
+aphthous	I-Adev
+stomatitis	I-Adev
+associated	O
+with	O
+oral	O
+calcineurin	O
+and	O
+mTOR	O
+inhibitors	O
+
+A	O
+79-year-old	O
+man	O
+with	O
+ischemic	O
+heart	O
+disease	O
+chronic	O
+atrial	O
+fibrillation	O
+chronic	O
+renal	O
+failure	O
+hypothyroidism	O
+and	O
+gout	O
+arthritis	O
+was	O
+hospitalized	O
+because	O
+of	O
+fatigue	B-Adev
+myalgia	I-Adev
+and	I-Adev
+leg	I-Adev
+weakness	I-Adev
+	O
+shortly	O
+after	O
+starting	O
+treatment	O
+with	O
+colchicine	O
+
+This	O
+report	O
+describes	O
+a	O
+case	O
+of	O
+paradoxical	O
+intravenous	O
+valproic	O
+acid-induced	O
+seizure	B-Adev
+exacerbation	I-Adev
+in	O
+a	O
+child	O
+with	O
+juvenile	O
+absence	O
+epilepsy	O
+documented	O
+by	O
+video-electroencephalography	O
+
+She	O
+was	O
+treated	O
+with	O
+acyclovir	O
+and	O
+subsequently	O
+developed	O
+VZV	B-Adev
+antigen-positive	I-Adev
+zoster	I-Adev
+	O
+
+CONCLUSIONS	O
+In	O
+these	O
+3	O
+cases	O
+the	O
+unique	O
+positive	O
+ocular	O
+finding	O
+was	O
+corneal	B-Adev
+endothelial	I-Adev
+deposits	I-Adev
+	O
+which	O
+may	O
+be	O
+related	O
+to	O
+the	O
+use	O
+of	O
+rifabutin	O
+
+Response	O
+of	O
+a	O
+promethazine-induced	O
+coma	B-Adev
+to	O
+flumazenil	O
+
+Response	O
+of	O
+a	O
+promethazine-induced	O
+coma	O
+to	O
+flumazenil	O
+
+First	O
+a	O
+review	O
+of	O
+the	O
+literature	O
+produced	O
+41	O
+anecdotic	O
+cases	O
+of	O
+neutropenia	B-Adev
+or	I-Adev
+agranulocytosis	I-Adev
+during	O
+treatment	O
+with	O
+olanzapine	O
+(Zyprexa)	O
+reported	O
+in	O
+a	O
+total	O
+of	O
+24	O
+publications	O
+
+Neurologic	B-Adev
+degeneration	I-Adev
+associated	O
+with	O
+nitrous	O
+oxide	O
+anesthesia	O
+in	O
+patients	O
+with	O
+vitamin	O
+B12	O
+deficiency	O
+
+Previous	O
+therapy	O
+with	O
+antiarrhythmics	O
+had	O
+resulted	O
+in	O
+intolerable	B-Adev
+adverse	I-Adev
+effects	I-Adev
+or	O
+no	O
+effect	O
+on	O
+the	O
+arrhythmia	O
+
+Previous	O
+therapy	O
+with	O
+antiarrhythmics	O
+had	O
+resulted	O
+in	O
+intolerable	O
+adverse	O
+effects	O
+or	O
+no	O
+effect	O
+on	O
+the	O
+arrhythmia	O
+
+Allergic	B-Adev
+contact	I-Adev
+dermatitis	I-Adev
+to	O
+compound	O
+tincture	O
+of	O
+benzoin	O
+
+PURPOSE	O
+To	O
+determine	O
+the	O
+cause	O
+of	O
+spontaneous	B-Adev
+choroidal	I-Adev
+hemorrhage	I-Adev
+in	O
+a	O
+67-year-old	O
+man	O
+after	O
+a	O
+myocardial	O
+infarction	O
+and	O
+administration	O
+of	O
+tissue	O
+plasminogen	O
+activator	O
+
+Forty-one	B-Adev
+days	I-Adev
+later	I-Adev
+	O
+she	O
+developed	O
+severe	O
+iatrogenic	O
+Cushing's	O
+syndrome	O
+due	O
+to	O
+the	O
+drug-drug	O
+interaction	O
+between	O
+triamcinolone	O
+and	O
+her	O
+boosted	O
+protease	O
+inhibitor	O
+therapy	O
+
+Pheripheral	B-Adev
+edema	I-Adev
+was	O
+observed	O
+in	O
+five	O
+female	O
+patients	O
+after	O
+taking	O
+proton	O
+pump	O
+inhibitors	O
+omeprazole	O
+lansoprazole	O
+or	O
+pantoprazole	O
+for	O
+7-15	O
+days	O
+for	O
+peptic	O
+acid	O
+diseases	O
+in	O
+recommended	O
+standard	O
+doses	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+child	O
+with	O
+metastatic	O
+osteosarcoma	O
+who	O
+experienced	O
+an	O
+anaphylactic/anaphylactoid	B-Adev
+reaction	I-Adev
+to	O
+methotrexate	O
+
+It	O
+is	O
+tempting	O
+to	O
+speculate	O
+that	O
+interferon	O
+alpha	O
+may	O
+be	O
+involved	O
+in	O
+the	O
+pathogenesis	O
+of	O
+lichen	B-Adev
+nitidus	I-Adev
+	O
+
+CONCLUSION	O
+Alendronate	O
+led	O
+to	O
+nodular	B-Adev
+scleritis	I-Adev
+and	O
+rechallenge	O
+caused	O
+recurrence	O
+of	O
+scleritis	O
+
+A	O
+massive	O
+digitoxin	O
+(DGTX)	O
+intoxication	O
+in	O
+a	O
+36-year-old	O
+man	O
+(35	O
+mg	O
+DGTX)	O
+was	O
+treated	O
+by	O
+prolonged	O
+and	O
+repeated	O
+i.v.-infusions	O
+of	O
+Fab	O
+fragments	O
+of	O
+anti-digitalis	O
+antibodies	O
+(FAB)	O
+
+Gold-salt	O
+therapy	O
+may	O
+result	O
+in	O
+damage	B-Adev
+to	I-Adev
+proximal	I-Adev
+tubules	I-Adev
+that	O
+leak	O
+renal	O
+tubular	O
+antigens	O
+which	O
+in	O
+turn	O
+complex	O
+with	O
+autoantibody	O
+and	O
+produce	O
+an	O
+autoimmune	O
+membranous	O
+nephropathy	O
+
+Only	O
+two	O
+case	O
+reports	O
+of	O
+adults	O
+with	O
+allergic	O
+contact	O
+dermatitis	O
+to	O
+this	O
+chemical	O
+exist	O
+in	O
+the	O
+literature	O
+and	O
+we	O
+describe	O
+three	O
+more	O
+cases	O
+of	O
+children	O
+with	O
+recalcitrant	O
+atopic	O
+dermatitis	O
+found	O
+to	O
+have	O
+potential	B-Adev
+allergic	I-Adev
+contact	I-Adev
+dermatitis	I-Adev
+to	O
+bisabolol-	O
+a	O
+component	O
+of	O
+the	O
+Aquaphor	O
+emollient	O
+they	O
+were	O
+using	O
+to	O
+treat	O
+their	O
+atopic	O
+dermatitis	O
+
+Recently	O
+CD20-negative	B-Adev
+tumors	I-Adev
+have	O
+been	O
+described	O
+after	O
+Rituximab	O
+therapy	O
+
+A	O
+48-year-old	O
+woman	O
+who	O
+was	O
+treated	O
+for	O
+thyrotoxicosis	O
+with	O
+methimazole	O
+developed	O
+agranulocytosis	B-Adev
+	O
+
+Methylene	O
+blue	O
+in	O
+the	O
+treatment	O
+and	O
+prevention	O
+of	O
+ifosfamide-induced	O
+encephalopathy	B-Adev
+	O
+report	O
+of	O
+12	O
+cases	O
+and	O
+a	O
+review	O
+of	O
+the	O
+literature	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+women	O
+in	O
+whom	O
+a	B-Adev
+malignant	I-Adev
+mixed	I-Adev
+mesodermal	I-Adev
+tumor	I-Adev
+was	O
+diagnosed	O
+while	O
+she	O
+was	O
+taking	O
+raloxifene	O
+which	O
+is	O
+also	O
+a	O
+selective	O
+estrogen	O
+receptor	O
+modulator	O
+
+Interactions	O
+between	O
+warfarin	O
+and	O
+cloxacillin	O
+can	O
+result	O
+in	O
+serious	B-Adev
+adverse	I-Adev
+reactions	I-Adev
+	O
+
+However	O
+a	O
+large	O
+case-control	O
+study	O
+included	O
+three	O
+cases	O
+of	O
+either	O
+Stevens-Johnson	B-Adev
+syndrome	I-Adev
+or	I-Adev
+toxic	I-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+associated	O
+with	O
+ofloxacin	O
+use	O
+but	O
+no	O
+details	O
+of	O
+the	O
+cases	O
+were	O
+given	O
+
+Acetazolamide	O
+may	O
+have	O
+accelerated	O
+the	O
+development	O
+of	O
+osteomalacia	B-Adev
+by	O
+several	O
+mechanisms	O
+including	O
+increased	O
+renal	O
+calcium	O
+excretion	O
+
+In	O
+conclusion	O
+RSDS	B-Adev
+is	O
+a	O
+relevant	O
+osteoarticular	O
+complication	O
+in	O
+patients	O
+receiving	O
+either	O
+anticalcineurinic	O
+drug	O
+(CyA	O
+or	O
+tacrolimus)	O
+even	O
+under	O
+monotherapy	O
+or	O
+with	O
+a	O
+low	O
+steroid	O
+dose	O
+
+There	O
+have	O
+been	O
+several	O
+reported	O
+cases	O
+of	O
+omeprazole-induced	O
+AIN	B-Adev
+	O
+
+This	O
+interaction	O
+may	O
+be	O
+overlooked	O
+by	O
+clinicians	O
+which	O
+may	O
+result	O
+in	O
+a	O
+serious	B-Adev
+bleeding	I-Adev
+risk	I-Adev
+for	O
+patients	O
+on	O
+warfarin	O
+
+Adriamycin-induced	O
+cardiomyopathy	B-Adev
+aggravated	O
+by	O
+cis-platinum	O
+nephrotoxicity	O
+requiring	O
+dialysis	O
+
+Adriamycin-induced	O
+cardiomyopathy	O
+aggravated	O
+by	O
+cis-platinum	O
+nephrotoxicity	B-Adev
+requiring	I-Adev
+dialysis	I-Adev
+	O
+
+An	O
+11-year-old	O
+boy	O
+who	O
+was	O
+treated	O
+with	O
+a	O
+relatively	O
+high	O
+dose	O
+of	O
+methotrimeprazine	O
+meleate	O
+(Levemepromazine)	O
+a	O
+phenothiazine	O
+antipsychotic	O
+drug	O
+was	O
+admitted	O
+to	O
+the	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+suffering	O
+from	O
+respiratory	B-Adev
+distress	I-Adev
+syndrome	I-Adev
+	O
+
+An	O
+adult	O
+male	O
+presented	O
+with	O
+central	B-Adev
+blindness	I-Adev
+after	O
+ingesting	O
+methanol	O
+
+All	O
+developed	O
+mucocutaneous	B-Adev
+side	I-Adev
+effects	I-Adev
+within	O
+20	O
+weeks	O
+of	O
+beginning	O
+im	O
+gold	O
+therapy	O
+at	O
+a	O
+time	O
+when	O
+RA	O
+had	O
+improved	O
+markedly	O
+compared	O
+to	O
+pretreatment	O
+status	O
+
+Two	O
+children	O
+1	O
+with	O
+idiopathic	O
+nephrotic	O
+syndrome	O
+and	O
+1	O
+with	O
+endo-extracapillary	O
+glomerulonephritis	O
+presented	O
+an	O
+episode	O
+of	O
+seizures	B-Adev
+and	I-Adev
+transient	I-Adev
+blindness	I-Adev
+at	O
+different	O
+times	O
+after	O
+i.v	O
+pulse	O
+methylprednisolone	O
+(IVPMP)	O
+treatment	O
+
+Stevens-Johnson	B-Adev
+syndrome	I-Adev
+in	O
+a	O
+boy	O
+with	O
+nephrotic	O
+syndrome	O
+during	O
+prednisolone	O
+therapy	O
+
+To	O
+our	O
+knowledge	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+an	O
+angio-oedema	B-Adev
+associated	O
+with	O
+VRC	O
+
+Insulin-induced	O
+cardiac	B-Adev
+failure	I-Adev
+	O
+
+The	O
+symptoms	O
+disappeared	O
+with	O
+clemastine	O
+and	O
+betametasone	O
+treatment	O
+
+This	O
+report	O
+rules	O
+out	O
+other	O
+causes	O
+of	O
+toxic	O
+epidermal	O
+necrolysis	O
+and	O
+implicates	O
+ofloxacin	O
+in	O
+what	O
+appears	O
+to	O
+be	O
+an	O
+atypical	O
+presentation	O
+of	O
+drug-induced	O
+toxic	B-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+	O
+
+Controversy	O
+concerning	O
+the	O
+nephrotoxicity	B-Adev
+of	O
+lithium	O
+is	O
+discussed	O
+and	O
+recommendations	O
+for	O
+the	O
+evaluation	O
+of	O
+renal	O
+failure	O
+during	O
+lithium	O
+therapy	O
+are	O
+provided	O
+
+A	O
+56-year-old	O
+male	O
+parkinsonian	O
+patient	O
+developed	O
+a	B-Adev
+unique	I-Adev
+behavioral	I-Adev
+change	I-Adev
+following	O
+the	O
+oral	O
+administration	O
+of	O
+cinepazide	O
+a	O
+cerebral	O
+vasodilator	O
+
+The	O
+currently	O
+available	O
+clinical	O
+and	O
+neuropharmacologic	O
+data	O
+suggest	O
+that	O
+carbamazepine	O
+may	O
+be	O
+an	O
+antagonist	O
+of	O
+dopamine	O
+and	O
+that	O
+this	O
+property	O
+is	O
+responsible	O
+for	O
+the	O
+production	O
+of	O
+dystonia	B-Adev
+	O
+
+Metamizole	O
+a	O
+nonsteroidal	O
+antiinflammatory	O
+agent	O
+is	O
+prohibited	O
+in	O
+the	O
+United	O
+States	O
+because	O
+of	O
+the	O
+risk	O
+of	O
+agranulocytosis	B-Adev
+but	O
+is	O
+widely	O
+used	O
+in	O
+Mexico	O
+and	O
+other	O
+countries	O
+
+We	O
+conclude	O
+that	O
+the	O
+use	O
+of	O
+hemopoietic	O
+colony	O
+stimulating	O
+factors	O
+might	O
+be	O
+a	O
+suitable	O
+means	O
+to	O
+achieve	O
+the	O
+correction	O
+of	O
+severe	O
+thionamide-induced	O
+hematologic	B-Adev
+adverse	I-Adev
+reactions	I-Adev
+
+We	O
+conclude	O
+that	O
+the	O
+use	O
+of	O
+hemopoietic	O
+colony	O
+stimulating	O
+factors	O
+might	O
+be	O
+a	O
+suitable	O
+means	O
+to	O
+achieve	O
+the	O
+correction	O
+of	O
+severe	O
+thionamide-induced	O
+hematologic	O
+adverse	O
+reactions	O
+
+Two	O
+case	O
+reports	O
+of	O
+bilateral	O
+granulomatous	O
+anterior	O
+uveitis	O
+are	O
+described	O
+in	O
+patients	O
+with	O
+open	O
+angle	O
+glaucoma	O
+treated	O
+with	O
+metripranolol	O
+0.6%	O
+eye	O
+drops	O
+
+Regardless	O
+of	O
+a	O
+negative	O
+history	O
+of	O
+asthma	O
+therefore	O
+life-threatening	B-Adev
+bronchospasm	I-Adev
+must	O
+be	O
+considered	O
+a	O
+possible	O
+complication	O
+of	O
+propranolol	O
+therapy	O
+
+In	O
+the	O
+present	O
+paper	O
+the	O
+authors	O
+describe	O
+2	O
+female	O
+patients	O
+who	O
+developed	O
+incontinence	B-Adev
+secondary	O
+to	O
+the	O
+selective	O
+serotonin	O
+reuptake	O
+inhibitors	O
+paroxetine	O
+and	O
+sertraline	O
+as	O
+well	O
+as	O
+a	O
+third	O
+who	O
+developed	O
+this	O
+side	O
+effect	O
+on	O
+venlafaxine	O
+
+Presented	O
+is	O
+a	O
+case	O
+story	O
+of	O
+a	O
+woman	O
+with	O
+classical	O
+rheumatoid	O
+arthritis	O
+who	O
+during	O
+introduction	O
+of	O
+sulphasalazine	O
+(SASP)	O
+therapy	O
+developed	O
+a	O
+severe	O
+and	O
+lasting	O
+psoriasis-like	B-Adev
+skin	I-Adev
+reaction	I-Adev
+	O
+
+Interstitial	B-Adev
+granulomatous	I-Adev
+dermatitis	I-Adev
+associated	O
+with	O
+darifenacin	O
+
+Reversal	O
+of	O
+severe	O
+methanol-induced	O
+visual	B-Adev
+impairment	I-Adev
+	O
+no	O
+evidence	O
+of	O
+retinal	O
+toxicity	O
+due	O
+to	O
+fomepizole	O
+
+Reversal	O
+of	O
+severe	O
+methanol-induced	O
+visual	O
+impairment	O
+no	O
+evidence	O
+of	O
+retinal	B-Adev
+toxicity	I-Adev
+due	O
+to	O
+fomepizole	O
+
+Proton-pump	O
+inhibitors	O
+(PPIs)	O
+are	O
+believed	O
+to	O
+decrease	O
+the	O
+risk	O
+of	O
+such	O
+complications	O
+though	O
+no	O
+randomized	O
+trial	O
+has	O
+proved	O
+this	O
+in	O
+patients	O
+receiving	O
+dual	O
+antiplatelet	O
+therapy	O
+
+The	O
+clinical	O
+course	O
+suggests	O
+that	O
+caffeine	O
+which	O
+is	O
+present	O
+in	O
+oolong	O
+tea	O
+was	O
+mainly	O
+responsible	O
+for	O
+the	O
+rhabdomyolysis	B-Adev
+as	I-Adev
+well	I-Adev
+as	I-Adev
+the	I-Adev
+delirium	I-Adev
+	O
+although	O
+severe	O
+hyponatremia	O
+has	O
+been	O
+reported	O
+to	O
+cause	O
+rhabdomyolysis	O
+on	O
+rare	O
+occasions	O
+
+Prevention	O
+of	O
+CNS	O
+relapse	O
+was	O
+satisfactorily	O
+achieved	O
+with	O
+HD	O
+IV	O
+MTX	O
+and	O
+intrathecal	O
+injections	O
+of	O
+MTX	O
+in	O
+children	O
+with	O
+increased-risk	O
+ALL	O
+or	O
+stage	O
+III	O
+and	O
+IV	O
+lymphoblastic	O
+lymphoma	O
+treated	O
+with	O
+our	O
+BFM-based	O
+treatment	O
+protocol	O
+in	O
+which	O
+cranial	O
+irradiation	O
+was	O
+omitted	O
+
+Prevention	O
+of	O
+CNS	O
+relapse	O
+was	O
+satisfactorily	O
+achieved	O
+with	O
+HD	O
+IV	O
+MTX	O
+and	O
+intrathecal	O
+injections	O
+of	O
+MTX	O
+in	O
+children	O
+with	O
+increased-risk	O
+ALL	O
+or	O
+stage	O
+III	O
+and	O
+IV	O
+lymphoblastic	O
+lymphoma	O
+treated	O
+with	O
+our	O
+BFM-based	O
+treatment	O
+protocol	O
+in	O
+which	O
+cranial	O
+irradiation	O
+was	O
+omitted	O
+
+Generalized	B-Adev
+lichen	I-Adev
+nitidus	I-Adev
+with	I-Adev
+involvement	I-Adev
+of	I-Adev
+the	I-Adev
+palms	I-Adev
+following	O
+interferon	O
+alpha	O
+treatment	O
+
+Hemorrhagic	B-Adev
+cystitis	I-Adev
+is	O
+a	O
+significant	O
+toxic	O
+effect	O
+of	O
+cyclophosphamide	O
+therapy	O
+
+Secondary	O
+hyperparathyroidism	O
+in	O
+certain	O
+patients	O
+with	O
+lithium	O
+nephrotoxicity	B-Adev
+is	O
+also	O
+possible	O
+
+We	O
+report	O
+a	O
+case	O
+in	O
+which	O
+hemorrhage	B-Adev
+occurred	O
+in	O
+an	O
+asymptomatic	O
+falx	O
+meningioma	O
+known	O
+beforehand	O
+after	O
+the	O
+internal	O
+use	O
+of	O
+low-dose	O
+aspirin	O
+for	O
+16	O
+months	O
+
+Minor	O
+electrocardiographical	B-Adev
+changes	I-Adev
+were	O
+noted	O
+in	O
+five	O
+out	O
+of	O
+six	O
+patients	O
+who	O
+were	O
+not	O
+receiving	O
+a	O
+cardiac	O
+glycoside	O
+and	O
+four	O
+out	O
+of	O
+six	O
+who	O
+were	O
+receiving	O
+ouabain	O
+and	O
+none	O
+of	O
+the	O
+16	O
+who	O
+were	O
+receiving	O
+digoxin	O
+
+Minor	O
+electrocardiographical	B-Adev
+changes	I-Adev
+were	O
+noted	O
+in	O
+five	O
+out	O
+of	O
+six	O
+patients	O
+who	O
+were	O
+not	O
+receiving	O
+a	O
+cardiac	O
+glycoside	O
+and	O
+four	O
+out	O
+of	O
+six	O
+who	O
+were	O
+receiving	O
+ouabain	O
+and	O
+none	O
+of	O
+the	O
+16	O
+who	O
+were	O
+receiving	O
+digoxin	O
+
+The	O
+allergic	B-Adev
+reaction	I-Adev
+started	O
+to	O
+develop	O
+after	O
+co-administration	O
+of	O
+pravastatin	O
+
+We	O
+propose	O
+that	O
+cyclophosphamide	O
+be	O
+added	O
+to	O
+the	O
+list	O
+of	O
+exposures	O
+potentially	O
+associated	O
+with	O
+hepatic	B-Adev
+angiosarcoma	I-Adev
+	O
+
+The	B-Adev
+ocular	I-Adev
+motor	I-Adev
+disturbances	I-Adev
+are	O
+probably	O
+an	O
+expression	O
+of	O
+regional	O
+5-FU	O
+neurotoxicity	O
+primarily	O
+affecting	O
+the	O
+brain	O
+stem	O
+
+Complications	O
+of	O
+chemotherapy	O
+for	O
+a	O
+synovial	O
+sarcoma	O
+in	O
+an	O
+eight-year	O
+old	O
+boy	O
+included	O
+cisplatinum	O
+nephrotoxicity	B-Adev
+and	O
+adriamycin	O
+cardiotoxicity	O
+
+Complications	O
+of	O
+chemotherapy	O
+for	O
+a	O
+synovial	O
+sarcoma	O
+in	O
+an	O
+eight-year	O
+old	O
+boy	O
+included	O
+cisplatinum	O
+nephrotoxicity	O
+and	O
+adriamycin	O
+cardiotoxicity	B-Adev
+	O
+
+Bacterial	B-Adev
+infection	I-Adev
+is	O
+a	O
+frequent	O
+event	O
+in	O
+renal	O
+transplant	O
+recipients	O
+and	O
+often	O
+requires	O
+the	O
+use	O
+of	O
+antimicrobial	O
+agents	O
+
+Study	O
+results	O
+suggest	O
+that	O
+ciclesonide	O
+significantly	O
+reduces	O
+the	O
+need	O
+for	O
+OCS	O
+in	O
+patients	O
+with	O
+severe	O
+persistent	O
+asthma	O
+while	O
+maintaining	O
+asthma	O
+control	O
+
+CONCLUSION	O
+This	O
+is	O
+to	O
+our	O
+knowledge	O
+the	O
+first	O
+report	O
+of	O
+severe	B-Adev
+myelopathy	I-Adev
+following	O
+accidental	O
+intrathecal	O
+administration	O
+of	O
+doxorubicin	O
+
+Multiple	B-Adev
+sclerosis-like	I-Adev
+disease	I-Adev
+secondary	O
+to	O
+alpha	O
+interferon	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+patient	O
+with	O
+mild	O
+chronic	O
+renal	O
+insufficiency	O
+who	O
+had	O
+been	O
+taking	O
+simvastatin	O
+for	O
+over	O
+a	O
+year	O
+and	O
+developed	O
+acute	B-Adev
+weakness	I-Adev
+within	O
+3	O
+weeks	O
+after	O
+the	O
+start	O
+of	O
+treatment	O
+with	O
+colchicine	O
+for	O
+acute	O
+gouty	O
+bursitis	O
+
+Shortly	O
+after	O
+chemotherapy	O
+and	O
+an	O
+injection	O
+of	O
+pegfilgrastim	O
+the	O
+patient	O
+developed	O
+poorly	B-Adev
+defined	I-Adev
+rapidly	I-Adev
+progressive	I-Adev
+erythema	I-Adev
+edema	I-Adev
+and	I-Adev
+pain	I-Adev
+in	I-Adev
+his	I-Adev
+right	I-Adev
+forearm	I-Adev
+	O
+
+To	O
+describe	O
+a	O
+probable	O
+interaction	O
+between	O
+enteral	O
+feeds	O
+and	O
+levodopa	O
+leading	O
+to	O
+neuroleptic	B-Adev
+malignant-like	I-Adev
+syndrome	I-Adev
+(NMLS)	I-Adev
+in	O
+a	O
+polytrauma	O
+patient	O
+with	O
+Parkinson's	O
+disease	O
+(PD)	O
+
+Second	O
+we	O
+report	O
+a	O
+case	O
+of	O
+neutropenia	B-Adev
+	O
+which	O
+proved	O
+to	O
+be	O
+fatal	O
+in	O
+a	O
+schizophrenia	O
+patient	O
+receiving	O
+olanzapine	O
+and	O
+thiazide	O
+
+While	O
+mild	O
+to	O
+moderate	O
+application	O
+site	O
+reactions	O
+(ASRs)	O
+are	O
+a	O
+well-known	O
+and	O
+common	O
+phenomenon	O
+associated	O
+with	O
+imiquimod	O
+the	O
+potential	O
+of	O
+TNF-alpha	O
+blockers	O
+to	O
+elicit	O
+cutaneous	B-Adev
+inflammatory	I-Adev
+reactions	I-Adev
+has	O
+only	O
+recently	O
+been	O
+recognized	O
+
+While	O
+mild	O
+to	O
+moderate	O
+application	B-Adev
+site	I-Adev
+reactions	I-Adev
+(ASRs)	I-Adev
+are	O
+a	O
+well-known	O
+and	O
+common	O
+phenomenon	O
+associated	O
+with	O
+imiquimod	O
+the	O
+potential	O
+of	O
+TNF-alpha	O
+blockers	O
+to	O
+elicit	O
+cutaneous	O
+inflammatory	O
+reactions	O
+has	O
+only	O
+recently	O
+been	O
+recognized	O
+
+Nineteen	O
+cases	O
+of	O
+allergic	B-Adev
+contact	I-Adev
+dermatitis	I-Adev
+to	O
+compound	O
+tincture	O
+of	O
+benzoin	O
+are	O
+described	O
+
+We	O
+report	O
+3	O
+children	O
+with	O
+epilepsy	O
+who	O
+developed	O
+facial	B-Adev
+motor	I-Adev
+tics	I-Adev
+after	O
+initiation	O
+of	O
+CBZ	O
+for	O
+complex	O
+partial	O
+seizures	O
+
+The	O
+toxicity	B-Adev
+of	O
+cadmium	O
+zinc	O
+and	O
+cadmium/zinc	O
+mixtures	O
+at	O
+concentrations	O
+ranging	O
+from	O
+1000	O
+to	O
+50000	O
+microg/l	O
+were	O
+investigated	O
+against	O
+cercariae	O
+and	O
+metacercariae	O
+of	O
+Parorchis	O
+acanthus	O
+obtained	O
+from	O
+the	O
+dog	O
+whelk	O
+Nucella	O
+lapillus	O
+
+We	O
+report	O
+the	O
+syndrome	B-Adev
+of	I-Adev
+inappropriate	I-Adev
+antidiuresis	I-Adev
+as	O
+a	O
+much	O
+earlier	O
+side-effect	O
+of	O
+carbamazepine	O
+administration	O
+in	O
+a	O
+29-year	O
+Nigerian	O
+female	O
+patient	O
+with	O
+generalized	O
+tonic-elonic	O
+seizures	O
+
+A	O
+patient	O
+was	O
+treated	O
+with	O
+warfarin	O
+for	O
+atrial	O
+fibrillation	O
+
+Mood	O
+stabilizer	O
+therapy	O
+and	O
+pravastatin	O
+higher	O
+risk	O
+for	O
+adverse	B-Adev
+skin	I-Adev
+reactions	I-Adev
+?	O
+
+Pulmonary	B-Adev
+leukostasis	I-Adev
+secondary	O
+to	O
+all-trans	O
+retinoic	O
+acid	O
+in	O
+the	O
+treatment	O
+of	O
+acute	O
+promyelocytic	O
+leukemia	O
+in	O
+first	O
+relapse	O
+
+A	O
+74-year-old	O
+hypercholestrerolaemic	O
+woman	O
+taking	O
+cerivastatin	O
+(0.15	O
+mg/day)	O
+for	O
+22	O
+days	O
+complained	O
+of	O
+general	B-Adev
+muscle	I-Adev
+weakness	I-Adev
+and	I-Adev
+muscle	I-Adev
+pain	I-Adev
+
+There	O
+have	O
+been	O
+only	O
+two	O
+reports	O
+of	O
+cimetidine-induced	O
+hepatitis	B-Adev
+	O
+
+A	O
+case	O
+is	O
+reported	O
+of	O
+theophylline	B-Adev
+intoxication	I-Adev
+due	O
+to	O
+a	O
+dramatic	O
+decrease	O
+in	O
+theophylline	O
+clearance	O
+following	O
+concomitant	O
+administration	O
+of	O
+viloxazine	O
+
+Anterior	B-Adev
+ischemic	I-Adev
+optic	I-Adev
+neuropathy	I-Adev
+secondary	O
+to	O
+interferon	O
+alfa	O
+
+PURPOSE	O
+To	O
+describe	O
+bilateral	B-Adev
+optic	I-Adev
+neuritis	I-Adev
+that	O
+occurred	O
+as	O
+an	O
+adverse	O
+effect	O
+of	O
+recombinant	O
+and	O
+natural	O
+interferon	O
+alpha	O
+administration	O
+
+Rofecoxib	O
+used	O
+for	O
+dysmenorrhea	O
+caused	O
+a	O
+herpetiform	B-Adev
+fixed	I-Adev
+drug	I-Adev
+eruption	I-Adev
+predominantly	I-Adev
+involving	I-Adev
+the	I-Adev
+lips	I-Adev
+with	I-Adev
+classic	I-Adev
+clinical	I-Adev
+and	I-Adev
+histological	I-Adev
+findings	I-Adev
+in	I-Adev
+a	I-Adev
+red-brown	I-Adev
+lesion	I-Adev
+on	I-Adev
+the	I-Adev
+dorsal	I-Adev
+hand	I-Adev
+	O
+
+Statin-associated	O
+myasthenia	B-Adev
+gravis	I-Adev
+	O
+report	O
+of	O
+4	O
+cases	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+Two	O
+reports	O
+of	O
+spindle	B-Adev
+coma	I-Adev
+are	O
+noted	O
+with	O
+alcohol	O
+and	O
+imipramine	O
+
+Cataracts	B-Adev
+induced	O
+by	O
+intermittent	O
+Decadron	O
+used	O
+as	O
+an	O
+antiemetic	O
+
+Severe	O
+osteomalacia	B-Adev
+was	O
+present	O
+in	O
+two	O
+epileptic	O
+patients	O
+who	O
+were	O
+under	O
+long-term	O
+treatment	O
+with	O
+congeners	O
+of	O
+phenytoin	O
+phenobarbital	O
+and	O
+acetazolamide	O
+
+Careful	O
+observations	O
+on	O
+hepatotoxicity	B-Adev
+are	O
+suggested	O
+when	O
+acetaminophen	O
+is	O
+prescribed	O
+with	O
+caffeine	O
+
+Erosion	B-Adev
+of	I-Adev
+psoriatic	I-Adev
+plaques	I-Adev
+	O
+an	O
+early	O
+sign	O
+of	O
+methotrexate	O
+toxicity	O
+
+After	O
+extensive	O
+neurological	O
+'work	O
+up'	O
+we	O
+realized	O
+that	O
+the	O
+anisocoria	B-Adev
+was	O
+related	O
+to	O
+the	O
+transdermal	O
+scopolamine	O
+patch	O
+that	O
+we	O
+had	O
+prescribed	O
+for	O
+weaning	O
+off	O
+the	O
+opioid	O
+
+Efficacy	O
+and	O
+safety	O
+of	O
+tifacogin	O
+(recombinant	O
+tissue	O
+factor	O
+pathway	O
+inhibitor)	O
+in	O
+severe	O
+sepsis	O
+a	O
+randomized	O
+controlled	O
+trial	O
+
+CASE	O
+A	B-Adev
+malignant	I-Adev
+mixed	I-Adev
+mesodermal	I-Adev
+tumor	I-Adev
+was	O
+diagnosed	O
+in	O
+a	O
+64-year-old	O
+woman	O
+with	O
+a	O
+bicornuate	O
+uterus	O
+while	O
+she	O
+was	O
+taking	O
+raloxifene	O
+for	O
+osteoporosis	O
+prevention	O
+
+After	O
+rechallenge	O
+with	O
+monotherapy	O
+pegvisomant	O
+however	O
+the	O
+hepatic	B-Adev
+enzyme	I-Adev
+disturbances	I-Adev
+reappeared	I-Adev
+within	O
+a	O
+few	O
+weeks	O
+indicating	O
+that	O
+most	O
+likely	O
+pegvisomant	O
+alone	O
+and	O
+not	O
+the	O
+long-acting	O
+somatostatin	O
+analog	O
+or	O
+the	O
+combination	O
+of	O
+these	O
+two	O
+drugs	O
+was	O
+responsible	O
+for	O
+this	O
+case	O
+of	O
+drug-induced	O
+hepatitis	O
+
+To	O
+evaluate	O
+the	O
+long-term	O
+(up	O
+to	O
+5	O
+years	O
+exposure)	O
+safety	O
+and	O
+efficacy	O
+of	O
+lacosamide	O
+as	O
+adjunctive	O
+therapy	O
+in	O
+patients	O
+with	O
+uncontrolled	O
+partial-onset	O
+seizures	O
+taking	O
+one	O
+to	O
+three	O
+concomitant	O
+antiepileptic	O
+drugs	O
+(AEDs)	O
+in	O
+open-label	O
+extension	O
+trial	O
+SP756	O
+(NCT00522275)	O
+
+Complete	O
+remission	O
+of	O
+the	O
+nephrosis	O
+occurred	O
+after	O
+discontinuation	O
+of	O
+hydroxychloroquine	O
+therapy	O
+
+CONCLUSIONS	O
+Clinicians	O
+treating	O
+elderly	O
+patients	O
+with	O
+olanzapine	O
+should	O
+be	O
+aware	O
+of	O
+the	O
+potential	O
+for	O
+rapidly	B-Adev
+developing	I-Adev
+hyperglycemia	I-Adev
+and	O
+monitor	O
+such	O
+patients	O
+accordingly	O
+
+We	O
+describe	O
+a	O
+case	O
+of	O
+PRES	O
+in	O
+a	O
+patient	O
+with	O
+collapsing	O
+focal	O
+glomeruloesclerosis	O
+(collapsing	O
+FGS)	O
+with	O
+complete	O
+recovery	O
+after	O
+withdrawal	O
+of	O
+cyclosporine	O
+(CSA)	O
+
+DISCUSSION	O
+The	O
+occurrence	O
+of	O
+priapism	B-Adev
+in	O
+our	O
+patient	O
+was	O
+related	O
+to	O
+zuclopenthixol	O
+
+Hepatic	B-Adev
+angiosarcoma	I-Adev
+occurring	O
+after	O
+cyclophosphamide	O
+therapy	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+After	O
+completion	O
+of	O
+induction-consolidation	O
+phase	O
+children	O
+with	O
+increased-risk	O
+(risk	O
+factor	O
+>	O
+0.8	O
+or	O
+T-lineage)	O
+ALL	O
+or	O
+stage	O
+III	O
+and	O
+IV	O
+lymphoblastic	O
+lymphoma	O
+were	O
+randomized	O
+to	O
+receive	O
+four	O
+courses	O
+of	O
+HD	O
+MTX	O
+(5	O
+g/m(2)	O
+over	O
+24	O
+hours	O
+every	O
+2	O
+weeks)	O
+and	O
+four	O
+intrathecal	O
+administrations	O
+of	O
+MTX	O
+(Arm	O
+A)	O
+or	O
+the	O
+same	O
+treatment	O
+schedule	O
+with	O
+additional	O
+HD	O
+IV	O
+Ara-C	O
+(1	O
+g/m(2)	O
+in	O
+bolus	O
+injection	O
+12	O
+and	O
+24	O
+hours	O
+after	O
+the	O
+start	O
+of	O
+each	O
+MTX	O
+infusion)	O
+(Arm	O
+B)	O
+
+The	O
+dose-limiting	O
+toxicity	O
+of	O
+KW-2149	O
+is	O
+pulmonary	B-Adev
+toxicity	O
+
+Flucloxacillin-induced	O
+aplastic	B-Adev
+anaemia	I-Adev
+and	I-Adev
+liver	I-Adev
+failure	I-Adev
+	O
+
+Thus	O
+we	O
+confirm	O
+that	O
+desensitization	O
+may	O
+be	O
+a	O
+safe	O
+procedure	O
+in	O
+patients	O
+with	O
+cancer	O
+who	O
+experience	O
+methotrexate-induced	O
+anaphylaxis	B-Adev
+	O
+
+We	O
+further	O
+used	O
+immunohistochemistry	O
+(IHC)	O
+to	O
+examine	O
+the	O
+relative	O
+role	O
+of	O
+platelet-derived	O
+growth	O
+factor-B	O
+(PDGF-B)	O
+insulin-like	O
+growth	O
+factor	O
+I	O
+(IGF-I)	O
+transforming	O
+growth	O
+factor-beta1	O
+(TGF-beta1)	O
+and	O
+cyclooxygenase-2	O
+(COX-2)	O
+in	O
+the	O
+pathogenesis	O
+of	O
+BCNU-related	O
+pulmonary	B-Adev
+fibrosis	I-Adev
+	O
+
+Physicians	O
+using	O
+this	O
+"new"	O
+drug	O
+must	O
+be	O
+aware	O
+of	O
+the	O
+potential	O
+danger	O
+of	O
+sulfonamide-induced	O
+injury	B-Adev
+to	I-Adev
+the	I-Adev
+urinary	I-Adev
+tract	I-Adev
+	O
+
+RESULTS	O
+Brimonidine	O
+was	O
+observed	O
+to	O
+cause	O
+IOP	B-Adev
+elevation	I-Adev
+	O
+confirmed	O
+on	O
+rechallenge	O
+scoring	O
+8	O
+(strong	O
+probability)	O
+on	O
+an	O
+adverse	O
+drug	O
+reaction	O
+probability	O
+score	O
+
+Severe	O
+leukopenia	B-Adev
+associated	O
+with	O
+mild	O
+hepatotoxicity	O
+in	O
+an	O
+HIV	O
+carrier	O
+treated	O
+with	O
+nevirapine	O
+
+The	O
+clinical	O
+effect	O
+and	O
+safety	O
+of	O
+Lp-TAE	O
+alone	O
+and	O
+combined	O
+with	O
+radiofrequency	O
+(RF)	O
+capacitive	O
+hyperthermia	O
+(HT)	O
+were	O
+evaluated	O
+in	O
+20	O
+patients	O
+with	O
+hepatocellular	O
+carcinoma	O
+(HCC)	O
+associated	O
+with	O
+cirrhosis	O
+of	O
+the	O
+liver	O
+
+Fibrosis	B-Adev
+of	I-Adev
+corpus	I-Adev
+cavernosum	I-Adev
+after	O
+intracavernous	O
+injection	O
+of	O
+phentolamine/papaverine	O
+
+We	O
+have	O
+cared	O
+for	O
+three	O
+children	O
+in	O
+whom	O
+four	B-Adev
+episodes	I-Adev
+of	I-Adev
+dystonia	I-Adev
+proceeding	I-Adev
+to	I-Adev
+opisthotonus	I-Adev
+occurred	O
+in	O
+association	O
+with	O
+carbamazepine	O
+use	O
+
+Juvenile	B-Adev
+absence	I-Adev
+epilepsy	I-Adev
+exacerbated	I-Adev
+by	O
+valproic	O
+acid	O
+
+These	O
+cases	O
+were	O
+chosen	O
+for	O
+study	O
+because	O
+they	B-Adev
+were	I-Adev
+all	I-Adev
+deaths	I-Adev
+as	O
+a	O
+result	O
+of	O
+suicidal	O
+ingestion	O
+of	O
+drugs	O
+in	O
+which	O
+quetiapine	O
+was	O
+considered	O
+a	O
+significant	O
+factor	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+hypereosinophilia	B-Adev
+related	O
+to	O
+zafirlukast	O
+therapy	O
+
+In	O
+patients	O
+with	O
+methotrexate-induced	O
+anaphylaxis	O
+discontinuation	O
+of	O
+treatment	O
+may	O
+increase	O
+the	O
+risk	O
+of	O
+death	B-Adev
+due	I-Adev
+to	I-Adev
+cancer	I-Adev
+progression	I-Adev
+	O
+
+In	O
+patients	O
+with	O
+methotrexate-induced	O
+anaphylaxis	B-Adev
+	O
+discontinuation	O
+of	O
+treatment	O
+may	O
+increase	O
+the	O
+risk	O
+of	O
+death	O
+due	O
+to	O
+cancer	O
+progression	O
+
+Pentazocine-induced	O
+fibrous	B-Adev
+myopathy	I-Adev
+and	I-Adev
+localized	I-Adev
+neuropathy	I-Adev
+	O
+
+Intensive	O
+high-flux	O
+hemodiafiltration	O
+is	O
+often	O
+used	O
+in	O
+the	O
+management	O
+of	O
+vancomycin	O
+toxicity	O
+
+Here	O
+we	O
+present	O
+the	O
+case	O
+of	O
+a	B-Adev
+generalized	I-Adev
+lichen	I-Adev
+nitidus	I-Adev
+with	I-Adev
+involvement	I-Adev
+of	I-Adev
+the	I-Adev
+palms	I-Adev
+in	O
+a	O
+patient	O
+with	O
+hepatitis	O
+C	O
+after	O
+systemic	O
+treatment	O
+with	O
+interferon	O
+alpha	O
+and	O
+ribavirin	O
+
+The	O
+authors	O
+describe	O
+a	O
+woman	O
+with	O
+chronic	O
+schizophrenia	O
+who	O
+experienced	O
+delirium	B-Adev
+grand	I-Adev
+mal	I-Adev
+seizure	I-Adev
+and	I-Adev
+photosensitivity	I-Adev
+after	O
+the	O
+addition	O
+of	O
+propranolol	O
+to	O
+her	O
+neuroleptic	O
+regimen	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+an	O
+infant	O
+with	O
+complex	O
+congenital	O
+heart	O
+disease	O
+who	O
+was	O
+placed	O
+on	O
+captopril	O
+for	O
+afterload	O
+reduction	O
+following	O
+cardiac	O
+surgery	O
+and	O
+subsequently	O
+developed	O
+pulmonary	B-Adev
+infiltrates	I-Adev
+with	I-Adev
+eosinophilia	I-Adev
+	O
+
+Possible	O
+pathophysiological	O
+mechanisms	O
+which	O
+may	O
+have	O
+been	O
+operative	O
+in	O
+this	O
+case	O
+include	O
+a	B-Adev
+direct	I-Adev
+central	I-Adev
+nervous	I-Adev
+system	I-Adev
+(CNS)	I-Adev
+toxic	I-Adev
+effect	I-Adev
+of	O
+valproic	O
+acid	O
+a	O
+paradoxical	O
+epileptogenic	O
+effect	O
+secondary	O
+to	O
+the	O
+drug	O
+and	O
+an	O
+indirect	O
+CNS	O
+toxic	O
+effect	O
+mediated	O
+through	O
+valproic	O
+acid-induced	O
+hyperammonemia	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+serotonin	B-Adev
+syndrome	I-Adev
+induced	O
+by	O
+pharmacokinetic	O
+and	O
+pharmacodynamic	O
+interactions	O
+between	O
+three	O
+different	O
+selective	O
+serotonin-reuptake	O
+inhibitors	O
+(SSRI)	O
+and	O
+possibly	O
+ciprofloxacin	O
+
+Generalised	B-Adev
+pustular	I-Adev
+psoriasis	I-Adev
+induced	O
+by	O
+cyclosporin	O
+a	O
+withdrawal	O
+responding	O
+to	O
+the	O
+tumour	O
+necrosis	O
+factor	O
+alpha	O
+inhibitor	O
+etanercept	O
+
+Generalised	O
+pustular	O
+psoriasis	O
+induced	O
+by	O
+cyclosporin	O
+a	O
+withdrawal	O
+responding	O
+to	O
+the	O
+tumour	O
+necrosis	O
+factor	O
+alpha	O
+inhibitor	O
+etanercept	O
+
+A	O
+36-y-o	O
+patient	O
+with	O
+schizophrenia	O
+who	O
+had	O
+consumed	O
+gradually	O
+increasing	O
+quantities	O
+of	O
+oolong	O
+tea	O
+that	O
+eventually	O
+reached	O
+15	O
+L	O
+each	O
+day	O
+became	O
+delirious	B-Adev
+and	O
+was	O
+admitted	O
+to	O
+a	O
+psychiatric	O
+hospital	O
+
+Intraventricular	B-Adev
+nafcillin-induced	O
+seizures	O
+in	O
+a	O
+neonate	O
+
+Nevertheless	O
+the	O
+coagulopathy	B-Adev
+seemed	O
+to	O
+be	O
+most	O
+closely	O
+associated	O
+with	O
+the	O
+administration	O
+of	O
+the	O
+cephalosporin	O
+
+Intrahepatic	B-Adev
+cholestasis	I-Adev
+and	I-Adev
+sicca	I-Adev
+complex	I-Adev
+after	O
+thiabendazole	O
+
+We	O
+recommended	O
+periodic	O
+examination	O
+of	O
+the	O
+serum	O
+proteins	O
+in	O
+patients	O
+receiving	O
+diphenylhydantoin	O
+in	O
+order	O
+to	O
+detect	B-Adev
+development	I-Adev
+of	I-Adev
+monoclonal	I-Adev
+gammopathy	I-Adev
+	O
+
+Moxalactam	O
+is	O
+more	O
+likely	O
+to	O
+be	O
+associated	O
+with	O
+platelet	B-Adev
+dysfunction	I-Adev
+	O
+
+This	O
+prompted	O
+us	O
+to	O
+suspect	O
+that	O
+ddI	O
+might	O
+be	O
+responsible	O
+for	O
+fulminant	B-Adev
+hepatitis	I-Adev
+in	O
+all	O
+three	O
+AIDS	O
+patients	O
+
+Two	O
+patients	O
+each	O
+receiving	O
+warfarin	O
+for	O
+stroke	O
+prophylaxis	O
+in	O
+association	O
+with	O
+chronic	O
+atrial	O
+fibrillation	O
+developed	O
+adverse	B-Adev
+effects	I-Adev
+after	O
+the	O
+initiation	O
+of	O
+tolterodine	O
+for	O
+urinary	O
+disorders	O
+
+CASE	O
+SUMMARY	O
+A	O
+45-year-old	O
+HIV-positive	O
+man	O
+(CD4+	O
+count	O
+450	O
+cells/mm(3)	O
+and	O
+history	O
+of	O
+AIDS-defining	O
+illness)	O
+presented	O
+with	O
+JHR	B-Adev
+after	O
+an	O
+initial	O
+intravenous	O
+dose	O
+of	O
+penicillin	O
+G	O
+for	O
+presumed	O
+neurosyphilis	O
+
+The	O
+second	O
+patient	O
+developed	O
+both	B-Adev
+autoimmune	I-Adev
+thyroid	I-Adev
+disease	I-Adev
+and	I-Adev
+a	I-Adev
+refractory	I-Adev
+pre-patellar	I-Adev
+bursitis	I-Adev
+after	O
+50	O
+months	O
+of	O
+IFN-beta	O
+therapy	O
+
+We	O
+report	O
+an	O
+additional	O
+case	O
+of	O
+isotretinoin	O
+teratogenicity	O
+in	O
+which	O
+the	O
+patient	O
+had	O
+agenesis	B-Adev
+of	I-Adev
+the	I-Adev
+cerebellar	I-Adev
+vermis	I-Adev
+multiple	I-Adev
+leptomeningeal	I-Adev
+neuroglial	I-Adev
+heterotopias	I-Adev
+hydrocephalus	I-Adev
+and	I-Adev
+abnormalities	I-Adev
+of	I-Adev
+the	I-Adev
+corticospinal	I-Adev
+tracts	I-Adev
+	O
+
+Reversible	B-Adev
+sclerotic	I-Adev
+changes	I-Adev
+of	I-Adev
+lumbar	I-Adev
+spine	I-Adev
+and	I-Adev
+femur	I-Adev
+due	O
+to	O
+long-term	O
+oral	O
+isotretinoin	O
+therapy	O
+
+A	O
+case	O
+of	O
+priapism	B-Adev
+associated	O
+with	O
+trazodone	O
+is	O
+described	O
+
+Severe	O
+adenovirus	B-Adev
+pneumonia	I-Adev
+(AVP)	O
+following	O
+infliximab	O
+infusion	O
+for	O
+the	O
+treatment	O
+of	O
+Crohn's	O
+disease	O
+
+No	O
+other	O
+endogenous	O
+or	O
+exogenous	O
+cause	O
+for	O
+the	O
+gynecomastia	B-Adev
+could	O
+be	O
+found	O
+except	O
+for	O
+the	O
+theophylline	O
+
+This	O
+is	O
+a	O
+case	O
+of	O
+pseudoephedrine-induced	O
+intracerebral	B-Adev
+hemorrhage	I-Adev
+in	O
+a	O
+patient	O
+with	O
+an	O
+underlying	O
+vascular	O
+malformation	O
+
+A	O
+58-year-old	O
+woman	O
+developed	O
+unilateral	B-Adev
+acute	I-Adev
+angle-closure	I-Adev
+glaucoma	I-Adev
+four	O
+days	O
+after	O
+the	O
+application	O
+of	O
+a	O
+patch	O
+of	O
+transdermal	O
+scopolamine	O
+delivery	O
+system	O
+(TRANSDERM-V)	O
+
+We	O
+report	O
+a	O
+50-year-old	O
+male	O
+patient	O
+with	O
+a	O
+15-year	O
+history	O
+of	O
+psoriasis	O
+including	O
+mutilating	O
+psoriatic	O
+arthritis	O
+in	O
+whom	O
+the	O
+withdrawal	O
+of	O
+cyclosporin	O
+A	O
+induced	O
+a	B-Adev
+generalised	I-Adev
+pustular	I-Adev
+exacerbation	I-Adev
+and	I-Adev
+a	I-Adev
+aggravation	I-Adev
+of	I-Adev
+the	I-Adev
+joint	I-Adev
+condition	I-Adev
+	O
+
+Six	O
+days	O
+after	O
+starting	O
+acyclovir	O
+she	O
+exhibited	O
+signs	O
+of	O
+lithium	B-Adev
+toxicity	I-Adev
+	O
+
+Toxicity	O
+of	O
+cadmium	O
+and	O
+zinc	O
+to	O
+encystment	O
+and	O
+in	O
+vitro	O
+excystment	O
+of	O
+Parorchis	O
+acanthus	O
+(Digenea	O
+Philophthalmidae)	O
+
+The	O
+syndrome	B-Adev
+of	I-Adev
+irreversible	I-Adev
+lithium-effectuated	I-Adev
+neurotoxicity	I-Adev
+(SILENT)	I-Adev
+	O
+
+One	O
+patient	O
+on	O
+ouabain	O
+also	O
+developed	O
+cardiomyopathy	B-Adev
+	O
+
+Data	O
+suggest	O
+that	O
+tamoxifen	O
+is	O
+involved	O
+in	O
+the	O
+pathogenesis	B-Adev
+	O
+
+Intrahepatic	B-Adev
+cholestasis	I-Adev
+and	I-Adev
+cutaneous	I-Adev
+bullae	I-Adev
+associated	O
+with	O
+glibenclamide	O
+therapy	O
+
+Prolonged-release	O
+oxycodone	O
+enhances	O
+the	O
+effects	O
+of	O
+existing	O
+gabapentin	O
+therapy	O
+in	O
+painful	O
+diabetic	O
+neuropathy	O
+patients	O
+
+OBJECTIVE	O
+To	O
+describe	O
+what	O
+is	O
+believed	O
+as	O
+of	O
+November	O
+4	O
+2003	O
+to	O
+be	O
+the	O
+first	O
+case	O
+published	O
+in	O
+the	O
+literature	O
+of	O
+acute	B-Adev
+interstitial	I-Adev
+nephritis	I-Adev
+(AIN)	I-Adev
+due	O
+to	O
+pantoprazole	O
+
+We	O
+report	O
+a	O
+patient	O
+of	O
+organic	O
+bipolar	O
+affective	O
+disorder	O
+who	O
+developed	O
+hiccups	B-Adev
+with	O
+the	O
+atypical	O
+antipsychotic	O
+aripiprazole	O
+
+A	O
+28	O
+year-old	O
+man	O
+with	O
+chronic	O
+hepatitis	O
+B	O
+was	O
+administered	O
+interferon-alpha	O
+(5	O
+x	O
+10(6)	O
+IU)	O
+intramuscularly	O
+once	O
+a	O
+day	O
+for	O
+28	O
+days	O
+
+The	O
+case	O
+of	O
+a	O
+patient	O
+taking	O
+high-dosage	O
+olanzapine	O
+who	O
+experienced	O
+parkinsonism	B-Adev
+after	O
+smoking	O
+cessation	O
+is	O
+reported	O
+
+A	O
+65-year-old	O
+woman	O
+with	O
+bipolar	O
+disorder	O
+and	O
+complicated	O
+cardiovascular	O
+disease	O
+who	O
+was	O
+on	O
+maintenance	O
+lithium	O
+therapy	O
+developed	O
+a	B-Adev
+movement	I-Adev
+disorder	I-Adev
+following	O
+high	O
+doses	O
+of	O
+trazodone	O
+for	O
+treatment	O
+of	O
+an	O
+acute	O
+depression	O
+
+The	O
+most	O
+common	O
+complication	O
+of	O
+warfarin	O
+use	O
+is	O
+adverse	B-Adev
+bleeding	I-Adev
+	O
+
+To	O
+report	O
+a	O
+case	O
+of	O
+autonomic	B-Adev
+neurological	I-Adev
+and	I-Adev
+neuromuscular	I-Adev
+instability	I-Adev
+following	O
+methylene	O
+blue	O
+infusion	O
+for	O
+parathyroidectomy	O
+to	O
+advance	O
+the	O
+argument	O
+for	O
+a	O
+diagnosis	O
+of	O
+serotonin	O
+syndrome	O
+and	O
+to	O
+consider	O
+this	O
+diagnosis	O
+in	O
+previous	O
+unexplained	O
+reports	O
+of	O
+adverse	O
+reactions	O
+amongst	O
+patients	O
+undergoing	O
+parathyroidectomy	O
+using	O
+methylene	O
+blue	O
+
+PVT	B-Adev
+during	O
+chemotherapy	O
+in	O
+children	O
+is	O
+a	O
+rare	O
+event	O
+and	O
+appears	O
+to	O
+be	O
+closely	O
+related	O
+to	O
+intensive	O
+chemotherapy	O
+containing	O
+busulfan	O
+and	O
+to	O
+be	O
+associated	O
+with	O
+HVOD	O
+
+It	O
+is	O
+hoped	O
+that	O
+this	O
+case	O
+report	O
+creates	O
+awareness	O
+that	O
+ofloxacin-induced	O
+toxic	B-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+is	I-Adev
+possible	I-Adev
+	O
+
+Concomitant	O
+use	O
+of	O
+simvastatin	O
+and	O
+amiodarone	O
+resulting	O
+in	O
+severe	O
+rhabdomyolysis	B-Adev
+	O
+a	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+CONCLUSIONS	O
+This	O
+report	O
+indicates	O
+clindamycin	O
+phosphate	O
+vaginal	O
+cream	O
+as	O
+the	O
+most	O
+probable	O
+cause	O
+of	O
+CDIC	B-Adev
+due	O
+to	O
+the	O
+temporal	O
+relationship	O
+between	O
+the	O
+occurrence	O
+of	O
+diarrhea	O
+and	O
+clindamycin	O
+administration	O
+lack	O
+of	O
+concomitant	O
+medications	O
+and	O
+documentation	O
+of	O
+C	O
+difficile	O
+toxin	O
+
+A	O
+case	O
+of	O
+intercerebral	O
+hematoma	O
+due	O
+to	O
+warfarin-induced	O
+coagulopathy	B-Adev
+is	O
+presented	O
+
+Severe	B-Adev
+visual	I-Adev
+loss	I-Adev
+after	O
+a	O
+single	O
+dose	O
+of	O
+vincristine	O
+in	O
+a	O
+patient	O
+with	O
+spinal	O
+cord	O
+astrocytoma	O
+
+Clonazepam	O
+thioridazine	O
+beta-blockers	O
+anticholinergics	O
+and	O
+bromocriptine	O
+did	O
+not	O
+ameliorate	O
+his	O
+akathisia	O
+
+Musculoskeletal	B-Adev
+complaints	I-Adev
+were	O
+the	O
+presenting	O
+symptoms	O
+in	O
+four	O
+of	O
+44	O
+children	O
+(9%)	O
+treated	O
+for	O
+relapsed	O
+Wilms'	O
+tumors	O
+with	O
+ifosfamide	O
+a	O
+derivative	O
+of	O
+cyclophosphamide	O
+
+Cutaneous	O
+exposure	O
+to	O
+warfarin-like	O
+anticoagulant	O
+causing	O
+an	B-Adev
+intracerebral	I-Adev
+hemorrhage	I-Adev
+	O
+a	O
+case	O
+report	O
+
+Gemcitabine	O
+should	O
+be	O
+added	O
+to	O
+the	O
+list	O
+of	O
+drugs	O
+known	O
+to	O
+cause	O
+radiation	B-Adev
+recall	I-Adev
+	O
+
+A	O
+paradoxical	B-Adev
+ocular	I-Adev
+effect	I-Adev
+of	O
+brimonidine	O
+
+Fixed	B-Adev
+drug	I-Adev
+eruption	I-Adev
+to	O
+rofecoxib	O
+
+DISCUSSION	O
+No	O
+published	O
+clinical	O
+studies	O
+in	O
+patients	O
+receiving	O
+clindamycin	O
+vaginal	O
+cream	O
+for	O
+bacterial	O
+vaginosis	O
+have	O
+documented	O
+C	O
+difficile	O
+toxin	O
+in	O
+stool	O
+samples	O
+of	O
+patients	O
+with	O
+diarrhea	O
+
+Acute	B-Adev
+interstitial	I-Adev
+nephritis	I-Adev
+due	O
+to	O
+pantoprazole	O
+
+Physicians	O
+should	O
+keep	O
+in	O
+mind	O
+that	O
+taxanes	O
+such	O
+as	O
+paclitaxel	O
+have	O
+the	O
+potential	O
+to	O
+cause	O
+pneumonitis	B-Adev
+and	I-Adev
+lung	I-Adev
+fibrosis	I-Adev
+	O
+
+Infant	O
+twins	O
+sustained	O
+severe	B-Adev
+circumoral	I-Adev
+and	I-Adev
+pharyngeal	I-Adev
+burns	I-Adev
+from	O
+a	O
+concentrated	O
+solution	O
+of	O
+benzalkonium	O
+(Zephiran)	O
+chloride	O
+prescribed	O
+for	O
+treatment	O
+of	O
+candidiasis	O
+
+Isotretinoin	O
+teratogenicity	B-Adev
+	O
+
+Hepatitis	B-Adev
+following	O
+cimetidine	O
+administration	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+an	O
+11-month-old	O
+female	O
+infant	O
+with	O
+a	B-Adev
+depressed	I-Adev
+level	I-Adev
+of	I-Adev
+consciousness	I-Adev
+after	O
+ingestion	O
+of	O
+ibuprofen	O
+whose	O
+mental	O
+status	O
+markedly	O
+improved	O
+with	O
+administration	O
+of	O
+naloxone	O
+
+Investigation	O
+confirmed	O
+the	O
+diagnosis	O
+of	O
+rhabdomyolysis	O
+and	O
+discontinuation	O
+of	O
+colchicine	O
+resulted	O
+in	O
+resolution	O
+of	O
+clinical	O
+and	O
+biochemical	O
+features	O
+of	O
+rhabdomylysis	B-Adev
+	O
+
+A	O
+73	O
+year-old	O
+patient	O
+with	O
+Wolff-Parkinson-White	O
+syndrome	O
+and	O
+paroxysmic	O
+supraventricular	O
+tachycardia	O
+developed	O
+an	O
+acute	B-Adev
+reversible	I-Adev
+encephalopathy	I-Adev
+within	O
+15	O
+days	O
+of	O
+initiation	O
+of	O
+flecainide	O
+
+Since	O
+the	O
+depressive	O
+symptoms	O
+returned	O
+sertraline	O
+medication	O
+was	O
+initiated	O
+
+Supravenous	B-Adev
+hyperpigmentation	I-Adev
+in	O
+association	O
+with	O
+CHOP	O
+chemotherapy	O
+of	O
+a	O
+CD30	O
+(Ki-1)-positive	O
+anaplastic	O
+large-cell	O
+lymphoma	O
+
+A	O
+33-year-old	O
+male	O
+presented	O
+with	O
+brown	B-Adev
+discolouration	I-Adev
+of	I-Adev
+the	I-Adev
+fingernails	I-Adev
+following	O
+the	O
+application	O
+of	O
+4%	O
+hydroquinone	O
+in	O
+sorbolene	O
+cream	O
+and	O
+0.1%	O
+tretinoin	O
+cream	O
+to	O
+the	O
+face	O
+intermittently	O
+for	O
+9	O
+months	O
+
+We	O
+describe	O
+two	O
+cases	O
+of	O
+sulfadiazine-induced	O
+crystalluria	B-Adev
+and	I-Adev
+renal	I-Adev
+failure	I-Adev
+in	O
+patients	O
+with	O
+acquired	O
+immunodeficiency	O
+syndrome	O
+review	O
+the	O
+pertinent	O
+literature	O
+and	O
+discuss	O
+the	O
+pathogenesis	O
+
+Acute	B-Adev
+eosinophilic	I-Adev
+pneumonia	I-Adev
+caused	O
+by	O
+calcium	O
+stearate	O
+an	O
+additive	O
+agent	O
+for	O
+an	O
+oral	O
+antihistaminic	O
+medication	O
+
+The	O
+cause	O
+of	O
+death	B-Adev
+was	O
+determined	O
+to	O
+be	O
+acute	O
+intoxication	O
+by	O
+olanzapine	O
+and	O
+the	O
+manner	O
+of	O
+death	O
+was	O
+accidental	O
+
+Long	B-Adev
+lasting	I-Adev
+respiratory	I-Adev
+depression	I-Adev
+induced	O
+by	O
+morphine-6-glucuronide?	O
+
+A	B-Adev
+toxic	I-Adev
+encephalopathy	I-Adev
+characterized	I-Adev
+by	I-Adev
+depressed	I-Adev
+level	I-Adev
+of	I-Adev
+consciousness	I-Adev
+marked	I-Adev
+irritability	I-Adev
+and	I-Adev
+ataxia	I-Adev
+developed	O
+in	O
+seven	O
+children	O
+5	O
+years	O
+of	O
+age	O
+and	O
+younger	O
+following	O
+administration	O
+of	O
+an	O
+antiemetic	O
+combination	O
+of	O
+pentobarbital	O
+and	O
+pyrilamine	O
+maleate	O
+
+Oculomotor	B-Adev
+disturbances	I-Adev
+associated	O
+with	O
+5-fluorouracil	O
+chemotherapy	O
+
+While	O
+doxorubicin	O
+was	O
+administered	O
+the	O
+patient	O
+presented	O
+thoracic	B-Adev
+pain	I-Adev
+and	I-Adev
+breathing	I-Adev
+distress	I-Adev
+due	O
+to	O
+superior	O
+vena	O
+cava	O
+perforation	O
+by	O
+the	O
+central	O
+catheter	O
+and	O
+subsequent	O
+extravasation	O
+of	O
+the	O
+drug	O
+into	O
+the	O
+mediastinum	O
+
+An	O
+18-year-old	O
+Japanese	O
+man	O
+weighing	O
+53	O
+kg	O
+with	O
+an	O
+anaplastic	O
+large	O
+cell	O
+lymphoma	O
+received	O
+continuous	O
+IV	O
+administration	O
+of	O
+TAC	O
+as	O
+post-transplantation	O
+prophylaxis	O
+against	O
+graft-versus-host	O
+disease	O
+(GVHD)	O
+after	O
+an	O
+allogeneic	O
+bone	O
+marrow	O
+transplantation	O
+(BMT)	O
+
+Intravenous	O
+administration	O
+of	O
+levodopa	O
+ameliorated	O
+a	O
+refractory	O
+akathisia	O
+case	O
+induced	O
+by	O
+interferon-alpha	O
+
+Intravenous	O
+administration	O
+of	O
+levodopa	O
+ameliorated	O
+a	O
+refractory	B-Adev
+akathisia	I-Adev
+case	O
+induced	O
+by	O
+interferon-alpha	O
+
+Patients	O
+with	O
+lymphoblastic	O
+lymphoma	O
+who	O
+had	O
+treatment	O
+with	O
+L-asparaginase	O
+and	O
+steroid	O
+are	O
+predisposed	O
+to	O
+the	O
+development	O
+of	O
+[['cortical	B-Adev
+venous	I-Adev
+thrombosis']	I-Adev
+['dural	I-Adev
+puncture	I-Adev
+headache']]	I-Adev
+rtical	O
+venous	O
+thrombosis	O
+and	O
+may	O
+have	O
+this	O
+syndrome	O
+in	O
+addition	O
+to	O
+a	O
+dural	O
+puncture	O
+headache	O
+
+Because	O
+sumatriptan	O
+can	O
+cause	O
+coronary	B-Adev
+artery	I-Adev
+vasospasm	I-Adev
+	O
+patients	O
+with	O
+significant	O
+risk	O
+factors	O
+for	O
+coronary	O
+artery	O
+disease	O
+should	O
+be	O
+carefully	O
+evaluated	O
+for	O
+cardiovascular	O
+disease	O
+prior	O
+to	O
+the	O
+use	O
+of	O
+sumatriptan	O
+
+This	O
+article	O
+describes	O
+the	O
+case	O
+of	O
+a	O
+25-year-old	O
+man	O
+found	O
+dead	B-Adev
+at	O
+home	O
+who	O
+had	O
+been	O
+prescribed	O
+olanzapine	O
+for	O
+schizophrenia	O
+
+A	O
+67-year-old	O
+man	O
+developed	O
+diarrhea	B-Adev
+shortly	O
+after	O
+a	O
+10-day	O
+course	O
+of	O
+oral	O
+ampicillin	O
+
+Prominent	B-Adev
+positive	I-Adev
+U	I-Adev
+waves	I-Adev
+appearing	O
+with	O
+high-dose	O
+intravenous	O
+phenylephrine	O
+
+Severe	B-Adev
+acidosis	I-Adev
+in	O
+patients	O
+taking	O
+metformin--rapid	O
+reversal	O
+and	O
+survival	O
+despite	O
+high	O
+APACHE	O
+score	O
+
+Seizures	B-Adev
+and	I-Adev
+transient	I-Adev
+blindness	I-Adev
+following	O
+intravenous	O
+pulse	O
+methylprednisolone	O
+in	O
+children	O
+with	O
+primary	O
+glomerulonephritis	O
+
+We	O
+report	O
+on	O
+a	O
+patient	O
+with	O
+acromegaly	O
+who	O
+developed	O
+severe	O
+drug-induced	O
+hepatitis	B-Adev
+during	O
+combined	O
+treatment	O
+with	O
+the	O
+long-acting	O
+somatostatin-analog	O
+octreotide	O
+and	O
+the	O
+GH	O
+receptor	O
+antagonist	O
+pegvisomant	O
+
+The	O
+primary	O
+efficacy	O
+population	O
+consisted	O
+of	O
+1754	O
+patients	O
+(>	O
+or	O
+=18	O
+years)	O
+with	O
+severe	O
+sepsis	O
+and	O
+a	O
+high	O
+INR	O
+(>	O
+or	O
+=1.2)	O
+randomly	O
+assigned	O
+to	O
+intravenous	O
+infusion	O
+of	O
+either	O
+tifacogin	O
+(0.025	O
+mg/kg	O
+per	O
+hour	O
+for	O
+96	O
+hours	O
+n	O
+=	O
+880)	O
+or	O
+placebo	O
+(arginine	O
+citrate	O
+buffer	O
+n	O
+=	O
+874)	O
+and	O
+201	O
+patients	O
+with	O
+a	O
+low	O
+INR	O
+(<1.2)	O
+randomly	O
+assigned	O
+to	O
+receive	O
+the	O
+same	O
+dose	O
+of	O
+either	O
+tifacogin	O
+or	O
+placebo	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+23-year-old	O
+man	O
+who	O
+developed	O
+a	B-Adev
+vancomycin-induced	I-Adev
+anaphylactic	I-Adev
+reaction	I-Adev
+in	O
+the	O
+treatment	O
+of	O
+methicillin-resistant	O
+Staphylococcus	O
+aureus	O
+infection	O
+
+Recovery	O
+of	O
+the	O
+tubular	O
+dysfunction	O
+took	O
+15	O
+days	O
+following	O
+cessation	O
+of	O
+the	O
+offending	O
+drug	O
+Amikacin	O
+
+L-asparaginase-induced	O
+pancreatitis	B-Adev
+has	O
+been	O
+reported	O
+during	O
+or	O
+closely	O
+following	O
+administration	O
+of	O
+the	O
+drug	O
+
+These	O
+novel	O
+findings	O
+may	O
+offer	O
+specific	O
+therapeutic	O
+targets	O
+in	O
+the	O
+treatment	O
+of	O
+BCNU-associated	O
+pulmonary	B-Adev
+fibrosis	I-Adev
+	O
+
+A	O
+58-year-old	O
+man	O
+with	O
+advanced	O
+renal	O
+cell	O
+carcinoma	O
+developed	O
+grade	B-Adev
+3	I-Adev
+proteinuria	I-Adev
+(8.5	I-Adev
+g/24	I-Adev
+h)	I-Adev
+without	I-Adev
+microscopic	I-Adev
+hematuria	I-Adev
+or	I-Adev
+renal	I-Adev
+insufficiency	I-Adev
+five	O
+days	O
+after	O
+temsirolimus	O
+infusion	O
+
+A	O
+2-year-old	O
+mentally	O
+retarded	O
+boy	O
+with	O
+frontal	O
+lobe	O
+epilepsy	O
+presented	O
+with	O
+an	B-Adev
+episode	I-Adev
+that	I-Adev
+resembled	I-Adev
+heat	I-Adev
+stroke	I-Adev
+during	O
+the	O
+administration	O
+of	O
+zonisamide	O
+
+[	O
+Serotonin	B-Adev
+syndrome	I-Adev
+following	O
+methylene	O
+blue	O
+infusion	O
+during	O
+parathyroidectomy	O
+a	O
+case	O
+report	O
+and	O
+literature	O
+review]	O
+
+Two	O
+patients	O
+treated	O
+with	O
+5-fluorouracil	O
+(5-FU)	O
+for	O
+disseminated	O
+adenocarcinoma	O
+of	O
+the	O
+colon	O
+developed	O
+cerebellar	B-Adev
+dysfunction	I-Adev
+typical	O
+of	O
+5-FU	O
+neurotoxicity	O
+
+Once	O
+extensive	O
+microbiological	O
+studies	O
+proved	O
+negative	O
+corticosteroids	O
+were	O
+given	O
+and	O
+a	O
+complete	O
+remission	O
+of	O
+clinical	O
+and	O
+radiological	O
+abnormalities	O
+was	O
+achieved	O
+
+Disseminated	B-Adev
+muscular	I-Adev
+cysticercosis	I-Adev
+with	I-Adev
+myositis	I-Adev
+induced	O
+by	O
+praziquantel	O
+therapy	O
+
+Cardiomyopathy	B-Adev
+after	O
+widely	O
+separated	O
+courses	O
+of	O
+adriamycin	O
+exacerbated	O
+by	O
+actinomycin-D	O
+and	O
+mithramycin	O
+
+Linear	B-Adev
+immunoglobulin	I-Adev
+A	I-Adev
+bullous	I-Adev
+dermatosis	I-Adev
+induced	O
+by	O
+gemcitabine	O
+
+The	O
+temporal	O
+association	O
+of	O
+the	O
+course	O
+of	O
+tolterodine	O
+with	O
+an	O
+elevated	B-Adev
+INR	I-Adev
+	O
+the	O
+return	O
+to	O
+the	O
+previous	O
+warfarin	O
+dose-INR	O
+response	O
+relationship	O
+after	O
+tolterodine	O
+discontinuation	O
+and	O
+the	O
+absence	O
+of	O
+other	O
+causes	O
+for	O
+the	O
+elevated	O
+INR	O
+were	O
+factors	O
+found	O
+in	O
+both	O
+patients	O
+
+The	O
+temporal	O
+association	O
+of	O
+the	O
+course	O
+of	O
+tolterodine	O
+with	O
+an	O
+elevated	O
+INR	O
+the	O
+return	O
+to	O
+the	O
+previous	O
+warfarin	O
+dose-INR	O
+response	O
+relationship	O
+after	O
+tolterodine	O
+discontinuation	O
+and	O
+the	O
+absence	O
+of	O
+other	O
+causes	O
+for	O
+the	O
+elevated	O
+INR	O
+were	O
+factors	O
+found	O
+in	O
+both	O
+patients	O
+
+The	O
+harlequin	B-Adev
+color	I-Adev
+change	I-Adev
+and	O
+association	O
+with	O
+prostaglandin	O
+E1	O
+
+A	O
+case	O
+of	O
+tuberculosis	B-Adev
+in	O
+a	O
+patient	O
+on	O
+Efalizumab	O
+and	O
+Etanercept	O
+for	O
+treatment	O
+of	O
+refractory	O
+palmopustular	O
+psoriasis	O
+and	O
+psoriatic	O
+arthritis	O
+
+Although	O
+the	O
+two	O
+local	O
+anesthetics	O
+usually	O
+do	O
+not	O
+cause	O
+methemoglobinemia	O
+we	O
+suspect	O
+that	O
+the	O
+displacement	O
+of	O
+lidocaine	O
+from	O
+protein	O
+binding	O
+by	O
+bupivacaine	O
+in	O
+combination	O
+with	O
+metabolic	O
+acidosis	O
+and	O
+treatment	O
+with	O
+other	O
+oxidants	O
+was	O
+the	O
+reason	O
+for	O
+the	O
+development	O
+of	O
+methemoglobinemia	B-Adev
+	O
+
+Nephrotic	B-Adev
+range	I-Adev
+pseudoproteinuria	I-Adev
+in	O
+a	O
+tolmetin-treated	O
+patient	O
+
+With	O
+the	O
+first	O
+cyclosporine	O
+dose	O
+the	O
+patient	O
+complained	O
+of	O
+leg	B-Adev
+pain	I-Adev
+that	O
+was	O
+most	O
+severe	O
+during	O
+the	O
+cyclosporine	O
+infusion	O
+
+We	O
+report	O
+on	O
+a	O
+patient	O
+who	O
+developed	O
+acute	B-Adev
+rhabdomyolysis	I-Adev
+after	O
+taking	O
+cerivastatin	O
+
+In	O
+a	O
+patient	O
+suffering	O
+from	O
+rheumatoid	O
+arthritis	O
+we	O
+report	O
+the	O
+first	O
+simultaneous	O
+occurrence	O
+of	O
+two	O
+side	O
+effects	O
+of	O
+low-dose	O
+methotrexate	O
+an	O
+acute	B-Adev
+megaloblastic	I-Adev
+anaemia	I-Adev
+and	I-Adev
+a	I-Adev
+pneumonitis	I-Adev
+	O
+
+We	O
+describe	O
+a	O
+57-year-old	O
+man	O
+with	O
+acral	O
+erythrocyanosis	O
+progressing	O
+to	O
+acute	B-Adev
+digital	I-Adev
+ischemia	I-Adev
+and	I-Adev
+gangrene	I-Adev
+that	O
+developed	O
+after	O
+combined	O
+chemotherapy	O
+(bleomycin	O
+and	O
+methotrexate)	O
+used	O
+to	O
+treat	O
+a	O
+metastatic	O
+squamous	O
+cell	O
+carcinoma	O
+of	O
+the	O
+hypopharynx	O
+
+We	O
+report	O
+a	B-Adev
+case	I-Adev
+of	I-Adev
+long	I-Adev
+lasting	I-Adev
+respiratory	I-Adev
+depression	I-Adev
+after	O
+intravenous	O
+administration	O
+of	O
+morphine	O
+to	O
+a	O
+7	O
+year	O
+old	O
+girl	O
+with	O
+haemolytic	O
+uraemic	O
+syndrome	O
+
+Although	O
+adverse	O
+effects	O
+are	O
+usually	O
+mild	O
+the	O
+author	O
+reports	O
+here	O
+a	O
+case	O
+of	O
+leucocytopenia	B-Adev
+and	I-Adev
+thrombocytopenia	I-Adev
+with	O
+quetiapine	O
+treatment	O
+that	O
+required	O
+its	O
+discontinuation	O
+
+Noncardiogenic	B-Adev
+pulmonary	I-Adev
+edema	I-Adev
+during	O
+intrabiliary	O
+infusion	O
+of	O
+mono-octanoin	O
+
+Cardiac	O
+glycosides	O
+are	O
+thought	O
+to	O
+prevent	O
+doxorubicin	O
+cardiomyopathy	O
+by	O
+competitively	O
+inhibiting	O
+doxorubicin	O
+at	O
+its	O
+receptor	O
+sites	O
+but	O
+ouabain	O
+has	O
+a	O
+much	O
+shorter	O
+half	O
+life	O
+than	O
+doxorubicin	O
+and	O
+its	O
+metabolites	O
+and	O
+so	O
+is	O
+less	O
+effective	O
+than	O
+digoxin	O
+
+Three	O
+hundred	O
+and	O
+thirty	O
+eight	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+painful	O
+diabetic	O
+neuropathy	O
+despite	O
+receiving	O
+their	O
+maximum	O
+tolerated	O
+dose	O
+of	O
+gabapentin	O
+had	O
+oral	O
+prolonged-release	O
+oxycodone	O
+or	O
+placebo	O
+tablets	O
+added	O
+to	O
+their	O
+therapy	O
+for	O
+up	O
+to	O
+12	O
+weeks	O
+
+We	O
+assessed	O
+the	O
+bleeding	B-Adev
+risk	O
+in	O
+patients	O
+treated	O
+with	O
+thromboprophylactic	O
+dabigatran	O
+etexilate	O
+with	O
+and	O
+without	O
+concomitant	O
+NSAID	O
+or	O
+ASA	O
+
+Dapsone-induced	O
+erythroderma	B-Adev
+with	I-Adev
+Beau's	I-Adev
+lines	I-Adev
+	O
+
+Methotrexate-induced	O
+hepatic	B-Adev
+necrosis	I-Adev
+requiring	O
+liver	O
+transplantation	O
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+
+We	O
+present	O
+three	O
+cases	O
+from	O
+the	O
+Provincial	O
+Toxicology	O
+Center	O
+of	O
+British	O
+Columbia	O
+Canada	O
+in	O
+which	O
+suicidal	B-Adev
+overdose	I-Adev
+deaths	I-Adev
+were	O
+associated	O
+with	O
+quetiapine	O
+
+Both	O
+patients	O
+developed	O
+hypoadrenalism	B-Adev
+while	O
+on	O
+o,p'-DDD	O
+and	O
+apparently	O
+adequate	O
+dexamethasone	O
+replacement	O
+therapy	O
+
+In	O
+the	O
+other	O
+patient	O
+a	O
+78-year-old	O
+woman	O
+Neisseria	B-Adev
+mucosa	I-Adev
+knee	I-Adev
+arthritis	I-Adev
+occurred	O
+after	O
+a	O
+single	O
+sodium	O
+hyaluronate	O
+injection	O
+
+Implanon	O
+failure	O
+in	O
+an	O
+HIV-positive	O
+woman	O
+on	O
+antiretroviral	O
+therapy	O
+resulting	O
+in	O
+two	B-Adev
+ectopic	I-Adev
+pregnancies	I-Adev
+	O
+
+Massive	B-Adev
+prolapse	I-Adev
+of	I-Adev
+the	I-Adev
+urethral	I-Adev
+mucosa	I-Adev
+following	O
+periurethral	O
+injection	O
+of	O
+calcium	O
+hydroxylapatite	O
+for	O
+stress	O
+urinary	O
+incontinence	O
+
+A	O
+35-year-old	O
+female	O
+with	O
+borderline	O
+lepromatous	O
+(BL)	O
+leprosy	O
+who	O
+suffered	O
+from	O
+dapsone-induced	O
+erythroderma	B-Adev
+is	O
+reported	O
+
+Well-known	O
+signs	O
+of	O
+methotrexate	O
+toxicity	O
+include	O
+bone	B-Adev
+marrow	I-Adev
+suppression	I-Adev
+and	I-Adev
+oral	I-Adev
+and	I-Adev
+gastrointestinal	I-Adev
+ulceration	I-Adev
+	O
+
+Hemorrhage	B-Adev
+from	I-Adev
+a	I-Adev
+falx	I-Adev
+meningioma	I-Adev
+after	O
+internal	O
+use	O
+of	O
+low-dose	O
+aspirin	O
+
+Severe	B-Adev
+respiratory	I-Adev
+syncytial	I-Adev
+virus	I-Adev
+pulmonary	I-Adev
+infection	I-Adev
+in	O
+a	O
+patient	O
+treated	O
+with	O
+fludarabine	O
+for	O
+chronic	O
+lymphocytic	O
+leukemia	O
+
+Nonsustained	B-Adev
+polymorphous	I-Adev
+ventricular	I-Adev
+tachycardia	I-Adev
+during	O
+amiodarone	O
+therapy	O
+for	O
+atrial	O
+fibrillation	O
+complicating	O
+cardiomyopathy	O
+
+Severe	O
+abdominal	B-Adev
+pain	I-Adev
+in	O
+low	O
+dosage	O
+clofazimine	O
+
+Behavioral	O
+side	O
+effects	O
+associated	O
+with	O
+clonazepam	O
+may	O
+include	O
+agitation	B-Adev
+aggression	I-Adev
+hyperactivity	I-Adev
+irritability	I-Adev
+property	I-Adev
+destruction	I-Adev
+and	I-Adev
+temper	I-Adev
+tantrums	I-Adev
+	O
+
+Coagulopathy	B-Adev
+associated	O
+with	O
+the	O
+use	O
+of	O
+cephalosporin	O
+or	O
+moxalactam	O
+antibiotics	O
+in	O
+acute	O
+and	O
+chronic	O
+renal	O
+failure	O
+
+Pamidronate	O
+therapy	O
+should	O
+be	O
+considered	O
+in	O
+patients	O
+with	O
+hypercalcemia	B-Adev
+secondary	O
+to	O
+acute	O
+vitamin	O
+D	O
+poisoning	O
+
+Pamidronate	O
+therapy	O
+should	O
+be	O
+considered	O
+in	O
+patients	O
+with	O
+hypercalcemia	O
+secondary	O
+to	O
+acute	O
+vitamin	O
+D	O
+poisoning	O
+
+Use	O
+of	O
+the	O
+Naranjo	O
+probability	O
+scale	O
+indicated	O
+a	O
+highly	O
+probable	O
+relationship	O
+between	O
+the	O
+observed	O
+cardiac	B-Adev
+toxicity	I-Adev
+and	O
+amphotericin	O
+B	O
+deoxycholate	O
+therapy	O
+in	O
+this	O
+patient	O
+
+Captopril-induced	O
+pulmonary	B-Adev
+infiltrates	I-Adev
+with	I-Adev
+eosinophilia	I-Adev
+in	O
+an	O
+infant	O
+with	O
+congenital	O
+heart	O
+disease	O
+
+Chronic	O
+fentanyl	O
+application	O
+induces	O
+adrenocortical	B-Adev
+insufficiency	I-Adev
+	O
+
+After	O
+discontinuing	O
+captopril	O
+and	O
+starting	O
+systemic	O
+steroids	O
+her	O
+symptomatology	O
+rapidly	O
+improved	O
+and	O
+her	O
+eosinophilia	O
+and	O
+radiographic	O
+abnormalities	O
+both	O
+resolved	O
+
+We	O
+present	O
+a	O
+surprising	O
+case	O
+of	O
+a	O
+woman	O
+schizophrenic	O
+patient	O
+treated	O
+with	O
+clozapine	O
+suffering	O
+from	O
+EPS	B-Adev
+	O
+
+Therefore	O
+we	O
+concluded	O
+that	O
+this	O
+patient's	O
+pulmonary	B-Adev
+disease	I-Adev
+was	O
+caused	O
+by	O
+calcium	O
+stearate	O
+an	O
+additive	O
+for	O
+an	O
+antihistaminic	O
+drug	O
+
+Benzocaine-induced	O
+methemoglobinemia	B-Adev
+has	O
+been	O
+reported	O
+in	O
+man	O
+dogs	O
+and	O
+cats	O
+
+We	O
+report	O
+two	O
+cases	O
+of	O
+fulminant	B-Adev
+hepatic	I-Adev
+failure	I-Adev
+in	O
+HIV-1-infected	O
+patients	O
+treated	O
+with	O
+didanosine	O
+(ddI)	O
+
+Leflunomide-associated	O
+weight	B-Adev
+loss	I-Adev
+in	O
+rheumatoid	O
+arthritis	O
+
+Antiretroviral-induced	O
+hepatic	B-Adev
+steatosis	I-Adev
+and	I-Adev
+lactic	I-Adev
+acidosis	I-Adev
+	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+A	O
+woman	O
+developed	O
+delusional	B-Adev
+parasitosis	I-Adev
+when	O
+taking	O
+phenelzine	O
+
+Percutaneous	O
+absorption	O
+of	O
+warfarin	O
+causing	O
+coagulopathy	B-Adev
+	O
+reported	O
+three	O
+times	O
+in	O
+the	O
+past	O
+is	O
+a	O
+significant	O
+risk	O
+if	O
+protective	O
+measures	O
+such	O
+as	O
+gloves	O
+are	O
+not	O
+used	O
+
+We	O
+present	O
+two	O
+cases	O
+of	O
+nitrofurantoin-induced	O
+pulmonary	B-Adev
+toxicity	I-Adev
+in	I-Adev
+which	I-Adev
+the	I-Adev
+initial	I-Adev
+HRCT	I-Adev
+showed	I-Adev
+a	I-Adev
+widespread	I-Adev
+reticular	I-Adev
+pattern	I-Adev
+and	I-Adev
+associated	I-Adev
+distortion	I-Adev
+of	I-Adev
+the	I-Adev
+lung	I-Adev
+parenchyma	I-Adev
+thought	I-Adev
+to	I-Adev
+represent	I-Adev
+established	I-Adev
+fibrosis	I-Adev
+	O
+
+Colchicine-induced	O
+rhabdomyolysis	B-Adev
+	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+severe	O
+AVP	B-Adev
+three	O
+weeks	O
+following	O
+the	O
+administration	O
+of	O
+infliximab	O
+for	O
+the	O
+treatment	O
+of	O
+Crohn's	O
+disease	O
+(CD)	O
+
+In	O
+each	O
+patient	O
+the	O
+initiation	O
+of	O
+tolterodine	O
+was	O
+associated	O
+with	O
+a	O
+significant	B-Adev
+increase	I-Adev
+in	I-Adev
+the	I-Adev
+patient's	I-Adev
+INR	I-Adev
+measured	O
+10-14	O
+days	O
+later	O
+
+DATA	O
+SYNTHESIS	O
+Genetic	O
+deficiencies	O
+in	O
+DPD	O
+the	O
+rate-limiting	O
+enzyme	O
+responsible	O
+for	O
+5-FU	O
+catabolism	O
+may	O
+occur	O
+in	O
+3%	O
+or	O
+more	O
+of	O
+patients	O
+with	O
+cancer	O
+putting	O
+them	O
+at	O
+increased	B-Adev
+risk	I-Adev
+for	I-Adev
+unusually	I-Adev
+severe	I-Adev
+adverse	I-Adev
+reactions	I-Adev
+(e.g.	I-Adev
+diarrhea	I-Adev
+stomatitis	I-Adev
+mucositis	I-Adev
+myelosuppression	I-Adev
+neurotoxicity)	I-Adev
+to	O
+standard	O
+doses	O
+of	O
+5-FU	O
+
+According	O
+to	O
+the	O
+Drug	O
+Interaction	O
+Probability	O
+Scale	O
+the	O
+development	B-Adev
+of	I-Adev
+supratherapeutic	I-Adev
+INRs	I-Adev
+was	O
+probably	O
+associated	O
+with	O
+concomitant	O
+acetaminophen	O
+and	O
+moxifloxacin	O
+use	O
+
+Both	O
+colchicine	O
+and	O
+statin	O
+therapy	O
+may	O
+be	O
+associated	O
+with	O
+myopathy	B-Adev
+	O
+which	O
+usually	O
+occurs	O
+after	O
+several	O
+months	O
+of	O
+therapy	O
+
+Cephalosporins	O
+are	O
+most	O
+likely	O
+associated	O
+with	O
+Vitamin	B-Adev
+K	I-Adev
+deficiency	I-Adev
+
+Embolia	B-Adev
+cutis	I-Adev
+medicamentosa	I-Adev
+following	O
+subcutaneous	O
+injection	O
+of	O
+glatiramer	O
+acetate	O
+
+Reversible	B-Adev
+valproic	O
+acid-induced	O
+dementia	O
+was	O
+documented	O
+in	O
+a	O
+21-year-old	O
+man	O
+with	O
+epilepsy	O
+who	O
+had	O
+a	O
+3-year	O
+history	O
+of	O
+insidious	O
+progressive	O
+decline	O
+in	O
+global	O
+cognitive	O
+abilities	O
+documented	O
+by	O
+serial	O
+neuropsychological	O
+studies	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+50-year-old	O
+woman	O
+with	O
+advanced	O
+non-small	O
+cell	O
+lung	O
+cancer	O
+who	O
+developed	O
+status	B-Adev
+epilepticus	I-Adev
+shortly	O
+after	O
+receiving	O
+cisplatin	O
+and	O
+gemcitabine	O
+chemotherapy	O
+
+Here	O
+we	O
+report	O
+a	O
+case	O
+of	O
+angio-oedema	B-Adev
+associated	O
+with	O
+VRC	O
+therapy	O
+
+Multiple	B-Adev
+syncopal	I-Adev
+episodes	I-Adev
+started	O
+to	O
+occur	O
+during	O
+thalidomide	O
+treatment	O
+and	O
+a	O
+Holter	O
+electrocardiogram	O
+showed	O
+multiple	O
+abnormalities	O
+with	O
+an	O
+episode	O
+of	O
+sustained	O
+ventricular	O
+tachycardia	O
+
+A	O
+25-year-old	O
+woman	O
+sought	O
+medical	O
+attention	O
+because	O
+of	O
+iliocaval	B-Adev
+manifestations	I-Adev
+of	I-Adev
+retroperitoneal	I-Adev
+fibrosis	I-Adev
+while	O
+she	O
+was	O
+taking	O
+methysergide	O
+
+Nodular	B-Adev
+scleritis	I-Adev
+following	O
+alendronate	O
+therapy	O
+
+Thus	O
+tolterodine	O
+was	O
+ineffective	O
+in	O
+both	O
+patients	O
+and	O
+was	O
+discontinued	O
+one	O
+to	O
+two	O
+days	O
+before	O
+the	O
+elevated	O
+INRs	O
+were	O
+determined	O
+during	O
+routine	O
+clinic	O
+visits	O
+
+However	O
+the	O
+use	O
+of	O
+lithium	O
+should	O
+be	O
+avoided	O
+with	O
+any	O
+patient	O
+who	O
+is	O
+purging	O
+since	O
+it	O
+may	O
+exacerbate	O
+the	O
+[['loss	B-Adev
+of	I-Adev
+intracellular	I-Adev
+potassium']	I-Adev
+['increasing	I-Adev
+the	I-Adev
+risk	I-Adev
+of	I-Adev
+cardiac	I-Adev
+toxicity']]	I-Adev
+ss	O
+of	O
+intracellular	O
+potassium	O
+thereby	O
+increasing	O
+the	O
+risk	O
+of	O
+cardiac	O
+toxicity	O
+
+Neurophysiological	O
+mechanisms	O
+which	O
+aid	O
+in	O
+elucidating	O
+the	O
+role	O
+of	O
+disulfiram	O
+in	O
+the	O
+etiology	O
+of	O
+catatonia	B-Adev
+are	O
+discussed	O
+
+Sagittal	B-Adev
+sinus	I-Adev
+thrombosis	I-Adev
+associated	I-Adev
+with	I-Adev
+transient	I-Adev
+free	I-Adev
+protein	I-Adev
+S	I-Adev
+deficiency	I-Adev
+after	O
+L-asparaginase	O
+treatment	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+This	O
+case	O
+demonstrates	O
+the	O
+association	O
+of	O
+selective	O
+IgA	O
+deficiency	O
+with	O
+remission	B-Adev
+in	I-Adev
+rheumatoid	I-Adev
+arthritis	I-Adev
+induced	O
+by	O
+fenclofenac	O
+as	O
+well	O
+as	O
+aurothiomalate	O
+and	O
+sulphasalazine	O
+
+This	O
+study	O
+provides	O
+the	O
+first	O
+evidence	O
+that	O
+co-administration	O
+of	O
+prolonged-release	O
+oxycodone	O
+and	O
+existing	O
+gabapentin	O
+therapy	O
+has	O
+a	O
+clinically	O
+meaningful	O
+effect	O
+in	O
+painful	O
+diabetic	O
+neuropathy	O
+
+In	O
+the	O
+present	O
+case	O
+report	O
+the	O
+concomitant	O
+administration	O
+of	O
+clarithromycin	O
+and	O
+sirolimus	O
+determined	O
+impressive	O
+increase	O
+of	O
+sirolimus	O
+trough	O
+blood	O
+concentrations	O
+from	O
+6.2	O
+up	O
+to	O
+54	O
+ng/mL	O
+and	O
+this	O
+increase	O
+was	O
+associated	O
+with	O
+an	O
+acute	B-Adev
+impairment	I-Adev
+of	I-Adev
+renal	I-Adev
+function	I-Adev
+	O
+almost	O
+completely	O
+reversed	O
+upon	O
+both	O
+drugs	O
+discontinuation	O
+
+In	O
+one	O
+case	O
+the	O
+readministration	O
+of	O
+riluzole	O
+was	O
+followed	O
+by	O
+the	B-Adev
+relapse	I-Adev
+of	I-Adev
+hepatitis	I-Adev
+	O
+
+Pseudoephedrine-induced	O
+hemorrhage	B-Adev
+associated	I-Adev
+with	I-Adev
+a	I-Adev
+cerebral	I-Adev
+vascular	I-Adev
+malformation	I-Adev
+	O
+
+PURPOSE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+severe	O
+corticosteroid-induced	O
+glaucoma	B-Adev
+after	O
+intravitreal	O
+injection	O
+of	O
+triamcinolone	O
+acetate	O
+in	O
+a	O
+34-year-old	O
+man	O
+without	O
+a	O
+history	O
+of	O
+glaucoma	O
+
+A	O
+transient	B-Adev
+tonic	I-Adev
+pupillary	I-Adev
+response	I-Adev
+denervation	I-Adev
+supersensitivity	I-Adev
+and	I-Adev
+abnormal	I-Adev
+visual-evoked	I-Adev
+potentials	I-Adev
+in	O
+quinine	O
+toxicity	O
+to	O
+our	O
+knowledge	O
+have	O
+not	O
+been	O
+previously	O
+reported	O
+
+Two	O
+days'	O
+administration	O
+of	O
+levomepromazine	O
+100	O
+mg	O
+led	O
+him	O
+to	O
+a	B-Adev
+coma	I-Adev
+for	I-Adev
+2	I-Adev
+days	I-Adev
+	O
+
+Methimazole-induced	O
+aplastic	B-Adev
+anemia	I-Adev
+in	O
+third	O
+exposure	O
+successful	O
+treatment	O
+with	O
+recombinant	O
+human	O
+granulocyte	O
+colony-stimulating	O
+factor	O
+
+BACKGROUND	O
+We	O
+describe	O
+the	O
+ophthalmic	O
+features	O
+and	O
+clinical	O
+course	O
+of	O
+two	O
+cases	O
+of	O
+acute	B-Adev
+syphilitic	I-Adev
+posterior	I-Adev
+placoid	I-Adev
+chorioretinitis	I-Adev
+(ASPPC)	O
+that	O
+developed	O
+after	O
+intravitreal	O
+triamcinolone	O
+acetonide	O
+(IVTA)	O
+injection	O
+
+Skin	B-Adev
+rash	I-Adev
+and	I-Adev
+splinter	I-Adev
+hemorrhages	I-Adev
+from	O
+ganciclovir	O
+
+We	O
+present	O
+a	O
+pediatric	O
+patient	O
+with	O
+leukemia	O
+and	O
+a	O
+severe	O
+L-asparaginase-induced	O
+necrotizing	O
+pancreatitis	O
+treated	O
+successfully	O
+with	O
+percutaneous	O
+drainage	O
+used	O
+to	O
+flush	B-Adev
+the	I-Adev
+infected	I-Adev
+necrotic	I-Adev
+parts	I-Adev
+
+We	O
+present	O
+a	O
+pediatric	O
+patient	O
+with	O
+leukemia	O
+and	O
+a	O
+severe	O
+L-asparaginase-induced	O
+necrotizing	B-Adev
+pancreatitis	I-Adev
+	O
+treated	O
+successfully	O
+with	O
+percutaneous	O
+drainage	O
+used	O
+to	O
+flush	O
+the	O
+infected	O
+necrotic	O
+parts	O
+
+Such	O
+anagen	B-Adev
+effluvium	I-Adev
+with	I-Adev
+lichenoid	I-Adev
+eruption	I-Adev
+following	O
+INH	O
+therapy	O
+has	O
+not	O
+been	O
+observed	O
+previously	O
+
+We	O
+conclude	O
+that	O
+MB	O
+is	O
+an	O
+effective	O
+treatment	O
+for	O
+ifosfamide-induced	O
+encephalopathy	B-Adev
+	O
+
+We	O
+conclude	O
+that	O
+MB	O
+is	O
+an	O
+effective	O
+treatment	O
+for	O
+ifosfamide-induced	O
+encephalopathy	O
+
+Hyponatraemia	B-Adev
+during	O
+low-dose	O
+carbamazepine	O
+therapy	O
+
+Acute	B-Adev
+coronary	I-Adev
+syndrome	I-Adev
+induced	O
+by	O
+capecitabine	O
+therapy	O
+
+A	O
+case	O
+of	O
+severe	B-Adev
+visual	I-Adev
+loss	I-Adev
+following	O
+a	O
+single	O
+dose	O
+of	O
+vincristine	O
+is	O
+described	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+young	O
+woman	O
+with	O
+SLE	O
+and	O
+thrombocytopenia	O
+who	O
+developed	O
+severe	B-Adev
+perspiration	I-Adev
+headache	I-Adev
+and	I-Adev
+seizure	I-Adev
+after	O
+receiving	O
+cyclosporine	O
+
+Although	O
+gabapentin	O
+withdrawal	O
+has	O
+been	O
+previously	O
+reported	O
+and	O
+usually	O
+consists	O
+of	O
+anxiety	O
+diaphoresis	O
+and	O
+palpitations	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+patient	O
+with	O
+generalized	B-Adev
+seizures	I-Adev
+and	I-Adev
+status	I-Adev
+epilepticus	I-Adev
+secondary	O
+to	O
+gabapentin	O
+withdrawal	O
+
+Self-limited	B-Adev
+edema	I-Adev
+is	O
+a	O
+well-recognized	O
+complication	O
+of	O
+insulin	O
+therapy	O
+
+It	O
+is	O
+very	O
+likely	O
+that	O
+the	O
+dexamethasone	O
+used	O
+in	O
+the	O
+antiemetic	O
+drug	O
+regimen	O
+contributed	O
+to	O
+the	O
+development	O
+of	O
+osteonecrosis	B-Adev
+in	O
+these	O
+patients	O
+
+A	O
+case	O
+is	O
+presented	O
+of	O
+a	O
+patient	O
+who	O
+experienced	O
+benzodiazepine	B-Adev
+withdrawal	I-Adev
+symptoms	I-Adev
+on	O
+discontinuation	O
+of	O
+nefazodone	O
+an	O
+antidepressant	O
+that	O
+inhibits	O
+the	O
+cytochrome	O
+P450	O
+3A4	O
+isoenzyme	O
+
+Isotretinoin	O
+a	O
+drug	O
+used	O
+for	O
+the	O
+treatment	O
+of	O
+acne	O
+has	O
+been	O
+shown	O
+to	O
+have	O
+teratogenic	B-Adev
+effects	I-Adev
+	O
+
+The	O
+capacity	O
+of	O
+zuclopenthixol	O
+to	O
+induce	O
+priapism	B-Adev
+is	O
+thought	O
+to	O
+be	O
+due	O
+to	O
+its	O
+antagonist	O
+activity	O
+on	O
+alpha-adrenergic	O
+receptors	O
+
+Two	O
+patients	O
+treated	O
+for	O
+chronic	O
+myeloid	O
+leukemia	O
+with	O
+high	O
+doses	O
+of	O
+CCNU	O
+(1100	O
+mg/m2	O
+and	O
+1240	O
+mg/m2	O
+respectively)	O
+developed	O
+a	O
+fatal	O
+pulmonary	B-Adev
+fibrosis	I-Adev
+	O
+
+CONCLUSIONS	O
+There	O
+is	O
+very	O
+little	O
+published	O
+information	O
+regarding	O
+ofloxacin-induced	O
+toxic	B-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+	O
+
+Our	O
+case	O
+is	O
+the	O
+second	O
+one	O
+in	O
+which	O
+hemorrhage	B-Adev
+from	I-Adev
+a	I-Adev
+meningioma	I-Adev
+may	O
+have	O
+been	O
+induced	O
+by	O
+aspirin	O
+prophylaxis	O
+
+Methemoglobinemia	B-Adev
+after	O
+axillary	O
+block	O
+with	O
+bupivacaine	O
+and	O
+additional	O
+injection	O
+of	O
+lidocaine	O
+in	O
+the	O
+operative	O
+field	O
+
+Nonconvulsive	B-Adev
+status	I-Adev
+epilepticus	I-Adev
+	O
+the	O
+role	O
+of	O
+morphine	O
+and	O
+its	O
+antagonist	O
+
+Acute	B-Adev
+myeloid	I-Adev
+leukemia	I-Adev
+evolving	O
+from	O
+essential	O
+thrombocythemia	O
+in	O
+two	O
+patients	O
+treated	O
+with	O
+hydroxyurea	O
+
+Central	O
+nervous	O
+system	O
+manifestations	O
+of	O
+an	O
+ibuprofen	O
+overdose	O
+reversed	O
+by	O
+naloxone	O
+
+BACKGROUND	O
+Aphthous	B-Adev
+stomatitis	I-Adev
+	O
+a	O
+common	O
+mucocutaneous	O
+disorder	O
+is	O
+a	O
+well	O
+accepted	O
+complication	O
+of	O
+sirolimus	O
+therapy	O
+
+The	O
+goal	O
+of	O
+this	O
+article	O
+was	O
+to	O
+describe	O
+a	O
+potential	O
+drug-drug	O
+interaction	O
+between	O
+propafenone	O
+and	O
+citalopram	O
+which	O
+caused	O
+symptoms	B-Adev
+of	I-Adev
+propafenone	I-Adev
+adverse	I-Adev
+effects	I-Adev
+	O
+
+Temporary	B-Adev
+neurologic	I-Adev
+abnormalities	I-Adev
+were	O
+observed	O
+in	O
+one	O
+out	O
+of	O
+23	O
+patients	O
+undergoing	O
+chemotherapy	O
+with	O
+high-dose	O
+methotrexate	O
+(HD-MTX)	O
+for	O
+osteogenic	O
+sarcoma	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+a	O
+possible	O
+interaction	O
+between	O
+propafenone	O
+and	O
+citalopram	O
+which	O
+caused	O
+propafenone	B-Adev
+adverse	I-Adev
+effects	I-Adev
+(eg	I-Adev
+dizziness	I-Adev
+falls)	I-Adev
+and	I-Adev
+mimicked	I-Adev
+coronary	I-Adev
+artery	I-Adev
+disease	I-Adev
+	O
+
+Spontaneous	B-Adev
+bacterial	I-Adev
+peritonitis	I-Adev
+induced	O
+by	O
+intraarterial	O
+vasopressin	O
+therapy	O
+
+Ciclesonide	O
+reduces	O
+the	O
+need	O
+for	O
+oral	O
+steroid	O
+use	O
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+persistent	O
+asthma	O
+
+Five	O
+cases	O
+(four	O
+from	O
+the	O
+literature	O
+and	O
+one	O
+new	O
+case)	O
+are	O
+presented	O
+in	O
+which	O
+patients	O
+unsuspected	O
+of	O
+having	O
+vitamin	O
+B12	O
+deficiency	O
+developed	O
+subacute	B-Adev
+combined	I-Adev
+degeneration	I-Adev
+of	I-Adev
+the	I-Adev
+spinal	I-Adev
+cord	I-Adev
+following	O
+nitrous	O
+oxide	O
+anesthesia	O
+
+CASE	O
+SUMMARY	O
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+31-year-old	O
+patient	O
+hospitalized	O
+due	O
+to	O
+behavioral	O
+alterations	O
+and	O
+treated	O
+with	O
+oral	O
+zuclopenthixol	O
+an	O
+antipsychotic	O
+from	O
+the	O
+thioxanthene	O
+family	O
+who	O
+developed	O
+an	O
+acute	B-Adev
+painful	I-Adev
+erection	I-Adev
+	O
+
+Three	O
+cases	O
+of	O
+acute	B-Adev
+renal	I-Adev
+toxicity	I-Adev
+in	O
+patients	O
+receiving	O
+long-term	O
+therapy	O
+with	O
+mitomycin	O
+C	O
+and	O
+5-fluorouracil	O
+are	O
+reported	O
+
+A	O
+40-year-old	O
+man	O
+with	O
+a	O
+long	O
+standing	O
+history	O
+of	O
+rheumatoid	O
+arthritis	O
+was	O
+treated	O
+with	O
+MTX	O
+over	O
+a	O
+6	O
+month	O
+period	O
+and	O
+developed	O
+an	B-Adev
+overwhelming	I-Adev
+hepatic	I-Adev
+necrosis	I-Adev
+	O
+
+In	O
+case	O
+1	O
+a	O
+total	O
+daily	O
+dose	O
+of	O
+25	O
+mg	O
+sertraline	O
+with	O
+nondetectable	O
+sertraline	O
+and	O
+desmethylsertraline	O
+blood	O
+levels	O
+resulted	O
+in	O
+a	O
+doubling	B-Adev
+of	I-Adev
+the	I-Adev
+lamotrigine	I-Adev
+blood	I-Adev
+level	I-Adev
+with	I-Adev
+symptoms	I-Adev
+of	I-Adev
+toxicity	I-Adev
+	O
+
+Since	O
+the	O
+bronchospasm	O
+was	O
+relieved	O
+with	O
+discontinuation	O
+of	O
+propranolol	O
+and	O
+supportive	O
+bronchodilator	O
+therapy	O
+the	O
+bronchospasm	B-Adev
+was	O
+believed	O
+to	O
+be	O
+caused	O
+by	O
+propranolol	O
+
+A	O
+depressed	O
+woman	O
+with	O
+no	O
+history	O
+of	O
+bipolar	O
+illness	O
+developed	O
+a	O
+manic	B-Adev
+episode	I-Adev
+during	O
+treatment	O
+with	O
+fluoxetine	O
+
+Priapism	B-Adev
+associated	O
+with	O
+trazodone	O
+therapy	O
+case	O
+report	O
+
+OBJECTIVE	O
+To	O
+report	O
+the	O
+occurrence	O
+of	O
+anterior	B-Adev
+ischemic	I-Adev
+optic	I-Adev
+neuropathy	I-Adev
+as	O
+a	O
+complication	O
+of	O
+treatment	O
+with	O
+interferon	O
+alfa	O
+and	O
+to	O
+consider	O
+the	O
+possible	O
+underlying	O
+mechanisms	O
+for	O
+this	O
+association	O
+
+Mequitazine	O
+seemed	O
+to	O
+play	O
+a	O
+part	O
+similar	O
+to	O
+chlorpromazine	O
+and	O
+absence	O
+of	O
+mequitazine-induced	O
+photosensitivity	B-Adev
+may	O
+be	O
+due	O
+to	O
+a	O
+relatively	O
+low	O
+dosage	O
+of	O
+the	O
+drug	O
+
+Although	O
+various	O
+manifestations	O
+of	O
+pentamidine-induced	O
+cardiotoxicity	B-Adev
+have	O
+been	O
+reported	O
+to	O
+our	O
+knowledge	O
+second-degree	O
+heart	O
+block	O
+associated	O
+with	O
+this	O
+agent	O
+has	O
+not	O
+been	O
+described	O
+
+Although	O
+various	O
+manifestations	O
+of	O
+pentamidine-induced	O
+cardiotoxicity	O
+have	O
+been	O
+reported	O
+to	O
+our	O
+knowledge	O
+second-degree	B-Adev
+heart	I-Adev
+block	I-Adev
+associated	O
+with	O
+this	O
+agent	O
+has	O
+not	O
+been	O
+described	O
+
+The	O
+mean	O
+weekly	O
+warfarin	O
+dose	O
+while	O
+the	O
+patient	O
+was	O
+receiving	O
+emtricitabine	O
+monotherapy	O
+was	O
+13.3	O
+mg	O
+(95%	O
+CI	O
+12.7	O
+to	O
+13.8)	O
+with	O
+a	O
+mean	O
+international	O
+normalized	O
+ratio	O
+(INR)	O
+of	O
+2.8	O
+(95%	O
+CI	O
+2.5	O
+to	O
+3.1)	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+penile	B-Adev
+fibrosis	I-Adev
+after	O
+intracavernous	O
+self-injection	O
+of	O
+a	O
+combination	O
+of	O
+phentolamine	O
+and	O
+papaverine	O
+
+This	O
+is	O
+to	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+the	O
+first	O
+report	O
+of	O
+a	O
+case	O
+in	O
+which	O
+agranulocytosis	B-Adev
+followed	O
+treatment	O
+with	O
+both	O
+propylthiouracil	O
+and	O
+methimazole	O
+in	O
+the	O
+same	O
+patient	O
+
+Itch	B-Adev
+and	I-Adev
+skin	I-Adev
+rash	I-Adev
+from	O
+chocolate	O
+during	O
+fluoxetine	O
+and	O
+sertraline	O
+treatment	O
+case	O
+report	O
+
+Oxycodone-gabapentin	O
+co-administration	O
+was	O
+associated	O
+with	O
+less	B-Adev
+escape	I-Adev
+medication	I-Adev
+use	I-Adev
+(P	I-Adev
+=	I-Adev
+0.03)	I-Adev
+and	I-Adev
+fewer	I-Adev
+nights	I-Adev
+of	I-Adev
+disturbed	I-Adev
+sleep	I-Adev
+(P	I-Adev
+<	I-Adev
+0.05)	I-Adev
+	O
+
+Gynecomastia	B-Adev
+in	O
+epileptics	O
+treated	O
+with	O
+phenobarbital	O
+phenytoin	O
+and	O
+fluoresone	O
+two	O
+case	O
+reports	O
+
+Captopril-induced	O
+lichen	B-Adev
+planus	I-Adev
+pemphigoides	I-Adev
+with	O
+pemphigus-like	O
+features	O
+
+The	O
+literature	O
+on	O
+thiabendazole-induced	O
+cholestasis	B-Adev
+and	O
+its	O
+association	O
+with	O
+sicca	O
+complex	O
+is	O
+reviewed	O
+
+How	O
+low	O
+can	O
+you	O
+go?	O
+Use	O
+of	O
+very	O
+low	O
+dosage	O
+of	O
+gold	O
+in	O
+patients	O
+with	O
+mucocutaneous	O
+reactions	O
+
+A	O
+55-year-old	O
+HIV-positive	O
+African	O
+woman	O
+received	O
+a	O
+single	O
+epidural	O
+triamcinolone	O
+injection	O
+for	O
+pain	O
+relief	O
+of	O
+postherpetic	O
+neuralgia	O
+
+Anaphylactoid	B-Adev
+shock	I-Adev
+disseminated	I-Adev
+intravascular	I-Adev
+coagulation	I-Adev
+and	I-Adev
+anuric	I-Adev
+renal	I-Adev
+failure	I-Adev
+requiring	I-Adev
+dialysis	I-Adev
+occurred	O
+in	O
+a	O
+patient	O
+receiving	O
+zomepirac	O
+sodium	O
+for	O
+toothache	O
+
+During	O
+dose-finding	O
+studies	O
+for	O
+intravenous	O
+proton	O
+pump	O
+inhibitors	O
+omeprazole	O
+and	O
+pantoprazole	O
+three	O
+of	O
+six	O
+young	O
+female	O
+volunteers	O
+receiving	O
+omeprazole	O
+and	O
+two	O
+young	O
+female	O
+volunteers	O
+receiving	O
+pantoprazole	O
+developed	O
+peripheral	B-Adev
+edema	I-Adev
+within	I-Adev
+8	I-Adev
+hr	I-Adev
+when	O
+high	O
+doses	O
+of	O
+the	O
+proton	O
+pump	O
+inhibitors	O
+were	O
+applied	O
+by	O
+continuous	O
+infusion	O
+together	O
+with	O
+large	O
+volumes	O
+of	O
+fluid	O
+
+During	O
+dose-finding	O
+studies	O
+for	O
+intravenous	O
+proton	O
+pump	O
+inhibitors	O
+omeprazole	O
+and	O
+pantoprazole	O
+three	O
+of	O
+six	O
+young	O
+female	O
+volunteers	O
+receiving	O
+omeprazole	O
+and	O
+two	O
+young	O
+female	O
+volunteers	O
+receiving	O
+pantoprazole	O
+developed	O
+peripheral	B-Adev
+edema	I-Adev
+within	I-Adev
+8	I-Adev
+hr	I-Adev
+when	O
+high	O
+doses	O
+of	O
+the	O
+proton	O
+pump	O
+inhibitors	O
+were	O
+applied	O
+by	O
+continuous	O
+infusion	O
+together	O
+with	O
+large	O
+volumes	O
+of	O
+fluid	O
+
+Intravenous	O
+levodopa	O
+25	O
+mg	O
+ameliorated	O
+his	O
+akathisia	O
+symptoms	O
+drastically	O
+
+Cyclosporine-induced	O
+pain	B-Adev
+syndrome	I-Adev
+in	O
+a	O
+child	O
+undergoing	O
+hematopoietic	O
+stem	O
+cell	O
+transplant	O
+
+Visual	B-Adev
+loss	I-Adev
+after	O
+a	O
+single	O
+small	O
+dose	O
+of	O
+vincristine	O
+has	O
+never	O
+been	O
+reported	O
+
+Slow	O
+acetylator	O
+genotypes	O
+as	O
+a	O
+possible	O
+risk	O
+factor	O
+for	O
+infectious	B-Adev
+mononucleosis-like	I-Adev
+syndrome	I-Adev
+induced	O
+by	O
+salazosulfapyridine	O
+
+Clinicians	O
+should	O
+be	O
+aware	O
+of	O
+raltegravir-induced	O
+DRESS	B-Adev
+syndrome	I-Adev
+as	O
+well	O
+as	O
+the	O
+potential	O
+for	O
+drug-drug	O
+interactions	O
+due	O
+to	O
+protease	O
+inhibitor-based	O
+therapy	O
+
+CONCLUSION	O
+Under	O
+certain	O
+circumstances	O
+topical	O
+brimonidine	O
+can	O
+cause	O
+paradoxical	O
+raised	B-Adev
+IOP	I-Adev
+necessitating	O
+vigilance	O
+in	O
+follow-up	O
+of	O
+patients	O
+on	O
+topical	O
+brimonidine	O
+
+Pharmacokinetic	O
+modeling	O
+suggested	O
+that	O
+the	O
+patient's	O
+initial	O
+over-treatment	O
+was	O
+as	O
+reported	O
+and	O
+that	O
+the	O
+predicted	O
+maximum	O
+serum	O
+concentration	O
+of	O
+chloroquine	O
+(902	O
+micro	O
+g/L)	O
+was	O
+within	O
+the	O
+range	O
+seen	O
+in	O
+fatal	B-Adev
+chloroquine	O
+overdose	O
+
+There	O
+was	O
+no	O
+apparent	O
+cardiovascular	O
+interaction	O
+between	O
+clopidogrel	O
+and	O
+omeprazole	O
+but	O
+our	O
+results	O
+do	O
+not	O
+rule	O
+out	O
+a	O
+clinically	O
+meaningful	O
+difference	O
+in	O
+cardiovascular	B-Adev
+events	O
+due	O
+to	O
+use	O
+of	O
+a	O
+PPI	O
+
+Anaphylactic/anaphylactoid	B-Adev
+reactions	I-Adev
+to	O
+methotrexate	O
+are	O
+rare	O
+
+Continuous	O
+bladder	O
+irrigation	O
+of	O
+a	O
+1%	O
+alum	O
+solution	O
+is	O
+a	O
+simple	O
+and	O
+generally	O
+safe	O
+method	O
+of	O
+chemical	O
+cautery	O
+to	O
+treat	O
+the	O
+bleeding	O
+urothelium	O
+
+The	O
+temporal	O
+relationship	O
+suggests	O
+that	O
+the	O
+spinal	B-Adev
+cord	I-Adev
+infarction	I-Adev
+may	O
+be	O
+related	O
+to	O
+the	O
+use	O
+of	O
+zolmitriptan	O
+
+Delusional	B-Adev
+parasitosis	I-Adev
+associated	O
+with	O
+phenelzine	O
+
+CONCLUSION	O
+The	O
+administration	O
+of	O
+tissue	O
+plasminogen	O
+activator	O
+was	O
+responsible	O
+for	O
+the	O
+large	B-Adev
+extent	I-Adev
+of	I-Adev
+hemorrhage	I-Adev
+and	O
+should	O
+be	O
+considered	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+hemorrhagic	O
+choroidal	O
+detachment	O
+
+Dihydropyrimidine	O
+dehydrogenase	O
+deficiency	O
+a	O
+pharmacogenetic	O
+defect	O
+causing	O
+severe	B-Adev
+adverse	I-Adev
+reactions	I-Adev
+to	O
+5-fluorouracil-based	O
+chemotherapy	O
+
+Interferon-beta	O
+(IFN-beta)	O
+is	O
+a	O
+type	O
+I	O
+interferon	O
+used	O
+in	O
+the	O
+management	O
+of	O
+multiple	O
+sclerosis	O
+
+Quetiapine-induced	O
+leucopenia	B-Adev
+and	I-Adev
+thrombocytopenia	I-Adev
+
+CONCLUSION	O
+Severe	B-Adev
+and	I-Adev
+sustained	I-Adev
+ocular	I-Adev
+hypertension	I-Adev
+may	O
+occur	O
+after	O
+intravitreal	O
+ranibizumab	O
+
+BACKGROUND	O
+To	O
+describe	O
+the	O
+occurrence	O
+of	O
+ocular	B-Adev
+hypertension	I-Adev
+in	O
+four	O
+patients	O
+following	O
+injection	O
+of	O
+ranibizumab	O
+intravitreally	O
+
+Vancomycin	O
+is	O
+widely	O
+used	O
+against	O
+methicillin-resistant	O
+Staphylococcus	O
+aureus	O
+infections	O
+but	O
+it	O
+is	O
+associated	O
+with	O
+many	O
+adverse	O
+effects	O
+such	O
+as	O
+nephrotoxicity	B-Adev
+ototoxicity	I-Adev
+gastrointestinal	I-Adev
+disturbances	I-Adev
+blood	I-Adev
+disorders	I-Adev
+and	I-Adev
+two	I-Adev
+types	I-Adev
+of	I-Adev
+hypersensitivity	I-Adev
+reactions	I-Adev
+-	I-Adev
+an	I-Adev
+anaphylactoid	I-Adev
+reaction	I-Adev
+known	I-Adev
+as	I-Adev
+"red	I-Adev
+man	I-Adev
+syndrome"	I-Adev
+and	I-Adev
+anaphylaxis	I-Adev
+	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+unintentional	O
+overdose	O
+of	O
+oral	O
+pilocarpine	O
+tablets	O
+that	O
+resulted	O
+in	O
+bradycardia	B-Adev
+mild	I-Adev
+hypotension	I-Adev
+and	I-Adev
+muscarinic	I-Adev
+symptoms	I-Adev
+in	O
+a	O
+patient	O
+with	O
+Sjogren's	O
+syndrome	O
+
+Moreover	O
+treatment	O
+with	O
+immunosuppressive	O
+drugs	O
+such	O
+as	O
+cyclosporine	O
+cisplatin	O
+tacrolimus	O
+and	O
+interferon-alpha	O
+can	O
+induce	O
+a	O
+condition	O
+resembling	O
+RPLS	B-Adev
+	O
+
+Case	O
+1	O
+a	O
+62-year-old	O
+woman	O
+developed	O
+bilateral	B-Adev
+optic	I-Adev
+neuritis	I-Adev
+with	I-Adev
+decreased	I-Adev
+sensation	I-Adev
+of	I-Adev
+vibration	I-Adev
+and	I-Adev
+increased	I-Adev
+deep	I-Adev
+tendon	I-Adev
+reflex	I-Adev
+in	I-Adev
+the	I-Adev
+lower	I-Adev
+extremities	I-Adev
+after	O
+a	O
+seven-month	O
+use	O
+of	O
+recombinant	O
+interferon	O
+alpha-2a	O
+for	O
+chronic	O
+active	O
+hepatitis	O
+C	O
+
+A	B-Adev
+syndrome	I-Adev
+of	I-Adev
+increased	I-Adev
+affect	I-Adev
+in	O
+response	O
+to	O
+risperidone	O
+among	O
+patients	O
+with	O
+schizophrenia	O
+
+Therapy	O
+with	O
+IFN-beta	O
+has	O
+rarely	O
+been	O
+associated	O
+with	O
+the	O
+development	O
+of	O
+autoimmune	B-Adev
+disorders	I-Adev
+	O
+
+Despite	O
+these	O
+antithrombotic	O
+effects	O
+the	O
+patient	O
+developed	O
+repeated	B-Adev
+venous	I-Adev
+thromboembolism	I-Adev
+during	O
+treatment	O
+with	O
+low-molecular-weight	O
+heparin	O
+
+Hyponatraemia	B-Adev
+developed	O
+after	O
+rechallenge	O
+with	O
+controlled	O
+release	O
+carbamazepine	O
+
+Azathioprine-induced	O
+warfarin	B-Adev
+resistance	I-Adev
+
+Reversible	O
+valproic	O
+acid-induced	O
+dementia	B-Adev
+	O
+a	O
+case	O
+report	O
+
+Parenteral-verapamil-induced	O
+sustained	B-Adev
+hypotension	I-Adev
+	O
+
+The	O
+main	O
+side-effects	O
+of	O
+Lp-TAE	O
+combined	O
+with	O
+HT	O
+were	O
+low-grade	B-Adev
+fever	I-Adev
+localized	I-Adev
+pain	I-Adev
+myelo-suppression	I-Adev
+and	I-Adev
+liver	I-Adev
+dysfunction	I-Adev
+	O
+but	O
+these	O
+were	O
+transient	O
+and	O
+eventually	O
+disappeared	O
+
+Unique	B-Adev
+behavioral	I-Adev
+change	I-Adev
+with	O
+cinepazide	O
+in	O
+parkinsonism	O
+
+The	O
+literature	O
+of	O
+vincristine	O
+optic	B-Adev
+nerve	I-Adev
+toxicity	I-Adev
+is	O
+reviewed	O
+
+PATIENTS	O
+Two	O
+patients	O
+ages	O
+40	O
+and	O
+51	O
+years	O
+undergoing	O
+treatment	O
+with	O
+interferon	O
+alfa	O
+for	O
+malignant	O
+neoplasms	O
+experienced	O
+sudden	O
+bilateral	B-Adev
+sequential	I-Adev
+visual	I-Adev
+loss	I-Adev
+with	I-Adev
+disc-related	I-Adev
+field	I-Adev
+defects	I-Adev
+and	I-Adev
+segmental	I-Adev
+optic	I-Adev
+disc	I-Adev
+edema	I-Adev
+	O
+
+Neurological	O
+improvement	O
+and	O
+rehabilitation	O
+potential	O
+following	O
+toxic	B-Adev
+myelopathy	I-Adev
+due	O
+to	O
+intrathecal	O
+injection	O
+of	O
+doxorubicin	O
+
+Generalised	B-Adev
+cutaneous	I-Adev
+rash	I-Adev
+associated	O
+with	O
+ganciclovir	O
+therapy	O
+has	O
+rarely	O
+been	O
+reported	O
+in	O
+literature	O
+
+Anaphylaxis	B-Adev
+after	O
+the	O
+injection	O
+of	O
+chymopapain	O
+occurs	O
+in	O
+about	O
+1%	O
+of	O
+such	O
+cases	O
+
+Heat	B-Adev
+stroke-like	I-Adev
+episode	I-Adev
+in	O
+a	O
+child	O
+caused	O
+by	O
+zonisamide	O
+
+An	O
+interaction	O
+between	O
+methylene	O
+blue	O
+and	O
+serotonergic	O
+agents	O
+may	O
+give	O
+rise	O
+to	O
+the	O
+serotonin	B-Adev
+syndrome	I-Adev
+	O
+
+These	O
+cases	O
+suggest	O
+the	O
+possibility	O
+that	O
+in	O
+some	O
+patients	O
+leukopenia	B-Adev
+or	I-Adev
+agranulocytosis	I-Adev
+during	O
+olanzapine	O
+treatment	O
+might	O
+be	O
+dose-related	O
+
+Adult	B-Adev
+respiratory	I-Adev
+distress	I-Adev
+syndrome	I-Adev
+after	O
+treatment	O
+with	O
+pegylated	O
+interferon	O
+alpha-2a	O
+and	O
+ribavirin	O
+
+CONCLUSIONS	O
+The	O
+increasing	O
+prevalence	O
+of	O
+Type	O
+2	O
+diabetes	O
+and	O
+its	O
+treatment	O
+with	O
+metformin	O
+might	O
+result	O
+in	O
+more	O
+cases	O
+of	O
+lactic	B-Adev
+acidosis	I-Adev
+	O
+
+Sustained	B-Adev
+ventricular	I-Adev
+tachycardia	I-Adev
+in	O
+a	O
+thalidomide-treated	O
+patient	O
+with	O
+primary	O
+plasma-cell	O
+leukemia	O
+
+The	O
+second	O
+is	O
+a	O
+29-year-old	O
+man	O
+with	O
+CD	O
+in	O
+whom	O
+nodular	B-Adev
+sclerosing	I-Adev
+Hodgkin's	I-Adev
+lymphoma	I-Adev
+was	O
+diagnosed	O
+3	O
+weeks	O
+after	O
+infusion	O
+with	O
+infliximab	O
+
+We	O
+suggest	O
+discontinuing	O
+gemcitabine	O
+if	O
+radiation	B-Adev
+recall	I-Adev
+is	O
+observed	O
+
+OBJECTIVE	O
+To	O
+report	O
+the	O
+occurrence	O
+of	O
+acute	B-Adev
+cytolytic	I-Adev
+hepatitis	I-Adev
+in	O
+a	O
+patient	O
+exposed	O
+to	O
+pulse	O
+itraconazole	O
+therapy	O
+for	O
+24	O
+weeks	O
+and	O
+provide	O
+a	O
+concise	O
+review	O
+of	O
+the	O
+literature	O
+on	O
+cases	O
+of	O
+itraconazole-induced	O
+hepatitis	O
+
+These	O
+findings	O
+should	O
+lead	O
+to	O
+further	O
+study	O
+of	O
+the	O
+role	O
+of	O
+lithium	O
+in	O
+the	O
+treatment	O
+of	O
+this	O
+symptom	O
+complex	O
+in	O
+patients	O
+with	O
+PTSD	O
+
+She	O
+was	O
+placed	O
+on	O
+adjuvant	O
+Adriamycin	O
+(doxorubicin)	O
+chemotherapy	O
+but	O
+6	O
+months	O
+later	O
+died	B-Adev
+of	I-Adev
+Adriamycin	I-Adev
+toxicity	I-Adev
+	O
+
+BACKGROUND	O
+Ovarian	B-Adev
+cancer	I-Adev
+arising	O
+from	O
+an	O
+endometriotic	O
+cyst	O
+in	O
+a	O
+postmenopausal	O
+woman	O
+under	O
+tamoxifen	O
+therapy	O
+is	O
+rare	O
+
+L-asparaginase-induced	O
+pancreatitis	B-Adev
+is	O
+an	O
+uncommon	O
+but	O
+potential	O
+lethal	O
+complication	O
+of	O
+the	O
+treatment	O
+of	O
+leukemia	O
+
+An	O
+89-year-old	O
+man	O
+receiving	O
+long-term	O
+anticoagulation	O
+with	O
+warfarin	O
+sodium	O
+(total	O
+weekly	O
+dosage	O
+of	O
+19	O
+mg)	O
+arrived	O
+at	O
+the	O
+anticoagulation	O
+clinic	O
+for	O
+his	O
+monthly	O
+visit	O
+
+Treatment	O
+with	O
+tifacogin	O
+had	O
+no	O
+effect	O
+on	O
+all-cause	O
+mortality	B-Adev
+in	O
+patients	O
+with	O
+severe	O
+sepsis	O
+and	O
+high	O
+INR	O
+
+Although	O
+lung	O
+specimens	O
+were	O
+lacking	O
+from	O
+these	O
+three	O
+patients	O
+it	O
+is	O
+suggested	O
+that	O
+the	O
+pulmonary	B-Adev
+toxicity	I-Adev
+of	O
+CCNU	O
+may	O
+be	O
+dose-related	O
+
+Concomitant	O
+use	O
+of	O
+clarithromycin	O
+or	O
+other	O
+potent	O
+inhibitors	O
+of	O
+CYP3A4	O
+with	O
+repaglinide	O
+may	O
+enhance	O
+its	O
+blood	B-Adev
+glucose-lowering	I-Adev
+effect	I-Adev
+and	I-Adev
+increase	I-Adev
+the	I-Adev
+risk	I-Adev
+of	I-Adev
+hypoglycemia	I-Adev
+	O
+
+Drug-induced	O
+fever	B-Adev
+due	O
+to	O
+diltiazem	O